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ABSTRACT 
CELLULAR IMMUNITY IN MOUSE MODELS OF VIRAL ENCEPHALITIS 
Christina Dawn Steel 
Eastern Virginia Medical School and Old Dominion University, 2010 
Director: Dr. Richard P. Ciavarra 
Evidence is presented herein that intranasal application of vesicular stomatitis virus (VSV) caused 
acute infection of the murine central nervous system (CNS) with associated morbidity and significant 
mortality in mice. However, VSV encephalitis was not invariably fatal, suggesting that the CNS contained 
a professional antigen-presenting cell (APC) capable of inducing or propagating a protective antiviral 
immune response. To examine this possibility, we administered VSV via the intranasal route and then 
characterized the cellular elements that infiltrate the brain as well as the activation status of resident 
microglia, cells widely believed to represent the major APC population in the CNS. To exclude a 
contribution of peripheral dendritic cells (DCs), a population with documented APC activity in vivo and 
capable of infiltrating the inflamed CNS, studies were conducted in a conditional ablation transgenic mouse 
model that allowed for the selective depletion of these cells with diphtheria toxin (DT). Microglia isolated 
from infected brains rapidly upregulated expression of major histocompatibility complex (MHC) class I 
antigens, program death receptor 1 (PD-1) and underwent a microgliosis indicating virus-induced activation 
and expansion. Peripheral blood cells started to infiltrate the virus infected brain around days 4-5, peaked 
on day 8 and achieved basal trace levels at 21 days post infection. The infiltrate was composed primarily 
of myeloid cells (CD45highCDl lb+), CD4+ and CD8+ T cells; the latter subset containing cells specific for 
the immunodominant VSV nuclear protein epitope. Although the CD45hlghCDl lb+ phenotype suggests that 
these cells are macrophages, subsequent 4-5-color flow cytometry demonstrated that this was primarily a 
granulocytic response (CD45highCDl lb+Gr-l^/SO"). The T cell infiltrate correlated temporally with a 
rapid and sustained upregulation of class I expression on microglia, whereas class II expression was 
markedly delayed. Ablation of peripheral DCs profoundly inhibited the inflammatory response as well as 
infiltration of virus-specific CD8+ T cells and this correlated with inefficient viral clearance in the brain and 
increased morbidity/mortality. Unexpectedly, the VSV-induced interferon-gamma (IFN-y) response in the 
CNS remained intact in mice rendered deficient of DCs suggesting that a resident brain cell produced this 
cytokine. In summary, these studies expanded prior work on the changes in resident microglia and the 
composition of brain leukocytes in the encephalitic brain. In addition, data demonstrated that peripheral 
DCs play an essential role in vivo in the inflammatory and certain components of the adaptive primary 
antiviral immune response in the CNS and as a result, modulate viral clearance and survivability for this 
pathogen. 
Because macrophages may also function as APCs in vivo, we used two different approaches to 
ablate peripheral macrophages in vivo to examine their role in VSV encephalitis and viral clearance in the 
CNS. Chemical ablation of macrophages using AP20187 in the MAFIA (macrophage fas-induced 
apoptosis) conditional ablation model did not diminish microglia numbers or activation and failed to alter 
the cellular composition of the infiltrate. In contrast, ablation of phagocytic cells by intravenous liposome -
encapsulated clodronate administration markedly suppressed the influx of leukocytes into the brain 
including CD8+ VSV-specific T cells and enhanced morbidity/mortality despite normal viral clearance 
from the brain. Intracerebroventricular (ICV) infusion of clodronate did not impair VSV encephalitis and 
eliminated a role for brain perivascular macrophages (PVM) and/or meningeal macrophages as contributors 
to viral clearance or antigen presentation. 
In summary, VSV encephalitis was characterized by i) microglial activation and expansion, ii) a 
prominent and early myeloid infiltrate dominated by granulocytes with smaller contributions of CD1 lc+ 
DCs and macrophages, iii) a lymphoid infiltrate of CD4+ and CD8+ T cells including a subset specific for 
the immunodominant nuclear protein epitope and iv) the absence of significant numbers of pDCs, B cells, 
NK and NK T cells. A role for peripheral DCs in the development of innate and adaptive antiviral 
immunity in the CNS, viral clearance and survivability was demonstrated in vivo using a conditional 
ablation mouse model. Enhanced VSV encephalitis was observed following depletion of circulating or 
brain-resident macrophages in the MAFIA transgenic model and following ICV infusion of liposome -
encapsulated clodronate. These data suggest that macrophages enhance pathogenesis during viral 
infections of the CNS. 
V 
The way to do research is to attack the facts at the point of greatest astonishment. 
-Celia Green, The Decline and Fall of Science, 1972 
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The immunological response to viral infection is complex and highly choreographed. The central 
nervous system (CNS) has long been held as an immunologically privileged site because of its inability to 
eliminate antigenic stimuli in the parenchyma. Immunological privilege is largely attributed to the blood-
brain barrier (BBB) (Galea et al., 2007a) and the absence of a classical lymphatic system. However, this 
view of the CNS as an immunocompromised site is rapidly changing. More recent studies indicate that 
BBB permeability is altered in response to injury or infection and permits the infiltration of peripherally-
derived leukocytes. Some areas of the brain are not protected by the BBB (meninges, choroid plexus, 
circumventricular organs and ventricles (Farina et al., 2007; Galea et al., 2007a). Several studies have 
demonstrated the presence of small populations of peripherally-derived leukocytes that patrol the naive 
CNS (Bechmann et al., 2007; Galea et al., 2007a). Finally, many cells of the CNS possess some intrinsic 
immunological capacity (Hart and Fabry, 1995). Thus, it is more appropriate to consider the CNS an 
unique immunological microenvironment. The immune response of the CNS must be orchestrated 
differently from in the periphery of an animal; inflammation and cytotoxicity in the brain would result in 
loss of critical neurons and other cell types. These cells do not repopulate quickly or well; their loss 
represents a devastating impact on survival. Therefore, understanding how the immune response in the 
CNS differs from that of the periphery represents an unique challenge and an important topic of study. 
To date, most research in CNS immunity has focused on demyelinating diseases such as 
experimental autoimmune encephalomyelitis (EAE) and persistent infections such as Theiler's murine 
encephalomyelitis virus (TMEV), primarily with regard to development of treatments for multiple 
sclerosis. Although these studies provide insights into the general inflammatory and adaptive immune 
responses in the CNS, they may not accurately reflect the events during acute viral infection. 
The model journal for this dissertation is Glia. 
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More recently, several viruses capable of producing acute infections in the CNS of mice have been studied, 
including lymphocytic choriomeningitis virus (LCMV), rabies virus, Borna disease virus, Theiler's murine 
encephalitis virus, and Sindbis virus. 
However, with the exception of rabies, these models do not address cytolytic infections such as 
VSV. Understanding neurological viral infections is critical to the treatment of several human diseases that 
are caused by or may include acute phases of infection. The primary cause of acute viral infections of the 
CNS is from arboviruses, including West Nile virus, Equine encephalitis viruses, Crimean-Congo 
haemorrhagic fever, Rift Valley Fever virus, Dengue, and Yellow fever (Binder and Griffin, 2003 a; Binder 
and Griffin, 2003b). Additional viruses that may result in acute-phase infections include HIV, several 
herpes viruses, measles, and rabies (Nair et al., 2007; Nelson et al., 2002; Ponomarev et al, 2005a). 
Developing a model for antiviral immunity in the CNS could provide therapeutic targets for acute viral 
infections in humans as well as animals. Therefore, this work focuses on characterizing the immune 
response in the CNS to an acute viral infection. 
At a very simplistic level, two aspects of the immune response are relevant: the innate 
(nonspecific) and adaptive (antigen-specific) responses. Both are involved in antiviral immunity in 
response to peripheral infections. The innate immune response is generally characterised by an influx of 
myeloid cells, including macrophages, dendritic cells, natural killer cells, and granulocytes, whose 
functions are to induce inflammation, recognize and destroy pathogens and to stimulate the adaptive 
immune response via antigen presentation and cytokine/chemokine secretion. For CNS infections, the 
innate immune system is rarely sufficient to clear virus (Griffin, 2003; Ireland and Reiss, 2006). The 
adaptive immune response is activated when the innate immune response fails to clear the antigen source, 
and is characterised by an infiltrating population of lymphocytes that are specific for the pathogen in 
question. These antigen-specific cells also recognise and destroy pathogens and infected cells and provide 
a pool of immunologic memory cells (Janeway et al , 2001). In all models of CNS inflammation, infection, 
or injury, cells from both the innate and adaptive responses have been demonstrated to enter the CNS. 
Their recruitment to the CNS, activation, and effector functions, however, remain poorly characterised. 
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In general, resolution of a viral infection follows a typical course beginning with viral replication 
and recruitment of nonspecific (innate) leukocytes such as granulocytes, macrophages, and dendritic cells. 
Dendritic cells enter the lymphatic system, secreting various cytokines that will serve to direct additional 
leukocytes to the infected location. Once in the draining lymph node, they present antigen to and activate 
lymphocytes, which rapidly migrate out of the lymph nodes and home toward the site of infection, directed 
by DC-secreted cytokine/chemokine gradients. Antigen-specific lymphocytes and innate leukocytes may 
secrete additional antiviral chemokines/cytokines, induce cell-contact-dependent apoptosis, or phagocytose 
infected target cells to mediate viral clearance. The next sections describe cell types and events likely to be 
critical to understanding antiviral immunity in the CNS. 
Anatomy and biology of the brain 
As previously noted, the brain is commonly considered to be immunologically privileged due to 
the blood-brain barrier (BBB). Until recently, it was held that the BBB represented a nearly impenetrable 
barrier through which only select substances may pass. Although the brain is generally considered to be a 
single organ, it possesses at least three distinct microenvironments defined by proximity to the blood-brain 
barrier (BBB): the parenchyma of the brain (protected by the BBB), the perivascular spaces on the border 
between the peripheral circulatory system and the BBB, and areas of the brain are not protected by the BBB 
(meninges, choroid plexus, circumventricular organs and ventricles (Farina et al., 2007; Galea et al., 
2007a). The history of the BBB and its more modern view are thoroughly reviewed in (Bechmann et al., 
2007). More recent studies indicate that BBB permeability is altered in response to injury or infection and 
permits the infiltration of peripherally-derived leukocytes (Archambault et al, 2005; Galea et al., 2007b; 
Komatsu et al, 1999; Lees et al., 2006; Nag, 2003; Pardridge, 1999; Persidsky, 1999; Persidsky et al., 
1999). Several studies have demonstrated the presence of small populations of peripherally-derived 
leukocytes that patrol the naive CNS (Bechmann et al., 2007; Galea et al., 2007a). 
Parenchymal cell types 
Many cells of the CNS possess some intrinsic immunological capacity (Hart and Fabry, 1995). In 
the CNS parenchyma, there are three primary cell types: neurons, astrocytes, and glial cell types. Neurons 
are generally considered to be immunologically quiescent cells, but a handful of studies imply that they 
may be able to directly participate in antiviral immunity, though their roles are unclear (Delhaye et al, 
2006; Neumann, 2001). Astrocytes are generally considered to be support scaffold cells for neurons, and 
the end-feet of astrocytes form the basement membrane of the BBB (Bechmann et al., 2007). Their 
potential role in antiviral immunity has been more thoroughly investigated than for neurons. Independent 
of their structural role in forming the BBB, astrocytes react to infections of the CNS. They have been 
shown to produce nitric oxide (a common cytotoxic/antiviral mechanism for viral clearance) (Barna et al., 
1996), as well as several cytokines and chemokines involved in immunity (refer to Appendix B), most of 
which are chemotactic for monocytes and macrophages (Barna et al., 1996; Constantinescu et al., 1996; 
Dong and Benveniste, 2001; Farina et al., 2007; Pardridge, 1999; Persidsky et al, 1999; Speth et al., 2007). 
Further evidence indicates that astrocytes may be able to present antigen (Aloisi et al., 1998; Barna et al., 
1996; Farina et al, 2007; Persidsky et al., 1999; Speth et al., 2007), though these data are primarily based 
on ex vivo culture studies and may not reflect in vivo capacity. Of the resident CNS cells with 
immunological capacity, microglia are widely regarded as the most critical and represent approximately 10-
20% of the brain parenchyma (Havenith et al, 1998; Lawson et al, 1990; Rock et al., 2004; Santambrogio 
et al., 2001; Town et al, 2005). They are also thought to provide a liaison between the immune and 
nervous systems (Ponomarev et al., 2005a; Ponomarev et al, 2005b). The origin of microglia is a hotly 
debated issue. Some studies indicate that they derive from monocyte precursors and migrate to the CNS 
during embryonic development, with poor subsequent repopulation from the periphery (Neumann, 2001; 
Town et al., 2005). However, others have demonstrated that some peripheral monocyte/macrophage cells 
from the periphery assume a microglial-like morphology and phenotype upon entry to the CNS following 
trauma or infection (Flugel et al., 2001; Town et al., 2005). Despite their shrouded origins, microglia are 
phenotypically characterised by an uniquely low to intermediate expression of CD45 (Ponomarev et al., 
2005a; Ponomarev et al., 2005b) and CD1 lb (Ponomarev et al., 2005b) and have a characteristic ramified 
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morphology when resting (Ponomarev et al., 2005b; Santambrogio et al., 2001; Town et al, 2005). CD45 
is an antigen widely expressed on leukocytes. Early characterization of this molecule revealed a role in 
vitro for macrophage adhesion (Roach et al , 1997). Microglia also express common macrophage markers 
such as CD1 lb, (commonly referred to as Mac-1, an a-integrin associated with cellular adhesion and is 
expressed on a wide variety of leukocytes) and F4/80 (which is expressed at low levels on microglia and 
high levels on macrophages). The biological function of the F4/80 target (an epidermal growth factor 
membrane protein) in immunity remains unclear (van den Berg and Kraal, 2005). Resting microglia are 
CD1 lc" (also an a-integrin variant, common to DCs), and are slightly smaller than peripheral CD45hlgh 
leukocytes (Ford et al., 1995). Microglia have been shown to respond (via activation and/or proliferation) 
to a wide variety of CNS events, including injury, ischaemia, autoimmune disorders, infection, and even 
aging (Ackman et al., 2006; Aloisi, 2001; Barna et al., 1996; Bulloch et al., 2008; Cosenza-Nashat et al., 
2006; Getts et al, 2008; Hickey, 2001; Juedes and Ruddle, 2001; Katz-Levy et al, 1999; Lalancette-Hebert 
et al, 2007; Mack et al., 2003; Miller et al., 2007; Morris et al, 1997; Nair et al., 2007; Nelson et al., 2002; 
Persidsky et al., 1999; Ponomarev et al, 2005b; Raivich et al., 1994; Reichmann et al., 2002; Rock et al, 
2004; Schilling et al, 2003; Stichel and Luebbert, 2007; Stoll and Jander, 1999; Stoll et al., 1998; Town et 
al., 2005; Watanabe et al., 1999). On infection, the microglia become activated (Ponomarev et al., 2005a; 
Ponomarev et al., 2005b), upregulating several cell surface antigens, including MHC II, CD80, and CD40 
(Ponomarev et al, 2005a; Ponomarev et al., 2005b), and assume a more spheroid shape. Microglia are also 
potent producers of a wide variety of cytokines and chemokines, depending on the stimulus (again, refer to 
Appendix B) (Aloisi, 2001; Nelson et al., 2002; Neumann, 2001; Olson and Miller, 2004; Persidsky, 1999; 
Prat et al., 2001; Rock et al., 2004; Speth et al., 2007; Walker et al., 2006; Wang and Suzuki, 2007). Thus, 
clarifying the role of microglia in antiviral immunity of the CNS will be an important focus of this work. 
Perivascular cell types 
The perivascular spaces were initially termed lymphatic clefts by Goldman (Bechmann et al, 
2007). This is an apt description, given the diversity of cell types that may be found in these regions. 
Current studies have clearly demonstrated localization of macrophages to these regions, which may 
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produce a localized region architecturally similar to lymphoid tissue (also known as tertiary lymphoid 
regions, (Galea et al., 2007a; Persidsky, 1999). Additional relevant cellular elements (DC, T cells, 
macrophages) that reside there may be sufficient to drive T cell activation and clonal expansion (Bechmann 
et al., 2007; Fischer and Reichmann, 2001; Matyszak and Perry, 1996; Newman et al., 2005). The brain 
also contains two strategically located macrophage populations, perivascular macrophages (PVM) and 
meningeal macrophages (MM), which represent the major macrophage populations resident in the brain. 
Several recent studies have demonstrated that macrophages residing in the perivascular spaces in the CNS 
play a key role in mediating the antiviral immune response and may be more important than microglia for 
antiviral immunity (Fabriek et al., 2005; Kim et al, 2006; Perry, 1998; Persidsky, 1999; Polfliet et al, 
2001b), although not all models agree (Galea et al., 2007b; Williams et al., 2001). Perivascular and 
meningeal macrophages are continuously repopulated from the periphery (Kim et al., 2006; Neumann, 
2001; Stoll and Jander, 1999; Williams et al, 2001). Their function(s) in the CNS, however, remains 
poorly defined. 
Infiltrating cell types 
Several studies have demonstrated the presence of small populations of peripherally-derived 
leukocytes that patrol the naive CNS (Bechmann et al., 2007; Galea et al., 2007a). Virtually all immune 
effector cells have been demonstrated to enter the CNS following injury or infection. These include both 
the nonspecific macrophages, dendritic cells, and natural killer cells, and granulocytes as well as adaptive, 
specific T cells and B cells (Bi et al, 1995a; Glabinski and Ransohoff, 1999; Persidsky, 1999; Rubin and 
Staddon, 1999). Therefore, it will be critically important to first determine which cell types are detectable 
in the CNS of virally infected animals for our own model. 
Vesicular stomatitis virus 
Vesicular stomatitis virus (VSV) is a neurotrophic ssRNA virus of the Vesiculovirus genus in the 
Rhabdoviridae family and is the prototypic virus of this family that includes rabies virus. This virus is used 
as a model for nearly all negative-sense ssRNA viruses, including measles. Currently, VSV is widely used 
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in laboratories due to its simple genome encoding only five proteins, leading to ease of manipulation. The 
glycoprotein (G) allows for fusion with the host cell membrane, thus permitting viral entry. The acid 
environment of endocytic vesicles results in the release of the negative-sense ssRNA, which is transcribed 
to a positive-sense RNA strand by the VSV-L polymerase in conjunction with the phosphoprotein (VSV-
P). As the host cells produce new transcripts and proteins, the matrix proteins (VSV-M) assemble into new 
virions encapsulating the viral genome and copies of the encoded proteins. The nucleocapsidprotein (N) 
coats the viral genome and associates with the matrix proteins during assembly. The nucleoprotein also 
includes the immunodominant epitope for antiviral recognition by CD8+ cytotoxic T lymphocytes 
(CTLs)(Puddington et al., 1986). VSV produces a cytolytic infection that has been well-characterised with 
regard to innate (nonspecific), biochemical (cytokine and chemokine), cellular (lymphocyte), and humoral 
(antibody-mediated) immune responses in mice (Buckler and Baron, 1966; Ciavarra and Burgess, 1988; 
Ciavarra and Tedeschi, 1994; Gobet et al., 1988). Following systemic infection, immunocompetent mice 
rapidly clear VSV from peripheral organs, produce IgM and neutralizing IgG antibodies and mount a 
robust CTL response although viral antigens persist for weeks in peripheral tissues (Battegay et al., 1996; 
Turner et al., 2007). When VSV is delivered via the intranasal route, it initially infects and replicates in 
olfactory receptor neurons and is then transmitted via the olfactory nerve to the central nervous system 
(CNS) within 12-24 hours (Forger et al., 1991; Plakhov et al., 1995). VSV replicates invasively in the 
olfactory bulb (OB) penetrating deeper layers of this structure, reaching the OB ventricle by days 4-5 post 
infection producing focal cytopathology. Depending on the dose and strain, virus can enter the ventricles 
causing inflammation and necrosis around the ventricles and travel caudally to the hindbrain by day 8 post 
infection. VSV does not use the trigeminal nerve for entry into the brain, as the trigeminal ganglion remains 
virus-free following intranasal infection (Reiss et al., 1998). 
Fig. 1 offers a visual map to VSV progression through the brain during infection. Although VSV 
infection of the CNS is associated with a high rate of morbidity and mortality, surviving mice completely 
clear infectious virus from the brain around days 10-12. We previously demonstrated that approximately 
one-third of mice acutely depleted of DC in vivo and infected peripherally with vesicular stomatitis virus 
(VSV) developed persistent brain infections (Ciavarra et al., 2006), characterised by a failure to clear VSV 
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from the CNS accompanied by weight loss, hindlimb paralysis, extreme morbidity and mortality. Because 
it was impossible to predict which mice supported CNS infections prior to euthanasia, we moved to an 
intranasal mode of VSV application that allowed us to achieve reproducible CNS infections in all mice. 
The susceptibility to and kinetics of VSV infection in the CNS were first described by the 
laboratories of Dr. Carol Reiss, and varied with mouse strain and gender (Barna et al., 1996; Forger et al., 
1991). The work of Huneycutt et al. demonstrated that VSV antigen was detectable in the olfactory bulb as 
early as 12 hours post-infection and spread caudally through the forebrain by 7 days post-infection, with 
only a few areas of the midbrain demonstrating antigen reactivity (Huneycutt et al., 1994). Previous studies 
by Reiss and colleagues demonstrated a high rate of morbidity/mortality in this model that correlated with 
high titres of VSV at 7 days post-infection and loss of the BBB function late in the infection. Surviving 
mice efficiently cleared VSV from the CNS, suggesting that the host can mount an efficient antiviral 
immune response in the CNS (Barna et al., 1996; Huneycutt et al., 1994; Plakhov et al., 1995). These data 
was further supported by immunohistochemical studies that demonstrated a VSV-induced CNS infiltrate 
composed primarily of macrophages and lymphocytes (Bi et al., 1995a). 
Fig. 1. Kinetics of VSVspread through the CNS of intranasally infected mice. 
This figure represents the caudal spread of VSV through the CNS following intranasal application of virus 
based on immunohistochemical results for the immunodominant VSV epitope (N52.59) defined by Reiss et 
al. (Bi et al., 1995a). VSV antigen is detectable as early as 12 hours post-infection and spreads caudally 
through various midbrain structures by 8 days post-infection. Mice that survive infection typically clear 
infection by 10-12 days post infection. Areas unaffected by virus are rendered in white. Image modified 
from "The Gene Expression Nervous System Atlas (GENSAT) Project, NINDS Contracts N01NS02331 & 
HHSN271200723701C to The Rockefeller University (New York, NY). (2008)" 
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Antigen presentation 
Dendritic cells (DC) continuously circulate throughout peripheral tissues as sentinels, sampling 
the environment for foreign antigens (Andrews et al., 2003). These cells are currently held as the most 
crucial and specialised antigen-presenting cell (APC) (Lipscomb and Masten, 2002; Matyszak and Perry, 
1996; Megjugorac et al, 2004; Pozzi et al., 2005; Probst and van den Broek, 2005; Randolph et al., 2005). 
On encounter with foreign antigen, they migrate to various lymphoid tissues where they present antigen to 
naive T and B cells (Bjorck, 2001; Lipscomb and Masten, 2002; Matyszak and Perry, 1996; Randolph et 
al., 2005). The current immunological paradigm holds DC as the exclusive cell type capable of activating a 
naive T cell (Abbas and Sharpe, 2005; Probst and van den Broek, 2005; Serbina and Pamer, 2003). Thus, 
they represent a bridge between the innate and adaptive immune responses. 
On encounter with foreign antigen, DCs migrate to various lymphoid tissues where they present 
antigen to nai've T and B cells (Bjorck, 2001; Lipscomb and Masten, 2002; Matyszak and Perry, 1996; 
Randolph et al., 2005). The current immunological paradigm holds DC as the exclusive cell type capable 
of activating a nai've T cell (Abbas and Sharpe, 2005; Probst and van den Broek, 2005; Serbina and Pamer, 
2003). Several subsets of DC exist, including the myeloid (CD8o>) and lymphoid (CD8a+) DC and 
plasmacytoid DC (pDC) (Andrews et al, 2003; Kronin et al., 2000; Lipscomb and Masten, 2002; 
Megjugorac et al., 2004; Town et al., 2005). Plasmacytoid DC are highly specialised and are often referred 
to as interferon-producing cells (IPC) for their unique ability to produce large amounts of Type 1 interferon 
(IFN-a/p) in response to pathogens (2003; Andoniou et al., 2005; Andrews et al., 2003; Barchet et al., 
2002; Bjorck, 2001; Fitzgerald-Bocarsly, 2002; Hornung et al., 2005; Kelsall et al., 2002; Krug et al, 2004; 
Lund et al, 2004; Megjugorac et al, 2004). Plasmacytoid dendritic cells express CD1 lc, B220, and Gr-1 
(Colonna et al, 2004; Kelsall et al, 2002; Krug et al, 2004; Shortman and Liu, 2002) as well as PDCA-1 
(Colonna et al, 2004; Krug et al, 2004), but do not express CD1 lb (Krug et al, 2004). The production of 
IFN-a by pDC has been confirmed by depletion with the 120G8 monoclonal antibody (mAb) in our lab 
(data not presented) and others (Colonna et al, 2004). Interferon a is largely regarded as a major antiviral 
cytokine which induces an antiviral state in resting tissues by suppressing proliferation, transcription, and 
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translation (Barchet et al., 2002; Dalod et al., 2002; Lund et al, 2004; Pogue et al., 2004; Stark et al., 
1998). 
The mechanisms by which DC direct Thl or Th2 mediated responses are still poorly understood; 
most implicate the production of cytokines such as IL-2, IL-4, and IFN-y, though some studies implicate 
antigen load (2003) and expression of various antigens such as CD1 lb (Kelsall et al., 2002). Our current 
studies demonstrate that dendritic cells and Type IIFN are not critical to early viral clearance. Our data 
and that of other researchers implies a crucial role for some marginal splenic macrophages in antiviral 
immunity and viral clearance (Ciavarra et al., 1997; Ciavarra et al, 2005; Claassen et al., 1995; Claassen et 
al., 1998; Oehen et al., 2002). One possible explanation for the observed differences is casually noted in a 
recent article by Pozzi et al. (Pozzi et al., 2005), which suggests that macrophages may be crucial to 
antiviral immunity after stimulation by T cells rather than playing a role in T cell activation. 
Several studies suggest that during CNS inflammation, activated DCs migrate to the cervical 
lymph nodes (Bailey et al., 2007; Dimier-Poisson et al., 2006; Galea et al., 2007a; Hatterer et al., 2006; 
Plakhov et al., 1995; Schwob et al., 2001; Velge-Roussel et al., 2000), where they activate naive 
lymphocytes, which then emigrate to the site of inflammation. The origin of these cells, whether 
peripherally-derived or brain-resident, is still contentious. Most research has not convincingly 
demonstrated the presence of DC in naive brain parenchyma (Lauterbach et al., 2006; Matyszak and Perry, 
1996; Perry, 1998; Serafini et al., 2000), although they are readily detected in areas unprotected by the 
BBB (Bailey et al., 2007; Fischer and Reichmann, 2001; Karman et al, 2006; Lauterbach et al., 2006; 
Matyszak and Perry, 1996; McMenamin, 1999; Miller et al., 2007; Newman et al., 2005; Perry, 1998; 
Serafini et al., 2000; Serot et al., 2000; Serot et al., 1997; Serot et al., 1998). Only a handful of recent 
studies, such as those by Fabry et al. and Bulloch et al. (Bulloch et al., 2008; Karman et al., 2006), have 
demonstrated DCs in the naive CNS parenchyma. These studies further indicate that either resident or 
infiltrating DCs provide APC function essential for propagation of innate and adaptive immunity in the 
CNS. It should be noted that identification of DCs in the CNS relies on a phenotypic rather than a 
functional definition for DCs; many of these studies also note that another population of CNS-resident cells 
may fulfil the role of APC. 
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Microglia are phenotypically highly similar to DC (Ponomarev et al., 2005a; Ponomarev et al., 
2005b; Shortman and Liu, 2002), but express CD45 (Ponomarev et al., 2005a; Ponomarev et al., 2005b) 
and CD1 lb (Ponomarev et al, 2005b) at low to intermediate levels. More recent studies on the function of 
CD45 have revealed additional roles in T and B cell activation (Saunders and Johnson) via enhanced T cell 
receptor (TCR) signalling, particularly for B-cell activating T helper 2 lymphocytes (Thauland et al., 2008). 
On infection, the microglia become activated (Ponomarev et al., 2005a; Ponomarev et al., 2005b), 
upregulating several cell surface antigens, including MHC II, CD80, and CD40 (Ponomarev et al., 2005a; 
Ponomarev et al., 2005b). MHC II is the primary means of antigen presentation to naive CD4+ T cells. 
CD80 (B7-1) provides necessary costimulatory signals in conjunction with CD28 or CD152 (CTLA-4) for 
full CD8+ T cell activation, while CD40 binds with CD 154 (CD40L) to provide costimulation leading to 
full activation of CD4+ T cells. Resting expression of CD45 and CD1 lb, along with upregulation of MHC 
II, CD80, and CD40 imply that microglia are capable of acquiring APC capacity and may be able to initiate 
and/or propagate the adaptive immune response in the CNS (Fischer and Reichmann, 2001; Juedes and 
Ruddle, 2001; Mack et al, 2003; Persidsky et al., 1999; Ponomarev et al., 2005a; Ponomarev et al, 2005b; 
Shortman and Liu, 2002). Activated microglia can present antigen to CD4+ T cells and secrete various 
chemokines (Persidsky et al, 1999) that help recruit activated leukocytes of monocyte origin. 
Although a peripheral immune system model would predict that the draining CLNs are the 
primary site for T cell activation, it is possible that the perivascular regions could fill this role for the CNS. 
Because of their strategic location and the observation that CD8+ T cell infiltration is markedly enhanced 
by cognate antigen recognition (Galea et al., 2007b), they are ideally suited to function as APCs. 
Perivascular macrophages have been shown to express MHC II and present antigen (Fabriek et al, 2005; 
Fischer and Reichmann, 2001; Griffin, 2003; Perry, 1998; Polfliet et al., 2001b; Stoll and Jander, 1999; 
Williams et al., 2001). Their unique location at entry points to the CNS (vascular spaces) makes them 
attractive targets as an in situ APC. 
Dendritic cells have not yet been shown to play a major role in CNS immunity (Matyszak and 
Perry, 1996), especially in regard to viral infections, although they have been shown to enter the 
cerebrospinal fluid (CSF) in response to bacterial infections (Matyszak and Perry, 1996; Pashenkov et al., 
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2002; Ponomarev et al., 2005b) and may penetrate the CNS during inflammation, independently of T cells 
(Reichmann et al., 2002). These studies may be questionable due to the difficulty in differentiating 
between activated microglia and dendritic cells based on the expression of cell surface antigens. 
Identification of the true APC in CNS infections is therefore a controversial area given the conflicting data 
for DCs and/or microglia as APCs. 
Leukocyte extravasation into the CNS 
T cells, DCs, granulocytes, and macrophages are recruited to the CNS during active infections (Bi 
et al., 1995a; Glabinski and Ransohoff, 1999; Persidsky, 1999; Rubin and Staddon, 1999). Although the 
precise mechanisms by which cells extravasate through the vascular endothelium and enter the CNS are not 
fully understood, several intracellular adhesion molecules (ICAMs) such as CD1 la (LFA-1), CD1 lb (Mac-
1) and CD49d (VLA-4) seem to play a role in homing to and penetration of the BBB (Persidsky, 1999). 
CD49d seems to be required for BBB penetration in some studies (Glabinski and Ransohoff, 1999). 
Notably, these antigens are all upregulated on activated lymphocytes. 
Additionally, the loss of BBB integrity during VSV encephalitis may play a role in leukocyte 
infiltration into the inflamed CNS. The normal BBB is composed of tight junctions between endothelial 
cells surrounded by a basement membrane and flanked by pericytes and astrocytic end feet (Miller, 1999). 
Astrocyte degradation and BBB failure is proposed to be contingent on large numbers of T cells infiltrating 
the CNS in (Bechmann et al., 2007). Critical to maintaining these tight junctions are three classes of 
proteins: the cadherins, selectins, and integrins. In the resting CNS, integrins are expressed at relatively 
low levels, which increase markedly in response to inflammation (Miller, 1999) and bind with ICAMs to 
promote leukocyte adhesion, a first step in CNS penetrance. Cytokines and chemokines have been shown to 
cross the BBB and may impact BBB integrity (Rubin and Staddon, 1999). Research has implicated a 
crucial role for nitric oxide and IL-12 in the breakdown of the BBB (Komatsu et al., 1999). Other 
cytokines, such as IL-ip, IFN-y, CXC, and TNF-a, have also been correlated with weakening of the BBB 
(Pardridge, 1999). Further degradation of the BBB may be accomplished \vrtfi"matrix metalloproteinases 
(MMPs), which can degrade the basement membrane (particularly MMP-3 and MMPs-2 and -9, the type 
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IV collagenases) and may actively participate in inflammation by interacting with E-cadherin, IL-1J3, pro-
TNFa, and osteopontin to recruit leukocytes (Agnihotri et al., 2001; Gearing et al., 1995; Noe et al, 2001). 
Many of these inflammatory mediators are produced by monocytic cells. Perhaps not surprisingly, 
microglia have also been shown to produce these critical cytokines and MMPs (Kawanokuchi et al., 2006; 
Suzuki et al., 2005; Walker et al., 2006; Wang and Suzuki, 2007), although their contribution during acute 
viral encephalitis has not been established. 
Mechanisms of viral clearance 
Macrophages are phagocytic, and in many models they mediate viral clearance. Our previous 
studies in the peripheral immune system indicate that they play a key role in clearance of VSV in 
immunocompetent mice (Ciavarra et al., 2006). In contrast, most acute viral infections of the CNS appear 
to be cleared by IFN-y dependent action of T cells, in particular, CD8+ CTL (reviewed in (Griffin, 2003)). 
In the CNS, interferon y (IFN-y) has been shown to inhibit viral replication and in some models is required 
for viral clearance (Komatsu et al, 1996; Parra et al., 1999). Furthermore, in vitro studies have shown that 
IFN-y can inhibit VSV replication (Binder and Griffin, 2001; Chesler and Reiss, 2002; Komatsu et al, 
1996; Komatsu et al, 1999). Not surprisingly, microglia have been shown to produce IFN-y (Kawanokuchi 
et al , 2006; Parra et al , 1999; Shaked et al., 2005; Wang and Suzuki, 2007) under a wide variety of 
conditions. IL-12 and TNF-a have also been shown to play key roles in mediating viral clearance in both 
in vitro and in vivo models (Chesler and Reiss, 2002; Komatsu et al., 1997; Komatsu et al., 1996; Komatsu 
et al., 1999; Lauterbach et al., 2006; Parra et al., 1999; Patterson et al., 2002), and again, these cytokines 
have been shown to be produced by microglia. Therefore, microglia may also play a key role in mediating 
viral clearance from the infected CNS. 
Current model of antiviral immunity in the CNS 
Cumulatively, the current model for viral clearance from the CNS indicates that DCs encounter 
antigen (either from the CNS or from the nasal mucosa) and migrate to the draining cervical lymph nodes. 
Here, they activate naive T cells, particularly CD8+ CTL. These cells appear to first migrate to the 
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perivascular spaces, where they require secondary stimulation by perivascular-resident APCs (Bechmann et 
al., 2007). Following this stimulation, BBB integrity declines (due to viral pathogenesis, contact-mediated 
or cytokine-mediated disruption), these lymphocytes migrate into the brain parenchyma (Bechmann et al, 
2007), where they mediate viral clearance in an IFN-y dependent manner. To evaluate this model, we 
intranasally infected mice with vesicular stomatitis virus (VSV) in order to produce viral infection of the 
brain. We next depleted mice of several critical cell populations to assess their contribution to antiviral 




The primary objective of this research was to develop a model for the primary immune response to 
acute viral infections of the central nervous system (CNS). This model must address the critical facets of 
the immune response: antigen presentation and lymphocyte activation, leukocyte migration and 
extravasation into the brain, and viral clearance. Several target cell populations exist that may be critical to 
mediating CNS immunity, including dendritic cells, microglia, macrophages, and antigen-specific 
lymphocytes. Therefore, we employed several depletion strategies to target each of these cell populations 
and clarify their relative contribution to antiviral immunity of the CNS. Concurrently, we assayed various 
cytokines and chemokines known to affect the course and development of antiviral immunity. For this 
model, we induced acute viral infection of the brain via intranasal application of vesicular stomatitis virus. 
VS V is a simple, well-characterised rhabdovirus that is rapidly cleared from the CNS of immunocompetent 
mice but replicates in immunocompromised mice, leading to morbidity and mortality. 
Specific Aim 1: Characterisation of the inflammatory response in the CNS. 
Several models of viral infection of the CNS exist, but very few address acute cytolytic (rather 
than persistent or lysogenic) viral infections. Our model of acute infection with VSV has previously been 
documented for particular strains of mice (Balb/c and C57BL/6). However, the exact cell types involved in 
the primary response may be dependent on multiple factors, including mouse strain, gender, and viral 
dosage. Thus, it is critical to first characterise the normal cellular and molecular immune response in our 
mice (Balb/c x C57BL/6 offspring, henceforth referred to as CB6F1). These experiments are discovery-
driven rather than hypothesis-driven; however, we predict that the cellular and chemokine/cytokine 
responses should agree with published data. We will pay particular attention to microglia throughout these 
studies; because they are phenotypically similar to both DCs and macrophages, their role in antiviral 
immunity in the CNS is unclear and they may be inhibited or depleted by the techniques that follow. These 
17 
studies will provide a basis for identifying dysregulated immune responses, either cellular or molecular, in 
subsequent studies. 
Specific Aim 2: Assess the role of dendritic cells in the inflammatory response of the CNS 
Our previous studies demonstrated that one-third of dendritic cell-depleted mice develop persistent 
brain infections following peripheral infection. These observations led directly to our interest in dendritic 
cells (DCs) as key regulators of the antiviral immune response of the CNS. Our data imply a novel role for 
DCs in controlling CNS infections. To date, DCs have not been shown to be involved in mediating viral 
clearance in the CNS. Their primary role in an immune response, whether peripheral or in the CNS, is 
antigen presentation to naive lymphocytes. Therefore, we hypothesise that circulating peripheral DCs 
serve as the primary antigen-presenting cell (APC) for the CNS. To test this hypothesis, we will 
selectively deplete mice of DCs using a transgenic mouse strain whose DCs are susceptible to diphtheria 
toxin and intranasally infect depleted mice with VSV to induce CNS inflammation. If the hypothesis is 
correct, we predict that loss of DCs will impair lymphocyte activation and subsequent infiltration into the 
brain without disruption of nonspecific cell types such as macrophages and granulocytes. Because 
lymphocytes appear to be the crucial mediators of viral clearance in the CNS, we can extend this 
hypothesis such that loss of DCs, and subsequent loss of lymphocytes, will result in impaired viral 
clearance within the CNS, leading to increased morbidity and mortality. We will concurrently observe 
the various leukocyte subsets (including microglia) and cytokine/chemokine production for loss of function 
relative to immunocompetent mice as revealed by Aim 1. Within this context, we should be able to explain 
the mechanistic failure underlying our previous observations of increased morbidity and mortality in our 
peripheral studies (a secondary objective of these studies). 
Specific Aim 3: Assess the role of macrophages in the inflammatory response of the CNS. 
Our previous results in peripheral models of VSV infection and macrophage depletion provided 
strong evidence that macrophages were direct mediators of viral clearance. There is also ample evidence 
from other models that macrophages can and do serve as functional APCs. Two significant pools of 
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macrophages exist: circulating macrophages and the brain-resident perivascular macrophages. Therefore, 
we propose two alternative hypotheses to those presented in Aim 2: first, that macrophages (either 
peripheral or CNS-resident) serve as functional APCs; and second, that macrophages directly 
mediate viral clearance in the CNS. To test these hypotheses, several depletion strategies will be 
employed to selectively target either circulating macrophages for depletion (MAFIA transgenic mice and 
intravenous administration of clodronate-bearing liposomes) or perivascular macrophages 
(intracerebroventricular administration of clodronate-bearing liposomes). If macrophages serve as 
functional APCs, then we predict that lymphocyte activation and infiltration into the CNS would be normal 
despite the loss of DCs in Aim 2, and impaired in macrophage-depleted mice. Macrophage-depleted mice 
should therefore also exhibit increased morbidity and mortality due to loss of antiviral lymphocytes. If the 
role of macrophages is strictly limited to viral clearance, we would predict normal clearance in mice 
depleted of DCs (Aim 2) with corresponding health of mice, whereas macrophage-depleted mice should 
exhibit increased pathogenesis, morbidity, and mortality. Again, we will monitor the various leukocyte 
subsets (including microglia) and cytokine/chemokine production for loss of function relative to 





MAFIA transgenic mice 
A transgenic mouse line (MAFIA, macrophage Fas-induced apoptosis, strain C57BL/6J-Tg 
(Csflr-EGFP-NGFR/FKBP1A/TNFRSF6) 2Bck/J, Jackson Laboratories, Bar Harbor, ME (Burnett et al., 
2004) was used for macrophage depletion studies. These mice constitutively co-express enhanced green 
fluorescent protein (EGFP) and a fas-mediated suicide gene under the control of a macrophage-specific 
promoter for c-ftns (gene for colony-stimulating factor 1 receptor, CSFR1). Intravenous injection with AP 
20187 dimeriser (Ariad Pharmaceuticals, Cambridge, MA) cross-links the transgenic, cytoplasmic fas 
proteins induces apoptosis and ultimately results in the peripheral depletion of macrophages. Breeding 
mice were obtained from Jackson Laboratories and maintained in the mouse colony at EVMS. MAFIA 
mice were bred in the animal facility using MAFIA x MAFIA crosses, as recent communications with 
Jackson Laboratories and Sandra Burnett (Brigham Young University, Provo, UT) indicated problems with 
MAFIA x WT crosses. To phenotype MAFIA mice, a drop of blood was obtained by a tail prick with a 
sterile lancet dipped in heparin, collected from the tail with a sterile, heparin-lined 200 uL pipette tip, and 
transferred to a sterile, heparin-lined microcentrifuge tube. Blood samples were then suspended in 200 uL 
flow cytometry wash buffer, and examined for EGFP expression by flow cytometry. Male or female mice 
were used for experiments at 6-8 weeks of age. Non-transgenic progeny were used as controls. 
Experimental conditions for these mice required intravenous injection of the AP20187 (Ariad 
Pharmaceuticals, Inc., Cambridge, MA) dimeriser at a dose of 20 mg/kg. These injections were 
administered via the lateral tail vein after heating the tail to dilate the vein for approximately one minute 
and swabbing the injection site with a 70% isopropyl alcohol pad (BD Biosciences, San Diego, CA). 
Alternatively, injections were administered via the retro-orbital venous sinus under 2% isoflurane 
anaesthesia in accordance with EVMS IACUC approved protocol #06-016. Mice were euthanized by C02 
asphyxiation. 
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CDllc/DTR transgenic mice 
Breeding mice were obtained from Jackson Laboratories (strain C.FVB-Tg(Itgax-
DTR/EGFP)57Lan/J). Male CD1 lc/DTR mice were bred with female C57BL/6 mice (Jackson Laboratory) 
to obtain CB6F1/DTR progeny that expressed H-2d/b haplotype MHC I (H-2b is required for antigen-
specific tetramer studies). These mice express the simian diphtheria toxin receptor (DTR) fused with green 
fluorescence protein (GFP) under the control of the CD1 lc promoter. Expression of CD1 lc is most highly 
expressed in the dendritic cell populations in mice (Jung et al., 2002). Although CD1 lc is expressed at 
significantly lower levels on other cell types (activated T cells, microglia, monocyte/macrophage 
populations), this is primarily noted during active infections and not typical of resting conditions. The 
simian DTR has a higher affinity for DT than the endogenous murine receptor. Therefore, DC can be 
selectively depleted in these mice by the administration of DT (Jung et al, 2002). 
Genotyping of the mice was performed at 10-14 days of age. The tails of pups were anaesthetised 
with ice, and then the distal 0.5-1 cm of the tail was quickly amputated using a sterile razor blade. Pressure 
was applied to the tail until bleeding stopped and pups were hand-warmed to prevent hypothermia. Tail 
sections were halved and stored in sterile microcentrifuge tubes. Tail sections were subsequently minced 
and suspended in 250 uL QuickExtract solution (Epicentre Biotechnologies, Madison, WI), vortexed for 15 
seconds, heated at 65°C for 6 minutes, vortexed again for 15 s, and heated at 98°C for 2 minutes. DNA 
was diluted at a 1:8 ratio, and quantitation was performed by spectrophotometry at 260 and 280nm. The 
DNA concentration was calculated and 40-80ng DNA was used in subsequent PCR reactions. Mice were 
genotyped for transgene expression by multiplex PCR reactions using established primers for DTR (DTR1, 
forward 5' GGG ACC ATG AAG CTG CTG CCG 3'; DTR2, reverse, 5' TCA GTG GGA ATT AGT CAT 
GCC 3') (Jung et al , 2002). Control reactions were performed using primers for the TCR-5 chain (TCRdl, 
forward 5' CAA ATG TTG CTT GTC TGG TG 3', TCRd2, reverse 5' GTC AGT CGA GTG CAC AGT 
TT 3'). Primer pairs were purchased from Integrated DNA Technologies, Coraville, IA. PCR reactions 
were performed with 3.66 uL nuclease-free water, 1.2 uL 10X PE Buffer II, 0.96 uL 25 mM MgCl2, 0.96 
uL 2.5 mM dNTP, 0.45uL each 20uM DTR1 and DTR2 primers, 0.3 uL each 20 uM TCRdl and TCRd2 
primers, 0.15 U/uL Taq polymerase, and 40-80ng DNA. PCR amplification was performed with an 
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initialisation step of 94°C for 3 minutes followed by 35 cycles as follows: denaturation, 94°C, 30 s; 
annealing, 62°C, 60 s; elongation, 72°C, 30 s. A final elongation step at 72°C for 2 minutes ended the PCR 
reaction. Products were held at 4°C overnight. PCR fragments were resolved on a 1% agarose gel at 100 
V for approximately 40 minutes with IX GelStar nucleic acid stain (Lonza Rockland, Inc., Rockland, ME). 
Bands at 600 bp indicated the presence of the DTR transgene; bands at 200 bp were indicative of the 
internal TCR-8 control. Mice lacking the transgene were used as non-DTRTg, wild type controls. Male 
and female adult mice ages 6-8 weeks were used for all experiments. 
Experimental conditions for these mice required intraperitoneal injections of diphtheria toxin 
(DT). Each lot of diphtheria toxin (Sigma, St. Louis, MO) was titrated to give optimal depletion of DC 
while maintaining the health and safety of the animals. Mice were weighed immediately prior to injections 
of DT and the determined dose administered per gram body weight. DT was administered one day before 
and after viral infections in accordance with EVMS IACUC approved protocol #06-016. Mice were 
euthanized by C02 asphyxiation. 
N15TCRTgMice 
N15 TCR Tg RAG-2"'" H-2b mice (Rag2tml TgN (N15)) were obtained from Taconic (Taconic 
Farms Inc., Germantown, NY) in cooperation with and courtesy of Dr. Ellis L. Reinherz (Harvard Medical 
School, Boston, MA) and maintained in sterile microisolators. The transgenic a and (3 TCR chains on 
MHC I+ (CD8+) T cells are specific for the VSV nucleoprotein octapeptide N52.59 specific (Ghendler et al., 
1997). Thus, virtually all CD8+ T cells in this mouse strain are specific for the immunodominant epitope of 
VSV. Gloves were washed with 70% ethanol prior to handling each cage of mice, and all animal 
manipulations were performed in a biosafety hood. Mice were bred in-house as N15 x N15 crosses. 
Mouse phenotype was confirmed by multicolour flow cytometry performed on a drop of blood obtained 
from the lateral tail vein (as described for MAFIA mice) and staining with FITC-a-TCR-VP (specific for 
the transgenic TCR type), PE-a-CD45R (B220), and PE-Cy7-a-CD8a, as recommended by by Dr. 
Reinherz. All antibodies were purchased from eBioscience. Mice were determined to have a 
predominantly CD8+TCR-Vp+ phenotype and were lacking in CD4+ cells and CD45R+ cells. Mice were 
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used in accordance with EVMS IACUC approved protocol #06-016 and were euthanized by C02 
asphyxiation. 
Clodronate Liposomes 
Preparations of liposome encapsulated dichloromethylene bisphosphonate (clodronate, CL2MDP) 
were a kind gift of Roche Diagnotics GmbH, Mannheim, Germany and were injected intravenously into 
mice at 200 uL/mouse via the retro-orbital venous sinus under 2% isoflurane anaesthesia in accordance 
with EVMS IACUC approved protocol #06-016. 
MGBG 
Methylglyoxal bis(guanylhydrazone) (MGBG) was provided as a gift from Pathologica, LLC (San 
Francisco, CA) in collaboration with Dr. Michael McGrath and Dr. Jeremy Blitzer. MGBG was diluted in 
PBS and administered intraperitoneally to mice at a dosage of 15 mg/kg three times weekly beginning 24 
hours prior to infection. It should be noted that the supply of MGBG was sufficient for only a single 
experiment, and IACUC approval covered only one pilot study to assess the efficacy of this depletion 
technique. 
Surgical Treatment of Mice 
Mice were initially induced to a surgical plane of anaesthesia under 5% isoflurane. For retro-
orbital injections, mice were removed from anaesthesia and injected via the retro-orbital venous sinus as 
previously described. Because these injections required only a few seconds to administer, mice did not 
require additional anaesthesia beyond induction and recovered rapidly. 
For intracerebroventricular injections of CL2MDP, mice were given children's ibuprofen in 
drinking water (100 mg/L) ad libitum 3 days before and after surgery. Mice were monitored twice daily for 
3 days following surgery. All surgical procedures were performed in collaboration with Dr. Larry Sanford 
(EVMS) by Dr. Laurie Wellman and Dr. Xianling Liu. Following induction, mice were weighed and the 
surgical site prepared by shaving, swabbing with betadine, and finally swabbing with 70% ethanol. Mice 
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given subcutaneous injections of potassium penicillin (100 IU/g body weight, 100 uL) and gentamicin 
(0.005 mg/g body weight, 100 uL) prior to surgery, then placed in a stereotaxic frame. An incision was 
made along the coronal suture and the scalp was retracted. The position of the left lateral ventricle was 
determined relative to the bregma with stereotaxic coordinates as follows: AP (anterior-posterior) -0.5 mm, 
ML (medial-lateral) -1.0 mm, and DV (dorsal-ventral) -2.0mm. A small hole was drilled into the skull and 
CL2MDP was infused at a rate of 0.67 uL/min for 12 min (8 uL per mouse). The skull was filled with 
bone wax and the scalp sutured. Mice were allowed to recover and were monitored every 15 minutes for 
the first 3 hours post-operative, then twice daily for the next 3 days. All surgeries were performed in 
accordance with EVMS approved IACUC protocol #05-017. 
Vesicular Stomatitis Virus (VSV) 
Wildtype vesicular stomatitis virus (VSV, Indiana serovar) was provided by Dr. Philip Marcus, 
University of Connecticut, and was grown and assayed in confluent monolayers of Vera cells and virus 
titers determined by standard plaque assays (Marvaldi et al., 1977; Sekellick and Marcus, 1979). For 
peripheral infections, mice were infected with VSV by a single i.p. injection of 2x10 PFU. For infections 
of the CNS, dosages of virus varied based on mouse strain and gender: female mice on the C57BL/6 
background received 2xl06 PFU intranasally (i.n.) in a 20 uL volume, while female Balb/c or CB6F1 mice 
received 2xl05 PFU i.n in a 10 uL volume. Male mice received a lower dose (25% of the dose given to 
female mice) of 5xl05 or 5xl04 PFU for C57BL/6 or Balb/c and CB6F1 mice, respectively, in a 10 uL 
volume. These dosages yielded similar morbidity across all strains and genders. 
During these studies, changes in animal husbandry protocols resulted in abnormal responses to our 
typical virus infection models. Specifically, protocols changed to require ventilation fans in the animal 
cage transfer workstations to be continuously on. Animals that were born before this change in protocol 
subsequently exhibited enlarged lymph nodes despite a lack of viral infection and were not used for these 
experiments. However, animals born after this protocol change showed increased resistance to VSV 
infection. A twofold higher dose of virus was required to induce similar levels of morbidity and leukocyte 
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infiltrate into the CNS of infected animals. Additional alterations in the immune response, if any, were not 
detectable in our models. Viral doses used for each experiment are noted in the figure legends. 
Organ and Tissue Harvest 
Whole blood was isolated from C02 euthanized mice by cardiac puncture with a 28 Vi gauge 
insulin syringe that was lined with heparin to prevent clotting. Blood was collected into heparin-lined 1.2 
mL microcentrifuge tubes. For collection of plasma, blood samples were centrifuged and the supernatant 
drawn off and stored in 600 uL microcentrifuge tubes at -80°C. For experiments using whole blood in flow 
cytometry, 200 uL whole blood was aliquotted per flow cytometry tube and lysed with IX PharmLyse 
buffer (BD Biosciences, San Diego, CA) to lyse red blood cells. Flow cytometry staining was performed in 
the PharmLyse buffer for these experiments. 
Peritoneal exudate cells (PEC) were obtained by lavage of the peritoneal cavity with 10-20 mL 
PBS. PEC were filtered through 0.4um nylon mesh cell strainers and centrifuged at 280 xg for 8 minutes. 
Spleens were harvested from mice and ground through a 0.4um nylon mesh cell strainer with a 
glass pestle until remaining connective tissue was white and gelatinous in appearance. Cell suspensions 
were filtered through a second nylon mesh filter and centrifuged at 280 xg for 8 minutes to pellet cells. 
Cells were resuspended in IX PharmLyse buffer at a density of 1 mL/spleen and incubated at room 
temperature for approximately 10 minutes. Cells were again centrifuged at 280 xg for 8 minutes. For 
experiments requiring enrichment of dendritic cells, spleens were removed from mice and injected with 
400U/mL collagenase D (Sigma, St. Louis, MO), then minced and incubated in lOOU/mL collagenase D for 
30 minutes at 37°C. Digested tissue was filtered through 0.4um nylon mesh cell strainers and centrifuged 
at 280 xg for 8 minutes to pellet cells. Red blood cells were lysed as described above. 
Lungs were removed from mice and digested with either collagenase D as described for spleens, 
or minced and digested with tumour digestion solution (1 mg/mL collagenase I, 0.1 mg/mL DNAse I, and 
2.5 U/mL hyaluronidase, Sigma, St. Louis, MO) in 10 mM HEPES buffer supplemented with 142 mM 
sodium chloride, 0.67mM potassium chloride, and 0.67 mM calcium chloride. Tissue was scrubbed through 
a nylon mesh cell strainer with a glass pestle until remaining connective tissue was white and gelatinous in 
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appearance. Cells were centrifuged and subjected to red blood cell lysis as described above. Alternatively, 
lungs were homogenised in a 5 mL glass Tenbroek homogeniser at 0.5 mL PBS/lung, followed by 
discontinuous Percoll centrifugation on a 70%-35%-0% gradient at 1200 xg for 45 minutes at 20°C. 
Bone marrow was obtained by careful dissection of both femurs from mice. Bone marrow was 
flushed from the femurs using 0.5mL RPMI via a 18 !4 gauge syringe. Cells were filtered through a 0.4 um 
nylon mesh cell strainer and red blood cells lysed as described above. 
Brains were removed by decapitation of mice. The skulls were cut along the sagittal and 
lamboidal sutures, and the skull bone carefully lifted from the brain with forceps. The brain was gently 
lifted from the posterior skull with forceps and placed in PBS. Brains were homogenised in 2 mL PBS 
with a 5 mL glass Tenbroek homogeniser using 20 strokes per brain. The homogenate was centrifuged at 
280 xg for 8 minutes and the supernatant stored for future use. Leukocytes were isolated by resuspending 
the pellet in 70% Percoll for discontinuous Percoll centrifugation on a 70%-35%-0% gradient at 1200 xg 
for 45 minutes at 20°C. 
Additional tissues that were investigated were handled similarly to the non-enzymatic preparation 
of the spleen. For some experiments, tissues were stored for future determination of viral titres at 0.1 g 
tissue/mL RPMI at -80°C. 
Tissue slices for immunohistochemistry were obtained prior to other processing and mounted in 
OCT cut face up, then flash-frozen in liquid nitrogen and stored at -80°C. For immunohistochemistry of 
brain tissue, the right atrium of a euthanized mouse was nicked, and 30 mL of 10% buffered formalin was 
slowly (approximately 1 mL/minute) perfused into the left atrium of the mouse using an 18 Vi gauge 
syringe, followed by an additional 30 mL ice-cold PBS. For some experiments requiring both flow 
cytometry and immunohistochemistry, perfusion with formalin was omitted and only PBS was used. 




Single-cell suspensions were prepared as described in Organ and Tissue Harvest. Two million 
cells were aliquotted to each flow cytometry tube. MHC class I tetramers specific for the immunodominant 
epitope VSV nucleoprotein VSV-N52-59 (NIH Tetramer Core Facility, Emory University, Atlanta, GA) were 
conjugated to allophycocyanin (APC), and were added to cells, then incubated for 30 minutes at room 
temperature. Volumes of stock fluorochrome-conjugated antibodies were calculated for optimal 
concentrations based on manufacturer's recommendations (see Appendix A: Antibodies for details) and 
diluted to 50 uL per flow cytometry tube. Antibody cocktails were added to cells and incubated for 30 
minutes at 4°C. Biotinylated antibodies were included in the antibody cocktails, and a second incubation 
was carried out with streptavidin-fluorophore conjugates (also listed in antibody table) at 4°C for 30 
minutes. Unconjugated, purified antibodies were added separately from cocktails, incubated 30 minutes at 
4°C, and followed with an anti-host biotinylated antibody (also separate from cocktail) for 30 minutes at 
4°C, and finally incubated for 30 minutes at 4°C with streptavidin-fluorophore. Washes were performed 
between each incubation step by diluting the cell-antibody cocktail solution with 2 mL flow cytometry 
wash buffer (PBS +1% goat serum and 0.1% sodium azide) and centrifugation for 8 minutes at 
approximately 300 xg. Following all incubations, three washes were performed prior to resuspension in 
200 uL flow cytometry wash buffer for data acquisition. In some instances, cells were resuspended in 1% 
paraformaldehyde in PBS and stored at 4°C for later acquisition; these samples were subsequently washed 
3 times in flow cytometry wash buffer and resuspended in 200 uL flow cytometry wash buffer prior to 
acquisition. 
Instrument compensation was performed by preparing experimental samples with a single 
fluorophore-conjugated antibody per tube (typically, the most highly expressed marker was chosen) and 
adjusting instrument settings to yield optimal acquisition conditions. 
Determination of Viral Titres (PFU Assay) 
Vero cells were cultured and grown to confluence in complete tissue culture media (RPMI 
supplemented with 10% FBS, 1% penicillin-streptomycin, 1% amphotericin-B, and 1% L-glutamine 
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(Cellgro Mediatech, Manassas, VA) at 37°C and 5% C02 and passaged every 2-3 days at a 1:3 dilution 
following dissociation with Trypsin-EDTA (Cellgro Mediatech) and gentle agitation. Tissues stored for 
determination of viral titre by plaque-forming unit (PFU) assay were thawed in a 37°C water bath, then 
subjected to 3 rapid freeze-thaw cycles using dry ice and a 37°C water bath to release virus. Serial tenfold 
dilutions were prepared from the supernatants of the frozen/thawed tissues and VSV stock. Each well of 
the 6-well tissue culture plates was coated with 200 uL attachment solution (RPMI supplemented with 6% 
FBS and 15 ug/mL diethylaminoethyl (DEAE) dextran) followed by 100 uL tissue supernatant or VSV. 
Plates were tilted gently to coat wells evenly, and incubated for 1 hour at 37°C and 5% C02 with gentle 
tilting every 15 minutes to ensure even distribution of virus. Wells were then covered with 1.6% agarose in 
DMEM supplemented with 6% FBS (final concentrations) and incubated at 37°C/5% C02 for 48-72 hours 
until plaques appeared in the Vero monolayer. Wells were stained with 2 mL 0.01% neutral red in PBS 
(pH 7.0; prepared from stock 0.1% at pH 6.0, pH adjusted with monobasic sodium phosphate) for 2 hours 
at 37°C. Neutral red stain was removed by pipette and 6-well plates were incubated an additional 2 hours 
at 37°C prior to counting plaques (unstained areas). 
ELISPOT Assay 
Single-cell suspensions of splenocytes or brain cells were prepared as described above. Assays 
were performed according to a BD Biosciences protocol (Ernst et al., 2006). ELISPOT plates (Millipore 
Multiscreen HTS, Millipore, Billerica, MA) were pre-wet with 15 uL 70% ethanol and rinsed with PBS. 
Purified capture antibodies (IL-2, IL-4, IFN-y; see Appendix A for details) were diluted to 2 ug/mL in PBS 
and plated at 100 uL/well overnight at 4°C. Plates were washed with ELISPOT wash buffer (PBS+10% 
goat serum and 0.05% Tween-20, Sigma) three times (200 uL/well), then blocked with complete tissue 
culture media for two hours at room temperature. Cells were typically plated at l-2xl06 cells/well in a 100 
uL volume in the absence of exogenous antigen or stimulation and incubated overnight at 37°C and 5% 
C02. The following day, plates were washed once with deionised water followed by three washes with 
ELISPOT wash buffer. Biotinylated detection antibodies were diluted to 2 ug/mL in blocking buffer 
(PBS+10% FBS) and incubated two hours at room temperature. Plates were washed three times with 
28 
ELISPOT wash buffer and then incubated with streptavidin-horseradish peroxidase (Sigma) for one hour at 
room temperature. Plates were washed four times with ELISPOT wash buffer and two to four times with 
PBS to remove traces of Tween-20. ELISPOTS were developed with 3-amino-9-ethyl carbazole (AEC, 
Sigma) prepared by dissolving 20 mg in 1 mL N,N-dimethylformamide. The final working solution was 
prepared by diluting 333 uL of the AEC solution in 10 mL of 0.1 M sodium acetate and 5 uL 30% H202. 
ELISPOT plates were monitored for development (approximately 10 minutes) and the reaction halted by 
rinsing with excess deionised water. ELISPOT plates dried overnight and were manually counted under a 
dissecting microscope the following day. 
ELISA Assay 
Supernatants from brain homogenates were prepared and stored at -80°C as previously described. 
GM-CSF ELISA assays were conducted according to eBioscience protocols (eBioscience, 2009). 
Secondary lymphoid chemokine (SLC, CCL21) ELISA assays were performed according to the 
manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN). Both protocols were similar. Corning 
EIA/RJA high-binding microplate wells (Corning Inc., Lowell, MA) were coated with capture antibody 
prepared in PBS (GM-CSF, 2 ug/mL, eBioscience; SLC, 4 ug/mL, R&D Systems) overnight at 4°C 
(eBioscience) or room temperature (R&D Systems). Plates were washed with ELISPOT wash buffer three 
times, then blocked with ELISA diluent (1% BSA in PBS) for 1 hour. Plates were again washed three 
times and samples (1:3 dilutions) and standards (8 pg/mL-1000 pg/mL, serial twofold dilutions) prepared in 
ELISA diluent were added to wells for two hours at room temperature. Plates were washed three to five 
times and detection antibody prepared in ELISA diluent (GM-CSF, 2 ug/mL; SLC, 50 ng/mL) was added 
to wells, then incubated one to two hours at room temperature (GM-CSF or SLC, respectively). Plates 
were washed and streptavidin-HRP (Sigma, 1 ug/mL or R&D Systems) was added to wells and incubated 
for 20-30 minutes at room temperature. Plates were washed five times and tetramethylbenzidine (TMB) 
substrate solution (Sigma) was added. Colour development was carefully monitored and the reaction was 
halted after 20-30 minutes by the addition of 2N H2SO4. Absorbance of the solution was determined at 
29 
450nm on a microplate spectrophotometer. A standard curve was plotted and the concentrations of 
experimental samples calculated in Microsoft Excel. 
Protein Cytokine Array 
The RayBio Mouse Cytokine Antibody Array C Series 1000 (Ray Biotech, Norcross, GA, 
Catalogue #AAM-CYT-1000) was used to assess the production of a panel of 96 cytokines in brain tissue. 
The assay was performed according to manufacturer's instructions with minor modifications for use with 
the Li-Cor Odyssey infrared detection system (Li-Cor, Lincoln, NE) (2006). Tissue samples from mouse 
brains were flash-frozen in liquid nitrogen and stored at -80°C for future use. Brain tissues were thawed, 
blotted dry on a Kimwipe, and 100 mg tissue was weighed. Tissue samples were homogenised in IX cell 
lysis buffer (kit component, Ray Biotech, Norcross, GA) supplemented with EDTA-free Protease Inhibitor 
Cocktail III (Calbiochem, San Diego, CA, Catalogue #539134) for 20 strokes. Homogenate was then 
centrifuged at 10,000 xg for 5 min and the supernatant retained for use. 
The protein concentration in the supernatant was determined using the Pierce BCA Protein Assay 
(Pierce Biotechnology, Rockford, IL, Catalogue #23227) according to manufacturer's protocols. Standards 
of bovine serum albumin (BSA) were prepared as described in Table 1 using cell lysis buffer and Protease 
Inhibitor Cocktail III as the diluent. Dilutions of samples were prepared at 1:2 and 1:10 ratios with the 
protease-supplemented cell lysis buffer as diluent. Standards and samples were aliquotted in triplicate to 
wells of a 96-well flat-bottomed plate at 25 uL/well. BCA working reagent was prepared as a 50:1 dilution 
of BCA Reagent A:BCA Reagent B (kit components, Pierce Biotechnology). Working reagent was added 
to wells (200 uL/well), the plate shaken for 30 seconds, then placed in an incubator at 37°C for 30 min. 
The plate was allowed to return to room temperature and the absorbance of each well was determined at 
570 nm. The absorbance of triplicate wells was averaged, and a standard curve plotted based on the BCA 
standards. The protein concentration of the samples was calculated based on this curve and the 
concentration of stock protein sample solutions was adjusted to yield a concentration of 250 ug/mL with 
Li-Cor Odyssey blocking buffer (Li-Cor, Lincoln, NE, Catalogue #927-40000) supplemented with 0.01% 
Tween-20 (henceforth referred to as Li-Cor blocking buffer, Sigma). 
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Volume & Source of BSA 
300 uL of Stock 
375 uL of Stock 
325 uL of Stock 
125 uLof B dilution 
125 uL of C dilution 
325 uL of E dilution 
325 uL of F dilution 
325 uL of G dilution 
OuL 










Ray Biotech protein array membranes 3 and 4 were incubated with Li-Cor blocking buffer for 30 
minutes at room temperature to block nonspecific binding. From this point forward, all incubations and 
washes were performed on a shaking platform. Li-Cor blocking buffer was decanted, and membranes were 
incubated with 1 mL of the 250 ug/mL protein samples for two hours at room temperature. Membranes 
were then washed three times with 2 mL of IX Wash Buffer I (kit component, Ray Biotech) for 5 
min/wash at room temperature followed by two washes (also 5 min/wash) with IX Wash Buffer II (kit 
component, Ray Biotech) for 5 min at room temperature. Membranes 3 and 4 were separated and 
incubated with 1 mL appropriate biotinylated antibodies (prepared by reconstituting kit provided antibodies 
with 100 uL Li-Cor blocking buffer followed by further dilution with 2 mL Li-Cor blocking buffer) 
overnight at 4°C. The next day, membranes were washed as previously described. The Li-Cor IRDye 
800CW-streptavidin (Li-Cor, Catalogue #926-32230) was prepared at a 1:1000 dilution in Li-Cor blocking 
buffer with a final concentration of 1 ug/mL. Membranes were incubated with 2 mL of the IR-streptavidin 
conjugate for 2 hours at room temperature. Finally, the membranes were washed four times with IX Wash 
Buffer I and twice with IX Wash Buffer II for 30 minutes/wash. Membranes were scanned on the Li-Cor 
Odyssey Imaging System. 
Fluorescence intensity of the protein array membranes was quantified using the Li-Cor Odyssey 
software (Li-Cor, version 2.1). A 3-pixel region was defined around each spot and this region used for 
background correction. The average intensity of duplicate spots was calculated. Due to extremely high 
signal intensity, positive control wells may have auto-quenched and thus appear dark. These wells would 
typically be used to normalise signals across groups for a particular membrane. Thus, pairwise 
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comparisons of all cytokines were made to identify pairs of spots with consistent ratios of fluorescence 
across the sets of membranes as recommended by RayBiotech. The standard deviation of each ratio was 
calculated and used to identify spots with the most consistent ratios. Cytokine spots with differences in the 
standard deviation of 0.01 were determined to be the most consistent. Four cytokines (two pairs) were 
identified per membrane that met this criterion, and signal intensities were normalised to each of these 
cytokines. The normalised intensities were then averaged and compared across treatment groups. 
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CHAPTER IV 
CHARACTERISATION OF THE INFLAMMATORY RESPONSE IN 
THE CENTRAL NERVOUS SYSTEM 
Introduction 
This chapter focuses on the initial characterisation of the primary immune response to viral 
(vesicular stomatitis virus, VSV) challenge in the central nervous system. Although this system has 
previously been investigated by Reiss et al. (Barna et al., 1996; Bi et al., 1995a; Huneycutt et al., 1994; 
Ireland and Reiss, 2006; Komatsu et al., 1999; Plakhov et al., 1995), their studies were conducted in Balb/c 
mice. Differences in the immune response for different genders and strains of mice have been reported 
(Barna et al., 1996; Forger et al., 1991). Our studies were conducted in the CB6F1 mouse strain (Balb/c x 
C57BL/6). This strain allowed us to track the antigen-specific immune response to VSV using MHC class 
I tetramers specific for the immunodominant VSV epitope (VSV-N52.59). Therefore, it was necessary to 
first characterise the cellular and cytokine immune responses to intranasal application of VSV in the 
CB6F1 mouse. In the following studies, we phenotyped the cellular infiltrate and the CNS-resident 
microglia in responding to viral challenge. These studies revealed a mixed leukocyte infiltrate in the CNS 
in response to viral infection. We further defined the kinetics for both infiltrating and resident leukocyte 
populations during the primary immune response to VSV in the CNS. Finally, we characterised the protein 
cytokine environment found during acute viral infection. These studies revealed a complex leukocyte and 
cytokine response to viral infection in the CNS. 
VSV encephalitis is characterized by a prominent mixed cellular infiltrate. 
Previous studies with intranasal applications of VSV indicated that kinetics and morbidity varied 
with mouse strain and gender. Therefore, our first experiments focused on identifying the peak of 
inflammation in the CB6F1 mouse strain. CB6F1 mice were infected with VSV and monitored for signs of 
illness. Mice became ill approximately 8 days post-infection, and brains were harvested for flow 
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cytometric analysis at this time. This time point correlated well with previously published results by Reiss 
et al. regarding kinetics of infection and loss of BBB integrity. We first phenotyped the cells recruited into 
the brain of mice following intranasal application of VSV. Microglia were gated as CD45low/lnlCDl lb+ 
cells (Fig. 2, box in panels a-b) which distinguished them from resident or infiltrating CD45h,ghCDl lb+ 
macrophages and CD45hlghCDl lb" lymphocytes. Microglia accounted for about 20% of cells recovered 
from normal, uninfected (mock-infected) mice and comprised approximately 90% of CD1 lb+ cells. Brains 
from mice infected with VSV also contained a prominent population of CD45hlghCDl lb+ myeloid cells and 
a smaller population of lymphocytes (CD45hlghCDl lb"). Microglia isolated from virus-infected, but not 
mock-infected brains, expressed MHC class II molecules suggesting an activated state (panels c-d). Mock-
infected mice contained only trace numbers of conventional (CD1 lc^PDCA-1") and pDCs (CD1 lc^DCA-
1+), CD4+ and CD8+ T cells, whereas VSV induced infiltration of conventional CD1 lc+ DCs (panels e-f), 
CD4+ and CD8+ T cells (panels g-h) but few NK cells, B cells (panels k-1) and pDCs (panels e-f). Staining 
with tetramers revealed a minor population of CDS^SV-N T cells indicating that the majority of CD8+ T 
cells did not recognize the immunodominant VSV nuclear protein determinant (panels i-j). Additional 
characterisation of the infiltrating leukocytes was performed in subsequent experiments including dendritic 
cell depletion and will be further discussed in Chapter V. 
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Fig. 2., Continued. Intranasal application of VSV induces a vigorous mixed cellular infiltrate in the brain. 
Mice were given either PBS (Mock) or intranasal VSV at 2xl05 PFU (VSV). Eight days post-infection, 
leukocytes were isolated from the brain and the infiltrate characterized by flow cytometry. Gates were 
defined for microglia based on expression of CD1 lb and CD45 (box in panels a-b) and expression of MHC 
class II evaluated (panels c-d). To characterize other infiltrating cell types, the presence of DC (panels e-f) 
and T cell subsets (panels g-h) was determined by flow cytometry. To identify VSV-N T cells, co-
expression of CDlla and tetramers were assessed on gated CD8+ cells (panels i-j). NK cells and B cells 
were identified as CD45highCD49b+ and CD45high CD45R+, respectively (panels k-1). These data are derived 
from the pooled brains of 4 mice per group. 
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Kinetics of the Inflammatory Response in the CNS 
The above study demonstrated that VSV recruited a variety of blood cells into the virus-infected 
brain corresponding to onset of morbidity in the animals. However, this study did not provide any insights 
into the kinetics of either the microglial response or the infiltrating leukocyte response. To address these 
questions, mice were inoculated with VSV for various periods of time and the number of microglia and the 
identity of infiltrating blood cells in the CNS determined by flow cytometry. It is apparent from Fig. 3A 
(panels a-c) that VSV induced an initial decrease in the number of microglia before a transient microgliosis 
became evident. This finding was reproducible in at least 3 experiments. It is possible that this decrease is 
due to altered expression of CD45 and CDllb; however, the forward scatter (FSC, size of cell) and side 
scatter (SSC, granularity of cell) profiles of brain-isolated leukocytes reveal a small (in terms of both 
quantity and size) but often distinct subpopulation of cells that is characteristically noted in the brain that 
was diminished in early VSV infection. Therefore, loss of CD45 and CD1 lb is unlikely to be the sole 
explanation for the reduced number of microglia noted. Although the infiltrate population in the naive 
mice (panel a) appears to be smaller than that seen in Fig. 2 and Fig. 9, this is reflective of a smaller 
number of events acquired by flow cytometry. This infiltrate population is quantified later (Fig. 9) and is 
quite small in terms of both percentage and absolute number despite an apparently large population visible 
in the flow cytometry density plots. Microglia expanded rapidly beginning around 5 days post-infection. 
While these studies cannot rule out the possibility that peripheral leukocytes entered the CNS and 
differentiated to a microglial-like phenotype, a corresponding increase in the FSC x SSC profile is noted. 
Therefore, it is unlikely that differentiation alone would account for this growth in the microglial 
population. Similar kinetics were observed for CD45hlgh blood cells (Fig. 3B, panel a), with an initial 
decrease of infiltrating leukocytes followed by rapid expansion beginning around 5 days post-infection. 
We also detected a gradual and sustained increase in the number of conventional CD1 lc+ DCs although 
their numbers were small relative to other myeloid and lymphoid elements in the brain (Fig. 3B, panel b). 
VSV did not induce a significant infiltrate of pDCs, NK and NKT cells at any of the time points tested (Fig. 
3B, panel e and data not shown). 
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Fig. 3. Kinetics of the inflammatory response following infection of the CNS. 
Mice were administered a single intranasal dose of VSV at the indicated times prior to euthanasia. Brains 
were excised, homogenized and the leukocyte fraction enriched by discontinuous Percoll gradient 
centrifugation. Cells were stained with the indicated mAbs and phenotyped by multiparameter flow 
cytometry. (A) Microglia isolated from mock (a) and VSV infected (b) brains were gated as 
CDllb+CD45 low/mt (box) and the absolute number of microglia calculated at each of the indicated time 
points (c). (B) A similar calculation to determine absolute numbers/brain was performed for infiltrating 
blood-derived leukocytes identified as CD45h,gh cells (d). The absolute numbers of conventional 
(CD45highCDl lc+PDCA-r) and pDCs (CD45highCDl lc+PDCA-l+) per brain were similarly determined (e). 
The values presented represent the mean ± S.E.M. cell yields from the pooled brains of 3-5 mice and 2-9 
experiments per time point. Absolute numbers were calculated based on cell recoveries in each organ and 
the percentage of microglia at each of the indicated time points. Note that the scales in Fig. 3B (panels d 
and e) are different. 
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The above results indicated that leukocytes, as a general class, reached peak infiltration around 7 
days post-infection. Dendritic cells accounted for approximately 10% of the peak leukocyte infiltrate; 
however, the fraction of cells that included antigen-specific T cells was unclear. Therefore, we next 
defined the kinetics of T cell subset infiltration into the CNS following infection with VSV. In addition, 
we assessed the specificity of infiltrating CD8+ cells using class I tetramers specific for the 
immunodominant epitope (VSV-N52-59). Fig. 4 indicates that the brain contained a small basal population 
of T cells that did not expand for several days after virus infection (panel A). CD8+ T cells began to 
infiltrate the brain on day 6, peaked on day 8 and gradually returned to basal levels on day 21-post 
infection. Similar kinetics were observed for CD4+ cells with the exception that the infiltrate was smaller 
and the kinetics were slightly delayed. Virus-specific CD8+ T cells (VSV-N) were detectable in the 
draining cervical lymph nodes (CLN) around day 3, reached maximal clonal expansion three days later and 
then their numbers rapidly diminished at a time when peak numbers appeared in the brain (panel B). Thus, 
VSV induces expansion of both CD8+ and CD4+ T cell populations including CD8+ T cells specific for the 
nuclear protein of this virus. These kinetics, defined by flow cytometric analysis, are consistent with 
immunohistochemical studies reported by Reiss and her colleagues (Bi et al., 1995b; Forger et al., 1991). 
Although the peak tetramer response in the CNS occurs at 8 days post-infection, the peak of the tetramer 
response in the CLN occurs at 6 days post-infection, a time point which also shows clear leukocyte 
infiltration in the brain (see also Fig. 9). This allowed us to observe the immune response in both the CNS 
and the putative organ of antigen presentation (CLN) simultaneously, within the same animal. Thus, this 
time point was chosen for subsequent studies. 
Phenotypic characterization of microglia isolated from cncephalitic brains. 
The presence of activated and an expanded population of VSV-N T cells in the brains of VSV-
infected mice suggests that primary antiviral immune responses may be either initiated and/or propagated 
in the CNS. If this is true, it implies that the brain possesses a professional APC capable of driving clonal 
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Fig. 4. Kinetics of T cell subset infiltration in the encephalitic brain. 
Mice were infected with VSV and at the indicated times post infection, brains were excised, pooled and 
leukocytes isolated by Percoll gradient centrifugation. Single cell suspensions of pooled cervical lymph 
nodes (CLNs) were also prepared from the same animals. Cell populations were then phenotyped by flow 
cytometry. (A) Leukocytes infiltrating the brain were stained with mAbs to either CD8 or CD4 and the 
number of each T cell subset per brain calculated based on cell recoveries and percentage of each subset. 
(B) Cells were incubated with VSV-N- specific tetramers, washed and then stained with mAb to CD8. The 
absolute number of CD8+ VSV-N T cells present in the brain and CLN was then calculated based on the 
cell recoveries in each organ and percentage of CD8+tetramer+ cells. These values represent the means ± 
SEM of 2-8 experiments with 3-5 mice per time point. 
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To examine the extent to which microglia may function as APCs, we evaluated microglial 
expression of several molecules essential for activation of naive CD8+ T cells during the early stages of the 
virus infection. As previously discussed, naive microglia of mice expressed low to intermediate levels of 
CD45 and coexpressed CD1 lb, but were CD1 lc". As previously reported, the vast majority of microglia 
from naive mice expressed undetectable to low levels of MHC class I antigens, indicating that antigen 
presentation to CD8+ T cells is not a constitutive function of these cells. However, virtually all microglia 
(96%) became class I+ by day 3 with significant (-50%) class I expression being detected as early as 48 
hours following infection (Fig. 5, panel A). Although the percentage of class I+ microglia dramatically 
increased, reduced yields of microglia during these early time points prevented a corresponding increase in 
the absolute number of microglia in the VSV-infected brain (Fig. 5B, panel a). Class I expression was 
sustained for two weeks but eventually waned to achieve mock-infected levels, correlating with CD8+ 
infiltrate (Fig. 4A). These results imply that microglia can acquire the capacity to present antigens to, and 
therefore activate, CD8+ T cells under conditions of infection. Microglia slowly upregulated class II 
antigens (Fig. 5 A, panel b) and as a result significant co-expression of these molecules was not seen until 
day 10 (Fig. 5B, panels b and c). Microglia also upregulated CD1 lc corresponding with onset of morbidity 
and increased inflammation in the brain (Fig. 5A and 4B, panel c). These results may imply improved T 
cell/microglial interactions during infection. Microglia did not upregulate CD80 or CD86 at early time 
points post-infection (data not shown), which are functionally required as costimulatory molecules to fully 
activate naive T cells. Thus, microglia may serve to propagate rather than initiate adaptive immunity. We 
did not evaluate these molecules at later time points because antigen presentation was already occurring in 
the cervical lymph nodes. Interestingly, high constitutive levels of PD-1 were detected on microglia and 
virus infection induced further expression of this molecule so that essentially all microglia were PD-1+ two 
days post-infection (Fig. 5 A and B, panel d). The physiological significance of the negative regulator PD-1 
during acute viral encephalitis is currently under investigation. 
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Fig. 5., Continued. Vesicular stomatitis virus induces the rapid activation of microglia and a delayed 
microgliosis. 
Mice were given a single intranasal instillation of VSV at the indicated times prior to euthanasia. Single 
cell suspensions of the brain were then prepared, subjected to Percoll gradient centrifugation and 
immunostained for flow cytometric analysis. (A) Microglia were defined as CD45low/imCDllb+ cells and 
expression of MHC I/II, CD lie, and PD-1 on gated microglia determined at early time points post-
infection (4 mice per time point). The numbers in each panel refer to either % positive (upper) or MFI 
(bottom). (B) Kinetics of VSV-induced upregulation of MHC class I (panel a), class II (panel b), CDllc 
(panel c), or PD-1 (panel d) molecules expressed either as a percentage of total leukocytes per brain or 
absolute number of microglia per brain (calculated from cell recoveries in each organ). The values in panel 
B represent the mean ± SEM of 2-7 experiments using the pooled brains of 3-5 mice at each time point. 
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Cytokine Production in Response to Viral Infection 
Cytokines and chemokines also play critical roles in immunity, particularly with regard to 
recruitment and activation of leukocyte subtypes. Therefore, to further characterise the immune response 
to VSV infection in the CNS, we assayed 96 cytokines using a membrane-based protein cytokine array 
(RayBiotech, Norcross, GA). Brain tissue was pooled from naiVe or VSV-infected mice (25 mg/mouse, 5 
mice/group) eight days post-infection and assayed with minor modifications to the manufacturer's 
protocols. Data was normalised to a group of cytokines with consistent ratios across all groups. Cytokines 
exhibiting a 50% change from uninfected levels were identified as up- or down-regulated in response to 
viral infection. 
Fig. 6 presents the normalised intensities for cytokines with a 50% change in expression levels. 
At this time point, the primary immune response consisted of nonspecific leukocyte infiltration as well as 
peak CD8+ T cell infiltration, small populations of dendritic cells, and proliferating microglia. Of these 
cytokines, only three (Dtk, SCF, and TECK) were significantly upregulated (GraphPad Prism 4, Two-Way 
ANOVA with Bonferroni Post-tests, <x=0.05). Dtk is a mouse growth factor receptor tyrosine kinase; it is 
highly expressed in the adult mouse brain, particularly by neurons (Gronowitz et al., 1984). SCF-1 (stem 
cell factor) belongs to the molecular class of inhibins and is involved in the growth and differentiation of 
myeloid leukocytes, and is synergistic with GM-CSF, G-CSF, and IL-7 in chemotaxis of leukocytes 
(Baghestanian et al, 1997) and is shown to be secreted by neurons in response to injury (Sun et al, 2004). 
TECK (thymus-expressed cytokine) was also significantly upregulated, which was surprising given that it 
is produced solely by thymic DCs (Vicari et al., 1997) and DCs are detected at low frequency by flow 
cytometry in the CNS at this time point. However, (Broxmeyer et al., 1999; Kim and Broxmeyer, 1999) 
some studies suggest that it may have chemotactic roles for macrophages and dendritic cells. Additional 
cytokines that were upregulated but did not achieve statistical significance included L-selectin, VEGF R2, 
and VEGF-D, which are likely involved in leukocyte adhesion and extravasation across the vascular 
endothelium into the CNS. FasL (apoptotic) was also upregulated by 50% but did not achieve statistical 
significance; this is likely due to expression on infiltrating lymphocytes and is involved in lysis of infected 




Fig. 6., Continued. Protein Cytokine Array Results for Naive and VSV-infected Animals 
Mice were intranasally infected with VSV or remained uninfected (naive). Brain tissues were harvested 8 
days post-infection and snap-frozen in liquid nitrogen before assays for cytokines were performed. Tissues 
from naive and VSV groups were pooled (25 mg tissue/mouse, 5 mice/group). Protein extracts were 
prepared using a protease inhibitor cocktail (Calbiochem) and protein concentrations adjusted to 250 
ug/mL prior to use with RayBiotech Cytokine Arrays. Protein spots were revealed with Streptavidin-IR 
800CW (Li-Cor Odyssey) and scanned on the Odyssey Imaging system. (A) Protein Arrays are depicted 
with background correction (maximal fluorescence intensity is shown as white). Cytokines upregulated 
50% above naive levels are boxed. (B) Quantitation of fluorescence signals: a 3-pixel background was 
subtracted from the integrated fluorescence intensity of each spot and results were normalised. Cytokines 
demonstrating a 50% increase or decrease in expression relative to nai've control mice were identified. 
Asterisks indicate statistical significance (a=0.05, GraphPad Prism 4). 
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Using a less stringent definition for upregulated cytokines of a 25-50% threshold change, 14 
additional cytokines were identified as upregulated and 2 additional cytokines were downregulated. These 
cytokines are summarized in Table 2 and can be grouped by general function as chemotactic (6/14), 
adhesion molecules (5/14), or mitogenic (4/14). A more complete description of their functions and 
sources may be found in Appendix B. 




























































































The present understanding of the CNS as an immune privileged site is rapidly changing in 
response to closer scrutiny. It is no longer held that the BBB is impenetrable because several studies have 
demonstrated that some areas of the brain are unprotected by a BBB. These areas (meninges, choroid 
plexus, circumventricular organs and ventricles (Farina et al., 2007; Galea et al., 2007a) and the 
perivascular spaces were initially termed lymphatic clefts by Goldman (Bechmann et al, 2007). Our results 
demonstrate low numbers of activated T cells in the draining cervical lymph nodes despite their presence in 
the brain, and provides indirect evidence for more direct, site-specific activation of antigen-specific T cells. 
The work of Huneycutt et al. demonstrated that VSV antigen is detectable in the olfactory bulb as 
early as 12 hours post-infection and spreads caudally through the forebrain by 7 days post-infection, with 
only a few areas of the midbrain demonstrating antigen reactivity (Huneycutt et al., 1994). Previous studies 
by Reiss and colleagues demonstrated a high rate of morbidity/mortality in this model that correlated with 
high titres of VSV at 7 days post-infection and loss of the BBB function late in the infection. Surviving 
mice efficiently cleared VSV from the CNS, suggesting that the host can mount an efficient antiviral 
immune response in the CNS (Barna et al., 1996; Huneycutt et al., 1994; Plakhov et al, 1995). This view is 
further supported by immunohistochemical studies that demonstrated a VSV-induced CNS infiltrate 
composed primarily of macrophages and lymphocytes (Bi et al., 1995a). The kinetics we demonstrated in 
the CB6Fl/DTRTg mouse are similar to those previously reported (Bi et al., 1995b). Starting as early as 3 
days post-infection, we observed a mixed infiltrate of leukocytes in the CNS. Consistent with the findings 
of Bi et al. (Bi et al, 1995b), the infiltrate contained primarily CD45h'shCDl lb+ macrophages/neutrophils, 
DCs, and T cells, but did not include B cells, NK or NKT cells. Macrophage and lymphocyte infiltration of 
the CNS increased sharply between days 6-8, corresponding with the peak of viral infection and onset of 
hindlimb paralysis, morbidity, and mortality. By 8 days post-infection, a significant number of both CD4+ 
and CD8+ T cells (both antigen-specific and nonspecific) had entered the brain. Our data demonstrate that 
CD8 infiltration coincides with CD4 entry into the brains of infected mice, consistent with previous studies 
(Ireland and Reiss, 2006). Peak numbers of antigen specific (VSV-N) T cells appeared initially in the CLN 
and then in the brain, suggesting that they were derived initially from the CLN. In this model, activation of 
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lymphocytes in the CLN correlated temporally with VSV replication in the CNS; this indicates that viral 
antigen is CNS-derived rather than originating from the nasal mucosa. These data imply that antigen 
presentation and T cell clonal expansion occurs initially in the CLN rather than in the brain. However, 
these data do not exclude the possibility that activated microglia induce further antigen-driven proliferation 
and effector cell development in the brain. 
Microglia become phenotypically similar to DC when activated (Ponomarev et al., 2005a; 
Ponomarev et al., 2005b; Shortman and Liu, 2002) and can upregulate several cell surface antigens, 
including MHC I and II, CD80, and CD40 (Ponomarev et al., 2005a; Ponomarev et al., 2005b) which are 
critical for full activation of naive T cells. Activated microglia can present antigen to CD4+ T cells and 
secrete various chemokines (Persidsky et al., 1999) that help recruit activated lymphocytes. Additionally, 
exposure to GM-CSF has been reported to direct the phenotypic and morphologic maturation of naive 
microglia into DC-like cells (Fischer and Reichmann, 2001). Juedes and Ruddle showed that CNS derived 
microglia can stimulate IFN-y production in T-MOG (myelin oligodendrocyte glycoprotein)-specific 
lymphocytes (Juedes and Ruddle, 2001). Following these studies, Mack et al. demonstrated that microglia 
from the inflamed CNS in the presence of antigen can serve as antigen-presenting cells (APC) for myelin 
proteolipid protein (PLPi39_i5i)-specific T cells, resulting in the production of IFN-y and cellular 
proliferation (Mack et al., 2003). Our results demonstrated that microglia upregulated MHC I and II in 
response to infection, with MHC I appearing as early as 2 days post-infection and MHC II increasing much 
later during the course of infection (days 6-10). The prompt expression of class I antigens on microglia is 
consistent with their putative role as APCs in the CNS. Together, these data suggest that microglia express 
peptide/MHC class I molecules essential for antigen recognition by naive CD8+ T cells. However, the 
infiltration of DCs into the virus-infected brain complicates evaluation of microglia functional APCs. Thus, 
their role as functional APCs for a primary antiviral immune response in the CNS remains to be confirmed. 
It is interesting to note that < 25% of CD8+ T cells bound class I tetramers at the peak of the 
proliferative response. This suggests that most brain infiltrating CD8 T cells are either not specific for 
VSV or recognize a novel VSV cryptic determinant displayed in the CNS but not in the periphery. Recent 
studies demonstrated an antigen-specific pathway for CD8+ T cells across the BBB (Bechmann et al., 
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2007). It is perhaps not surprising that non-specific CD8+ T cells infiltrate the brain. VSV upregulates 
both early (CD25/IL-2 receptor, CD69) and late (CD1 la/integrin a, CD49d/integrin a4) activation antigens 
on essentially all CD8+ and CD4+ T cells by a DC-independent mechanism. CD69 has been shown to play 
a role in the very early activation of T cells independently of macrophage/dendritic cell stimulation 
(Nakamura et al., 1989). Interleukin 2 (IL-2) also promotes proliferation of T cells. Expression of some 
the later activation antigens (CD1 la, CD49d) may be required for penetration of the BBB, given their roles 
in leukocyte adhesion and extravasation. VSV also disrupts the BBB and this may contribute to T cells 
penetration of the brain parenchyma (Bi et al., 1995b). Thus, all of these factors may contribute to the 
predominance of CD8+ T cells in the CNS that lack obvious specificity for the inducing virus. It is unclear 
why activated CD8+ T cells remain in the brain in the absence of cognate antigen. 
The cascade of cytokines, critical for leukocyte attraction and activation, that occurs in response to 
viral infection remains poorly studied in CNS infections. The study presented here represents one of the 
first to apply protein array detection methods to investigating cytokine production in the central nervous 
system. Previous detection of cytokines in the CNS in response to viral infection relied on RNase 
protection assays, which semiquantitatively determine steady-state mRNA levels, but may not accurately 
reflect protein levels. The work of Carol Reiss et al. determined that CCL1 and CXCL10 mRNA levels 
were upregulated early during infection and persisted at high levels throughout the infection (Ireland and 
Reiss, 2006). CCL1 is primarily responsible for neutrophil and macrophage chemotaxis (Devi et al, 1995; 
Doyle and Murphy, 1999). Based on the protein array data acquired, we found that CCL1 was detectable at 
above-average levels but was not upregulated in response to viral infection. Production of CXCL10 is 
induced by IFN-y and TNF-a in many cell lineages including monocytes. It has direct 
antibacterial/microbicidal activity. In experimental autoimmune encephalitis (EAE), CXCL10 was shown 
to be chemotactic for inflammatory monocytes and inhibition was correlated with improvement in clinical 
and histological symptoms (Fife et al., 2001). Our data for CXCL10 revealed only low levels of this 
cytokine that were also unresponsive to viral infection. RNase protection assays also demonstrated 
upregulation of mRNA for MIP-2, IL-ip, and IL-10. MIP-2 is primarily known for chemotaxis of 
neutrophils, which is consistent with reports of those cells being the first to enter the CNS in response to 
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infection (Ireland and Reiss, 2006). IL-ip has been shown to be constitutively expressed in the brain 
(Rothwell, 1991) and is proinflammatory, serving as both a chemoattractant and mitogen for leukocytes 
(Beck et al., 1986; Hestdal et al., 1992; Rothwell, 1991). IL-10 is generally anti-inflammatory: it reduces 
proliferation of activated T cells and indirectly inhibits production of pro-inflammatory cytokines (Howard 
and O'Garra, 1992). We found that these cytokines were also expressed at low levels but were not 
upregulated during VSV infection. The lack of MIP-2 is particularly concerning, given the high 
granulocytic infiltrate (likely to remain high in neutrophils, although this cell type was not directly 
phenotyped; neutrophils may comprise up to 40% of leukocytes) observed during VSV infection, including 
eight days post-infection (the time point studied). We found high levels of other cytokines in mice (MCP-
1, IL-12) that did not increase during infection and were not detectable by RNase protection assays. It is 
interesting to note here that IL-12 was previously demonstrated to have a protective effect in VSV 
infections of the CNS (Bi et al., 1995b; Chesler and Reiss, 2002; Komatsu et al., 1997) despite the lack of 
mRNA upregulation (Ireland and Reiss, 2006). These differences may reflect differential regulation at the 
mRNA and protein levels, rapid reuptake and degradation of the cytokine (low levels of free/detectable 
cytokine), or may be due to differences in sensitivity and detection method. RANTES, MlP-la, and 
eotaxin were common to both the RNAse protection assays performed by Reiss et al. and our protein 
cytokine array and demonstrated consistent upregulation at both the mRNA and protein levels. All three of 
these cytokines are involved in leukocyte recruitment to sites of infection (Janeway et al., 2001). 
Our data shows that a number of cytokines are responsive to viral infection, although very few 
reach statistical significance. Of these, Dtk is constitutively expressed in the adult mouse brain and has 
defined roles in neuronal survival. Its role in immunity in the CNS, if any, is unclear. However, two recent 
studies imply that the marked upregulation of this cytokine may have implications for immunomodulation: 
it has been shown to inhibit toll-like receptors and the resultant chemokine cascades in vitro, which would 
lead to an anti-inflammatory condition in the brain (Rothlin et al., 2007). Dtk has also been shown to play 
a pivotal role in NK cell differentiation (Caraux et al., 2006). Although NK cells were not observed by 
flow cytometric analysis at this time point, it is possible that the cytokine may have a novel impact on the 
development of the immune response of the CNS. This cytokine may also work in concert with SCF-1, 
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which was also upregulated, and has defined roles differentiation of leukocytes. Together, these two 
cytokines could play a role in directing microglial differentiation/development in response to viral 
challenge in the CNS. SCF-1 has also been demonstrated to be chemotactic for leukocytes. In this regard, 
SCF-1 would likely augment leukocyte extravasation in concert with L-selectin, VEGF R2, and VEGF-D, 
all three of which belong to the integrin class of cell surface molecules and promote leukocyte adhesion. 
Further studies, including tandem RNA/protein studies, need to be performed in order to fully determine 
whether these cytokines are truly affected by viral infections and the physiological relevance of such 
regulation. 
These experiments demonstrate a complex, mixed cellular infiltrate into the CNS of virally 
infected animals that corresponds well with previously reported studies. Microglia respond early and with 
prolonged duration to viral challenge, upregulating several key surface molecules that imply APC function. 
Our data indicate that viral antigen is presented in the CLN rather than directly in the CNS, leading to 
activation of lymphocytes. Cytokine and chemokine production is highly varied and indicative of 
recruitment of broad leukocyte subtypes into the CNS. Infiltration of various leukocyte and lymphocyte 
populations corresponds well to viral clearance and mouse survival. These studies provide several attractive 
targets for APC capacity (DCs, macrophages, microglia) and antiviral clearance (CD8+ T cells, 
macrophages, microglia) that will be further evaluated in the next chapters. 
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CHAPTER V 
IMPACT OF PERIPHERAL DENDRITIC CELL ABLATION ON 
THE INFLAMMATORY RESPONSE IN THE CENTRAL NERVOUS 
SYSTEM 
Introduction 
The primary focus of this chapter is to determine whether peripheral DCs serve as primary APCs 
for CNS infections. Our secondary goal was to determine the mechanistic basis for the failure of viral 
clearance from the CNS following peripheral viral infection when dendritic cells were selectively ablated 
via diphtheria toxin administration in transgenic mice. Those early studies indicated a crucial role for 
peripheral dendritic cells in modulating the antiviral immune response in the CNS, which had not been 
previously reported. However, the unpredictable infection rate of CNS infections (33%) observed with the 
intraperitoneal infection model necessitated the change to an intranasal mode of infection. This chapter 
focuses on testing the hypothesis that peripheral DCs serve as the primary APC in viral infections of 
the CNS. We used diphtheria toxin (DT) to selectively deplete peripheral dendritic cells (DCs) in a 
transgenic mouse line (CB6Fl/DTRTg). Based on the current model for antiviral immunity in the CNS, we 
predicted that loss of DCs would impair T cell activation within the cervical lymph nodes (CLN) and result 
in loss of proliferation and infiltration into the CNS of infected animals. Concurrent with the loss of 
infiltrating lymphocytes, we anticipated poor viral clearance and increased morbidity/mortality of mice. 
We first characterised the impact of DT treatment on brain-resident populations to ensure that 
microglial populations were not susceptible to DT-mediated depletion. We next confirmed that a loss of 
peripheral DCs impaired viral clearance as noted with the intraperitoneal model of infection. As with the 
initial characterisation of the primary antiviral immune response, we investigated changes in the frequency 
and phenotype of leukocytes infiltrating the CNS during viral infection resulting from loss of peripheral 
DCs. We also evaluated changes in the cytokine response during primary viral infection associated with 
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depletion of peripheral DCs. These studies demonstrate a global suppression of leukocyte infiltrate into the 
CNS that correlates with increased morbidity and impaired viral clearance in the absence of DCs 
Diphtheria Toxin depletes peripheral, but not brain-resident, dendritic cells. 
The diphtheria toxin transgenic (DTRTg) mouse line allows for the selective depletion of dendritic 
cells in vivo. Expression of the high-affinity simian diphtheria toxin receptor gene is driven by the ITGAX 
(integrin a-x) promoter, resulting in selective expression of the receptor on CD1 lc+ cells. We previously 
reported that administration of diphtheria toxin (DT) intraperitoneally resulted in depletion of splenic 
dendritic cells (Ciavarra et al., 2006). However, it was not known whether dendritic cells in the brain 
would be depleted by this technique as well. Therefore, we treated DTRTg mice with either PBS or 4ng/g 
DT i.p. 48 hours apart. This schedule corresponds to the dosing and infection schedule that we typically 
used to induce acute infection in the brain, with virus given on the intervening day. Mice were euthanized 
24 hours following the last DT treatment, transcardially perfused with PBS and ice-cold 10% buffered 
formalin, and brains were snap-frozen in OCT using liquid nitrogen. Tissues were sectioned by the 
histology core facility at EVMS and immunohistochemistry was performed by Ms. Debbie Sullivan 
(laboratory of Dr. Woong-Ki Kim) for CDllc (N418 clone). Sections of naive spleen were used for 
positive controls. Dendritic cells were readily identifiable in the choroid plexus (Fig. 7) of untreated 
animals, but not in DT-treated animals. Arrows indicate comparable regions of the choroid plexus that 
stained positive for CD1 lc in naive animals, but were unstained in DT-treated mice. This indicates 
successful depletion of dendritic cells resulting fromDT treatment in regions of the brain unprotected by 
the blood-brain barrier. Dendritic cells were not detectable by immunohistochemistry in the brain 
parenchyma, which is consistent with flow cytometric analysis. Note that due to the quality of the 
histological sections, perivascular regions could not be identified with confidence, and thus their status with 
regard to DT-mediated depletion is unknown. 
We also evaluated potential depletion of microglia and/or perivascular macrophages resulting 
from administration of DT. Brain sections were stained with antibodies directed against the macrophage 
marker F4/80, which is expressed at differential levels on microglia (low expression) and macrophages 
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(high expression). The biological role of this marker is currently unknown. Microglia were readily 
identifiable as lighter-colored dendriform cells in the brain parenchyma, while perivascular macrophages 
clustered around blood vessels and stained more intensely for F4/80. Fig. 8 shows that treatment of mice 
with DT does not deplete either CNS-resident parenchymal microglia or perivascular macrophages. 
These initial studies indicate that DT treatment successfully depletes DCs of the periphery (and 
locations of the CNS unprotected by the BBB), while leaving brain-resident microglia and perivascular 
macrophage populations intact. Therefore, we can specifically address the role of peripheral DCs in the 
immune response of the CNS during acute viral challenge. 
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Fig. 7. Immunohistochemistry of diphtheria toxin mediated depletion of dendritic cells. 
DTRTg mice were treated with PBS or 4ng/g diphtheria toxin (DT) i.p. 48 hours apart, corresponding to 
the treatment schedule used in future experiments (viral infection would be performed on the intervening 
day). Mice were euthanized 24 hours following the second DT treatment and transcardially perfused with 
PBS followed by ice-cold 10% buffered formalin. Brains were excised and snap-frozen in OCT for 
sectioning and immunohistochemistry with CDllc. Images were acquired for regions of the brain not 
protected by a blood-brain barrier (choroid plexus) and parenchyma for peripheral and brain-resident 
dendritic cells. Dendritic cells (CDllc+ appear as dark, sharply defined cells in these images. Note that 
dendritic cells are absent in the parenchyma of both normal and DT-treated mice, but are markedly depleted 
in the choroid plexus of DT-treated animals. Arrows indicate DCs in a region of naive choroid plexus that 
are absent in the DT-treated mouse. These results are representative of 3-4 mice. Magnification 20X. 
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Fig. 8. Treatment with diphtheria toxin does not deplete microglia or perivascular macrophages. 
DTRTg mice were treated with PBS or 4ng/g diphtheria toxin (DT) i.p. 48 hours apart, corresponding to 
the treatment schedule used in future experiments (viral infection would be performed on the intervening 
day). Mice were euthanized 24 hours following the second DT treatment and transcardially perfused with 
PBS followed by ice-cold 10% buffered formalin. Brains were excised and snap-frozen in OCT for 
sectioning and immunohistochemistry with F4/80. This antibody stains both perivascular macrophages 
with differential intensity. Arrows indicate likely perivascular macrophages identified by more intense 
expression of F4/80 and their proximity to blood vessels, while lighter-stained, dendriform cells are 
parenchymal microglia. These results are representative of 3-4 mice. Magnification 20X. 
Depletion of peripheral dendritic cells impairs viral clearance, survival, and inflammation. 
Our previous results demonstrated that microglia became activated in response to viral infection of 
the CNS and expressed surface molecules appropriate for antigen presentation. This virally-induced 
phenotypic change implied that microglia may serve as functional APCs. However, DCs also infiltrated the 
encephalitic CNS, complicating the identification of the true APC. To address this concern, we depleted 
DCs from DTRTg mice with either PBS (mock) or DT and infected with VSV via the intranasal route. 
Mice were monitored for survival, euthanized when moribund, and virus titres determined on the brain and 
peripheral organs. It is apparent from Fig. 9 (panel A) that the majority (63%) of mice depleted of 
peripheral DCs did not survive this dose of virus, whereas only 15% of control mice became moribund and 
had to be euthanized. Decreased survival was associated with delayed viral clearance in the brain in mice 
depleted of DCs (panel B). As previously reported, VSV was rapidly cleared from peripheral organs even 
in moribund mice depleted of DCs (Ciavarra et al., 2006). Thus, ablation of peripheral DCs specifically 
inhibits viral clearance from the CNS and as a result likely contributes to the observed increase in 
morbidity/mortality. 
The inability of mice to efficiently clear VSV from the CNS suggests that the antiviral immune 
response was impaired in mice depleted of DCs. To assess this possibility DTRTg mice were treated with 
either PBS or DT and then infected intranasally with VSV. Six days post-infection, the number of myeloid 
(CD1 lb+CD45hlsh) and lymphoid (CD1 lb"CD45high) cells in the brain was examined by flow cytometry. 
This time point was used due to extreme morbidity and mortality noted in DC-depleted mice. At six days 
post-infection, a robust microglial and infiltrating response was underway despite varying kinetics of 
individual subsets of leukocytes (demonstrated in Figs. 3-4). Furthermore, we were able to simultaneously 
evaluate the draining cervical lymph nodes for activation and proliferation of lymphocytes prior to their 
migration to the CNS; by 8 days post-infection, this response was significantly less noticeable (Fig. 4). As 
expected, microglia were readily detectable as a CD45low/lnt CD1 lb+ population (Region 1, Rl) in mock-
infected mice (Fig. 9B, panel a). No significant changes in the number of microglia were observed in mice 
treated with DT alone, a result consistent with low endogenous CD1 lc expression on resting microglia 
(panel b) and immunohistochemistry (Fig. 7). However, VSV infection was associated with a microgliosis 
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that was not inhibited by prior DC depletion (compare Rl, panels c and d). These data also imply a 
marked proliferation of microglia in DT+VSV treated mice by percentage (Fig. 9C, bottom). However, the 
absolute number of microglia per brain is very similar to VSV-infected mice that were not depleted (Fig. 
9C, upper). This discrepancy between percentage and absolute number is reflective of smaller cellular 
recoveries in general from brains of DT+VSV treated mice. 
As expected, infection of the brain induced a potent inflammatory response revealed by the 
accumulation of a prominent population of CD45hlgh CD1 lb+ cells (R2) in the brains of VSV infected mice. 
Surprisingly, prior DT treatment profoundly inhibited this infiltrate (panel d). This was evident whether 
data were expressed as a percentage or absolute number of infiltrating myeloid cells (panel C). Clonal 
expansion and/or infiltration of VSV-N T cells into the encephalitic brain were also profoundly suppressed 
by prior DC ablation (panel D). Thus, DT treatment of transgenic mice ablates DCs but preserves resident 
microglia. In the absence of peripheral DCs, the inflammatory response as well as the accumulation of 
clonally expanded CD8+ VSV-specific T cells is markedly suppressed in the CNS. This likely contributes 
to poor viral clearance and increased morbidity and mortality of mice. 
As demonstrated in Fig. 9 (panel D), a well-defined CD8+ tetramer+ population was present in the 
encephalitic brain despite the absence of CD45hlghCDl lb" cells (panel C). This apparent contradiction may 
reflect VSV-induced upregulation of CD1 lb on activated T cells at this time point. Thus, most of the 
infiltrating CD8+ T cells would be found in the CD45hlghCDl lb+ gate. This finding is consistent with 
reports from other models of inflammation (Andersson et al., 1994; Bullard et al., 2005; Christensen et al, 















































































Fig. 9., Continued. Ablation of peripheral dendritic cells in vivo markedly suppresses the CNS innate and 
adaptive antiviral immune response. 
(A) DTRTg mice were given either PBS or DT one day before and after intranasal instillation of VSV 
(2xl05 PFU). Mice were then monitored for morbidity (panel a). Grey triangles represent VSV-infected 
mice, while black circles represent DT+VSV-treated mice. Mice were euthanized when moribund and 
brains and peripheral organs evaluated for VSV titres by plaque assay (panel b). Again, grey triangles 
represent VSV-infected mice and black circles represent DT+VSV-treated mice. These data are derived 
from 17 VSV-infected mice and 18 DT-treated, VSV-infected mice. (B) Mice were treated with either PBS 
(panels a, c) or DT (panels b, d). Cohorts either remained uninfected (panels a, b) or were given an 
intranasal inoculation of VSV at 2x105 PFU/mouse (panels c, d). Six days post-infection, brains were 
homogenized and then subjected to Percoll gradient centrifugation to enrich for leukocytes. Cells were then 
phenotyped by flow cytometry and a microglia gate defined as CD1 lb+CD45low/mt cells (panel a, Rl gate). 
A second gate was established for peripheral macrophages/monocytes defined as CD1 lb+CD45h,gh (panel c, 
R2). A final CDllb"CD45high gate was used to evaluate lymphocytes (panel d, R3). (C) The percent 
positive and absolute number of cells was then calculated within each of these gates and is summarized in 
the bar graphs. (D) To identify CDS^VSV-specific T cells, cells were first incubated with H-2Kb/VSV-
N52-59 tetramers and then stained with mAbs to CD45, CD8, and the activation antigen CD49d. CD8+ 
cells were gated and the percentage of VSV-specific T cells within this gate determined by tetramer 
staining and co-expression of CD49d. Brains from 3-5 mice were pooled within each group. This 
experiment has been repeated two additional times and yielded similar results. 
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Phenotypic characterization of infiltrating leukocytes in encephaiitic brains. 
We demonstrated in Fig. 2 that VSV induced a large mixed infiltrate of leukocytes into the brains 
of mice infected intranasally. Fig. 2, panels a-b show that the infiltrating leukocyte population is primarily 
CD1 lb+, a phenotype typically associated with macrophages. However, we also observed a large infiltrate 
of CD1 lc+ cells that are found in the CD1 lb+CD45h,gh population (Fig. 2), which clearly demonstrated the 
heterogeneity of this population. Dendritic cells are typically identified by flow cytometry due to high 
expression of CD1 lc. The expression of other surface molecules may be used to differentiate among the 
various subpopulations of DCs: PDCA-1 for plasmacytoid DCs, CD1 lb or 33D1 for myeloid DCs, and 
CD8 for lymphoid DCs provide a general characterisation of the heterogeneous population. Although the 
CD1 lc+ cells identified in this previous study coexpressed CD1 lb, it was unclear whether these cells truly 
represented myeloid DCs, or whether CD1 lb was a more general characteristic of infiltrating leukocytes. 
Plasmacytoid DCs were not found during our initial experiments (Fig. 2) and were not further explored. 
This experiment provided a more in-depth characterisation of DC subtypes that infiltrate the VSV-infected 
CNS and may be sensitive to DT-mediated depletion, which could potentially aid in identification of a 
crucial DC subtype involved in antigen presentation. 
We performed five-colour flow cytometric analysis (Fig. 10), to more clearly differentiate myeloid 
or lymphoid DCs based on additional surface antigens. Within the standard infiltrating leukocyte 
populations (defined in panels a-c), myeloid DCs were distinguished by coexpression of 33D1 (Lu et al., 
1995; Lu et al, 1994; Masurier et al., 1999; Pulendran et al., 1997) and CD1 lc (panels d-f), which has 
previously been used to identify DCs in the brains of mice with chronic CNS infections of Toxoplasmosis 
gondii (Fischer et al., 2000; Nussenzweig et al, 1982). Both the antigen recognised by and the 
physiological role of the 33D1 monoclonal antibody are currently unknown. Lymphoid DCs were defined 
as CD8a+ (panels g-i). It is interesting to note that the infiltrating CD1 lc+ cells did not express either 
canonical marker for myeloid or lymphoid DCs; thus, their nature remains unclear. However, the 
upregulation of the CD1 lb integrin is likely reflective of adhesion to the vascular endothelium, required for 
migration across the BBB. Since these cell types were not detectable in VSV-infected animals, we were 
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unable to determine whether one particular subclass of DCs was more sensitive to DT-mediated depletion 
than another. 
The CD1 lb+CD45h'gh population defined in Fig. 2 included a large, apparently macrophage-based 
infiltrate. Therefore, we attempted to further define this population based on expression of granulocytic 
markers (Gr-1) and a recently reported marker for inflammatory macrophages, CD49b. It should be noted 
that CD49b, clone DX5, is also used to identify natural killer cells, which are not seen in Fig. 2. Despite 
the lack of a large population, it remained possible that more selective gating might reveal expression of 
this marker on a subset of macrophages and shed light on their role during CNS inflammation. Within this 
population, we showed approximately a 50% F4/80+ macrophage-lineage cells and 50% granulocytic cells 
(panels j-1). The F4/80+ infiltrating macrophages did not coexpress CD49b (Fig. 10, panels m-o), which 
indicates that they are not phenotypically inflammatory macrophages (Getts et al, 2008). Influx of these 
cells into the CNS of infected mice was markedly inhibited following DC depletion, but is not likely to be 
directly related due to lack of coexpression of CD1 lc. 
Finally, the CD1 lb+CD45hlgh gate (infiltrate) was previously demonstrated to include both CD4 
and CD8+ lymphocytes. Here again, lymphocyte infiltration into the CNS was significantly impaired 
following DT-mediated depletion of DCs. The results presented in panels p-r are consistent with 
previously described lymphocyte infiltrates for both T cell subsets. 
Taken together, administration of DT to deplete peripheral DCs greatly suppressed but did not 
completely abolish influx of all infiltrating leukocyte subsets. In light of the poor survival of DC-deficient 
mice, it is apparent that resident CNS cells (such as microglia, which maintained a robust response) are 
insufficient to mediate viral clearance alone. This strongly suggests that one or more infiltrating leukocyte 
populations are responsible for or contribute to antigen presentation and subsequent viral clearance. These 
results also exclude microglia as likely candidates for APC function, since they were not depleted by DT 
and were insufficient to drive lymphocyte activation and proliferation. However, the global loss of 
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Fig. 10., Continued. Depletion of DCs alters frequency, but not phenotype, of infiltrating leukocytes. 
DTRTg mice were treated with 4ng/g DT i.p. one day before and after intranasal infection with 2xl05 PFU 
VSV. Mice were euthanized six days post-infection, and brains were harvested and pooled for multicolour 
flow cytometry. Microglia were defined as CD45low/,ntCDl lb+ (panels a-c, left box). Infiltrating leukocytes 
were gated on forward and back scatter, followed by a CD45hlgh expression profile (panels a-c, right-hand 
box). The cellular composition of the infiltrate gate was assessed for myeloid and lymphoid DC subsets 
(panels d-f and g-i, respectively). Granulocytes and macrophages within the infiltrate gate were readily 
distinguished by F4/80 expression (j-1), but were not inflammatory macrophages (CD49b", panels m-o). 
Lymphocytes within the infiltrate gate were defined as CD4+ or CD8+ (panels p-r), with few or no antigen-
specific cells detected in this experiment. This experiment has been repeated twice with similar results 
except for the lack of VSV-N tetramer staining noted in this experiment. 
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We further investigated the phenotypic characteristics of CD1 lb+CD45high infiltrating leukocytes 
by observing costimulatory markers within this population. These cellular antigens provide indications 
about the activation status of lymphocytes (particularly CD8+ T cells) that are entering the CNS, and may 
further help define which cells are driving the antigen-specific response. Leukocytes were harvested from 
brains of VSV-encephalitic mice at 6 days post-infection and phenotyped by multicolour flow cytometry in 
Fig. 11. Gates in all panels were set with appropriate isotype controls; based on this definition, the majority 
of infiltrating (CD45hlgh) leukocytes expressed intermediate levels of CDllb (Fig. 11A, panels a-b). Thus, 
the infiltrating leukocyte population was divided into a CD1 lb+CD45high group and a CD1 lb"CD45high 
group. Given that the majority of the infiltrating leukocytes (-74%) expressed CD1 lb at intermediate 
levels, we focused on the phenotype of these cells. Note that infected mice demonstrated a fairly typical 
CD8+ influx (panels c-d) and that a subset of the CD8+ cells were antigen-specific (e-f); however, due to 
limitations in cell recoveries and staining combinations, the CD1 lb x CD45 profile could not be 
determined for these cells in this experiment. As previously observed in Fig. 9, depletion of DCs 
profoundly inhibited the CD45hlgh infiltrate. These data expands on the observed loss of infiltrate to 
demonstrate that CD4+ and CD8+ T cell populations are both inhibited by the loss of peripheral DCs (panels 
d-f) as well as antigen-specific CTLs (panels g-i). These populations were quantified in Fig. 1 IB. 
With regard to the CD1 lb+CD45hlgh infiltrate , the majority of cells in both naive and virally 
infected animals expressed chemokine receptor 7 (CCR7; panels g-h; 86-98%, respectively). A slight loss 
in CCR7 expression was observed for DC-depleted animals, as only 66% of infiltrating leukocytes were 
positive. CCR7 is primarily noted on lymphocytes and macrophages, but not granulocytes (Kim et al., 
1998; Reape et al., 1999). This receptor enables expressing lymphocytes to respond to the chemotactic 
ligand macrophage inflammatory protein 3p (MIP-3P). As in Fig. 9, a marked increase in CD1 lb+CDl lc+ 
infiltrate was observed in response to viral infection (44% above nai've control animals). Infiltrating 
leukocytes continued to express CD1 lc in the absence of peripheral DCs. Infiltrating CD1 lb+ cells also 
expressed the costimulatory marker CD40 and macrophage colony stimulating factor (M-CSF receptor, 
CD115) at high levels, as well as the T-cell activation antigen CD80. These costimulatory antigens on 
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lymphocytes must be engaged by their corresponding ligands on DCs to fully activate naive T cells. Of 
these antigens, all were significantly diminished in DC-depleted mice. Therefore, it is likely that those few 
lymphocytes that do enter the CNS in DT+VSV treated mice are functionally inactive or naive, and may 
not be capable of mediating cytotoxic effect/viral clearance. Since peripheral DCs are not present to drive 
lymphocyte activation, this idea is consistent with a model of lymphocyte activation occurring at a site 
outside the CNS (such as the cervical lymph nodes). Notably, expression of these costimulatory markers in 
VSV-only mice greatly exceeds the relative frequencies of any particular leukocyte subset, implying that 
they are broadly upregulated on multiple cell types in response to viral encephalitis. Thus, it is plausible 
that additional costimulatory signals may be required in the CNS for a fully productive immune response 
resulting in viral clearance and survival. Furthermore, these data indicates that microglia alone (despite 
upregulation of primary antigen-presenting MHC complexes) are insufficient to activate T cells in the CNS. 






























































































































































Fig. 11., Continued. Phenotypic characterisation of infiltrating leukocytes in VSV-encephalitic 
brains of normal and DC-depleted mice. 
(A) DTRTg mice were given either PBS or DT one day before and after intranasal instillation of VSV 
(2xl05 PFU). Six days post-infection, brains were homogenized and then subjected to Percoll gradient 
centrifugation to enrich for leukocytes. Cells were then phenotyped by flow cytometry and a microglia gate 
defined as CDllb+CD45lovv/mt cells (panels a-c, left regions). A second gate was established for peripheral 
mO/monocytes defined as CD1 lb+CD45high (panels a-c, upper right regions). A final CD1 lb"CD45high gate 
was used to evaluate lymphocytes (panels a-c, lower right regions). Infiltrating leukocytes were evaluated 
for CD4+ and CD8+ T cell frequency (panels d-f), and a CD8+ gate established. The frequency of CD49d+ 
tetramer+ T cells was determined based on the CD8+ gate (panels g-i). Note that panels a-i not gated on 
CDllb/CD45 expression. Subsequent analysis was performed on the CDllb+CD45high infiltrating 
leukocytes to examine costimulatory and activation markers (panels j-r). (B) The absolute numbers of 
infiltrating leukocytes and (C) CDllb+CD45hlgh cells expressing various antigens (lower) was calculated 
based on frequency and cell recoveries. These results were obtained based on 3-4 mice per group. These 
staining protocols are unique to this experiment; however, results at this time point are reproducible with 
other experiments presented herein. 
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Resting lymphocytes do not express CD1 lb. However, the number of CD4+ and CD8+ cells 
exceeded the number of CD1 lb" leukocytes in the brain. This did not make sense if in fact lymphocytes 
were CD1 lb". We therefore hypothesised that lymphocytes may upregulate CD1 lb in response to viral 
infection of the CNS. To address this discrepancy, we specifically stained for antigen-specific T cells (as a 
true lymphocyte) and CD1 lb in the same sample for flow cytometry. 
Cells from naive animals, VSV-infected animals, and DT+VSV animals were harvested seven 
days post-infection and stained for multicolour flow cytometry. Gates were established on forward (FSC) 
and side scatter (SSC) characteristics of leukocytes, followed by infiltrating cells (CD45hlgh). The 
expression of CD8a and antigen-specific tetramers was used to identify lymphocytes, and backgating 
analysis was then performed using Flow Jo to show the CD8+ populations in the previous gates (Fig. 12). 
This analysis shows that lymphocytes are distributed primarily in the CD1 lblow/intCD45high populations 
described in Fig. 9 and Fig. 11, which verifies that lymphocytes in this infection model do express CD1 lb. 
Furthermore, depletion of DCs with DT does not have a marked impact on the distribution of lymphocytes 
in the CD1 lb/CD45 or FSC/SSC gates, although the frequency of these T cells is markedly suppressed in 
treated mice. Although the functional significance of CD1 lb upregulation on T cells remains unclear, it is 
likely that it aids in leukocyte extravasation across the BBB and penetrance into the CNS (Christensen et 
al., 2001; Persidsky, 1999; Prieto et al., 1988). 
These studies reveal an infiltrating leukocyte population of predominantly CD1 lb+ cells, which 
includes the T cells and cells that express CD1 lc, but are not clearly definable as any particular subset of 
DCs (myeloid, lymphoid, or plasmacytoid). Further studies will be required to clarify the roles of both 
CD1 lc and CD1 lb in CNS immunity. Administration of diphtheria toxin, and the resulting suppression of 
leukocyte infiltration into the CNS, strongly supports a novel role for peripheral DCs in directing the 
immune response of the CNS. Furthermore, these results indicate that resident CNS cells, despite 
phenotypic APC capacity, are insufficient to initiate lymphocyte activation in response to viral challenge. 
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Fig. 12. CNS-infiltrating lymphocytes express CDllb. 
Mice were treated with DT one day before and after intranasal infection with VSV. Seven days post-
infection, mice were euthanized and perfused with PBS, and brains were harvested. Leukocytes were 
purified by Percoll centrifugation and analysed by flow cytometry. Panels a-c are derived from naive 
animals; d-f are from VSV-infected animals, and g-i are from DT+VSV animals. These data were obtained 
from the pooled brains of 4 mice/group. Backgating analysis performed by Flow Jo shows CD8+Tetramer+ 
cells (heavy black dots) in each of the gating profiles. 
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Blood-brain barrier integrity is maintained in the absence of dendritic cells. 
We previously demonstrated a lack of cellular infiltrate in the CNS of DC-depleted mice. 
However, the mechanistic basis for the failure of leukocyte infiltration was unclear. Furthermore, while a 
suppression of T cell activation and infiltration was anticipated, we were surprised that other, nonspecific 
peripheral leukocytes (CD8" CD45hlgh) cells such as neutrophils and macrophages would also fail to enter 
the CNS. These results conflicted with our prediction that only lymphocyte and DC migration into the 
CNS would be impaired. The work of Reiss et al. has demonstrated that intranasal application of VSV 
results in a loss of blood-brain barrier integrity beginning around six days post-infection in Balb/c mice (Bi 
et al., 1995a). Therefore, we hypothesised that dendritic cells may play a key role in regulation of blood-
brain barrier integrity. If dendritic cells contributed to breakdown of the BBB, we anticipated that in DT-
treated (DC deficient) mice, the BBB would be maintained. This would prevent VSV-induced penetration 
of nonspecific leukocytes into the CNS. Thus, we injected VSV-infected and DT+VSV mice intravenously 
with 2% Evans blue 15 minutes prior to euthanasia. Mice were euthanized and transcardially perfused with 
PBS to remove Evans blue from the brain vasculature to improve visualisation of dye leakage into the 
parenchyma. 
Fig 13. shows that Evans blue penetration of the virally infected parenchyma was pronounced at 
seven days post-infection. These results are consistent with the observations of Reiss et al., and closely 
correspond with the reported kinetics of the spread of VSV through the CNS, which indicate that viral 
antigen is detectable in the ventral striatum and caudate putamen at seven days post-infection (arrow in Fig. 
13). However, mice acutely depleted of DCs prior to infection showed no leakage of dye into the CNS 
parenchyma even at eight days post-infection despite extreme morbidity, which demonstrates that the BBB 
remained intact. These data supports the hypothesis that the failure of leukocyte infiltration is the result of 
dysregulation of blood-brain barrier permeability caused by loss of peripheral DCs. 
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Fig. 13. Blood-brain barrier integrity is maintained in mice acutely depleted of dendritic cells prior to viral 
infection. 
DTRTgFl mice were treated with 4ng/g DT i.p. one day before and after VSV infection with 2xl06 PFU 
VSV i.n (n=8). CB6F1 mice were infected on the same schedule (n=9). DT+VSV mice became ill starting 
5 days post-infection (1 found dead; 3 morbid). At 6 days p.i., 1 additional DT+VSV mouse was ill. 7 
days p.i., 2 VSV-only mice were sick (one with hindlimb paralysis, one morbid). All surviving mice were 
euthanized at 8 days p.i. Mice were injected with -200 uL Evans Blue (2% in 0.9% NaCl, filter sterile) one 
hour prior to euthanasia with C0 2 at all time points. Mice were then perfused with -30 mL PBS until the 
lungs were white and the livers blanched to remove Evans Blue from the vasculature. Brains were excised 
and examined under a dissecting microscope, then photographed. The arrow indicates a region of dark 
Evan's blue staining in a VSV-only brain. No DT+VSV brains exhibited significant dye penetration in the 
parenchyma of the CNS at any time points. 
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Antigen presentation in the cervical lymph nodes is impaired in the absence of dendritic cells. 
This model indicates a failure of leukocyte infiltration into the CNS of mice depleted of peripheral 
DCs. However, it was not clear whether this failure was due to the aberrantly regulated BBB (Fig. 13), or 
whether it was due to a failure of antigen presentation. Therefore, we evaluated clonal expansion of 
activated antigen-specific T cells in the draining cervical lymph nodes (CLN). 
Fig. 14 shows that activated, antigen-specific CD8+ T cells were detectable in the CLN of VSV-
infected mice at low frequency (panels b). Although the cell frequency is lower than we might expect, this 
is likely due to the fact that activated T cells rapidly (within hours) migrate from the draining lymph nodes 
(here, the CLN) to the site of infection and do not accumulate significantly within the lymph nodes. Data 
from the VSV-infected animals was included as part of the study on kinetics in the CLN documented in 
Fig. 4. 
In the CLN of DC-depleted mice, antigen-specific T cells failed to proliferate normally (panel c). 
These results indicate that a critical APC population was depleted by DT treatment, and supports the 
hypothesis that peripheral DCs are the primary APCs for viral infections of the CNS. Furthermore, these 
results indicate a novel role for DCs in driving the antiviral immune response of the CNS as modulators of 
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Fig. 14. Antigen presentation is impaired in the cervical lymph nodes of DC-depleted mice. 
DTRTg mice were given either PBS or DT one day before and after intranasal instillation of VSV (2xl05 
PFU). Six days post-infection, cervical lymph nodes (CLN) were harvested from mice and subjected to 
flow cytometry. The frequency of CD49d+ tetramer+ T cells was determined based on the CD8+ gate 
(panels a-c). These results were obtained from the pooled CLN of 3-4 mice per group. 
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Virus-induced IFN-y response in the CNS is not dependent on peripheral dendritic cells. 
Although we have addressed potential cellular mechanisms of viral clearance, cytokines also have 
direct antiviral roles. In the CNS, interferon y (IFN-y) has been shown to inhibit viral replication and in 
some models is required for viral clearance (Komatsu et al., 1996; Parra et al., 1999). Furthermore, in vitro 
studies have shown that IFN-y can inhibit VSV replication (Binder and Griffin, 2001; Chesler and Reiss, 
2002; Komatsu et al., 1996; Komatsu et al., 1999). Because IFN-y is largely considered a T cell product 
(Kundig et al., 1993) and these cells are not present in the CNS of DC-depleted mice, it is plausible that 
lack of IFN-y represents a mechanism for the failure of viral clearance. Although IFN-y is not the sole 
cytokine that may be directly involved in mediating viral clearance in the CNS, it appeared to be the most 
likely candidate. Therefore, we assayed the number of IFN-y producing cells in the CNS by ELISPOT 
assay. It should be noted that cells were cultured overnight in ELISPOT plates in the absence of exogenous 
virus or viral peptide to more accurately estimate the number of actual cytokine-producing cells in vivo. 
IFN-y-producing cells were detected at very low frequencies in the brains of uninfected mice. 
However, IFN-y-producing cells were readily detected in the brains of mice infected with VSV (Fig. 15). 
These results are consistent with previous reports of high levels of IFN-y in the CNS of infected mice 
(Chesler and Reiss, 2002; Komatsu et al., 1997). In striking contrast to the proliferative response of class I-
restricted VSV-N (antigen-specific) T cells, mice depleted of DCs mounted a normal VSV-induced IFN-y 
cytokine response in the CNS. This was consistently observed whether the data was expressed as 
frequency (upper panel) or total number of IFN-y-producing cells per brain (lower panel). Indeed, in 
some experiments DC ablation actually enhanced this response (data not shown). Although an IFN-y 
response could be detected in the CLNs, this response was modest at this time point relative to the CNS 
(data not presented). Thus, the VSV-induced IFN-y cytokine response in the CNS is not inhibited by 
systemic depletion of conventional and pDCs and implicates that T cells are not essential for IFN-y 
production; therefore, microglia or other resident CNS cells may be the source of this cytokine. 
Furthermore, our data indicate that IFN-y alone is not responsible for viral clearance in the CNS. 
Additional cytokines were evaluated in the following studies using protein cytokine array detection 
methods. 
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Mock VSV DT+VSV 
Mock VSV DT+VSV 
Fig. 15. Systemic ablation of peripheral dendritic cells does not suppress the virus-induced IFN-y response 
in the CNS. 
Mice were given a single intranasal instillation of VSV after being treated with either PBS (VSV) or DT 
(DT + VSV). Control mice were not infected (mock). Six days post-infection, brains were removed, 
pooled and leukocytes isolated by Percoll gradient centrifugation. Cells were seeded into ELISPOT plates 
in triplicate at up to 2xl06 cells/well and incubated overnight. No exogenous virus or viral peptide was 
added to these cultures. The following day plates were developed and the number of ELISPOTs/input cell 
number determined under a dissecting microscope. The number of ELISPOTs/106 cells determined for 
each triplicate input cell number was averaged and expressed as the mean ± S.E.M. (top panel). The total 
number of IFN-y-producing cells/brain was then calculated based on this value and cell recoveries (bottom 
panel) per organ. Brains from 4-5 mice were pooled within each group. This experiment is representative 
of two additional experiments. 
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Protein Cytokine Array in DC-depleted mice 
Our previous results indicated that the BBB was maintained in DC-deficient mice. This 
represented one possible explanation for the failure of leukocyte penetrance into the CNS. The integrity of 
the BBB and leukocyte recruitment (chemotaxis) are primarily cytokine/chemokine-mediated events. 
Chemokines may be derived from either CNS-resident cells (such as microglia) or from periperhal 
leukocytes (such as activated DCs and lymphocytes). This leads to two possible causes for the lack of BBB 
disruption in DC-deficient mice: chemokine/cytokine dysregulation from either the periphery or from 
within the CNS. If cytokines/chemokines were dysregulated in the CNS, this could imply either a failure to 
recruit leukocytes to the brain or a failure to mediate BBB disruption directly. However, if the 
cytokine/chemokine profile in the brain were normal, this would implicate peripheral dysfunction. We 
therefore analysed the cytokine profile in DC-depleted mice using a membrane-based cytokine array. This 
array included a wide variety of chemokines involved in chemotaxis, BBB integrity, viral clearance, and 
cellular activation. 
For this experiment, mice were harvested and analysed concurrently with the groups from Fig. 6. 
Statistical analysis of the normalised integrated fluorescence intensities revealed that only one cytokine 
(Dtk, Fig. 16) was significantly inhibited (69% reduction in protein levels) in DT+VSV mice relative to 
VSV-only mice. The loss of Dtk may reflect neuropathogenicity of VSV and cell death. Several other 
cytokines showed lesser, non-significant dysregulation (Table 3). Under conditions of DC ablation, all 
upregulated cytokines corresponded directly to chemotaxis of granulocytes/monocytes with the exception 
of CTACK (cutaneous T-cell attracting chemokine, CCL27), which has no known function in the CNS. 
Despite the upregulation of these chemotactic cytokines, leukocyte infiltration into the CNS of virally 
infected, DC-depleted mice remained strikingly poor. This implies that attempts to recruit leukocytes to the 
CNS are relatively intact and points toward peripheral dysfunction. Furthermore, it indicates that there may 
be a CNS-localized source of these cytokines such as microglia, since these cells are not directly affected 
by DT-mediated depletion. However, there was a reduction in protein levels for HGF R (haematopoietic 
growth factor receptor), TARC (thymus and activation regulated cytokine) and SCF (stem cell factor). SCF 
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belongs to the molecular class of inhibins, involved in growth and differentiation of CD34+ 
(undifferentiated myeloid leukocytes), and synergistic with GM-CSF, G-CSF, and IL-7 in chemotaxis of 
leukocytes. SCF, along with TECK, were significantly upregulated in response to VSV infection. 
Following depletion with DT, levels of both cytokines declined somewhat (25-35% of VSV-infected levels, 
Table 3). The loss of these cytokines tends to indicate that they may be peripherally derived, particularly 
since they are implicated in haematopoeisis (HGF R), leukocyte maturation (SCF), and T cell maturation 
(which occurs in the thymus; TARC and TECK). IGF-1 (insulin-like growth factor 1) was also impaired, 
which indicates dysregulation of circulating glucose, but is also reported to be neuroprotective. This may 
reflect the aggravated morbidity and weight loss observed in DC-depleted mice. Perhaps most notable was 
a loss in MMP-3 (matrix metalloproteinase 3), which is directly involved in degradation of the blood-brain 
barrier (Gurney et al., 2006) and is expressed during inflammation of the CNS (Rosenberg, 2002). Loss of 
this protein corresponds well with observations that Evans blue does not penetrate the parenchyma of DC-
depleted mice supporting VSV infections of the CNS. Microglia are the only CNS cell type currently 
reported to play a role in secretion of MMP-3 under inflammatory conditions (Candelario-Jalil et al, 2009; 
Rosenberg, 2002). Loss of MMP-3 tends to indicate that this cytokine may in fact be peripherally derived, 
since resident CNS populations of microglia are intact and other cytokines (such as IFN-y, Eotaxin, 
CXCL16, CTACK, and CXCL10) continue to be expressed at or above levels noted for VSV infection in 
DC-intact mice. 
With regard to antiviral cytokines, IL-12 and TNF-a have been shown to play key roles in 
mediating viral clearance in both in vitro and in vivo models (Chesler and Reiss, 2002; Komatsu et al., 
1997; Komatsu et al., 1996; Komatsu et al., 1999; Lauterbach et al., 2006; Parra et al., 1999; Patterson et 
al., 2002). These two cytokines were also assayed using the protein array, but failed to show significant 
increases in response to VSV using this technique despite sensitivities of 100 pg/mL for both IL-12 and 
TNF-a. Both IL-12 and TNF-a were unaffected by DT treatment. These results, combined with the 
information from IFN-y ELISPOT assays, indicate that the primary mechanism of viral clearance from the 
CNS is not cytokine-mediated, but rather cellular. This is in keeping with current models that hold that 
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CD8+ CTL are primarily responsible for control of viral infection, and the inability of DC-deficient mice 
(with corresponding defect in CD8+ lymphocyte activation and recruitment) to clear virus. 























































































































Fig. 16., Continued. Protein Cytokine Array Results for DC-deficient, VSV-infected mice. 
Mice were treated with 4ng/g DT IP one day before and after intranasal VSV infection. Brain tissues were 
harvested 8 days post-infection and snap-frozen in liquid nitrogen before assays for cytokines were 
performed. Tissues from VSV and DT+VSV groups were pooled (25 mg tissue/mouse, 5 mice/group). 
Protein extracts were prepared using a protease inhibitor cocktail (Calbiochem) and protein concentrations 
adjusted to 250 ug/mL prior to use with RayBiotech Cytokine Arrays. Protein spots were revealed with 
Streptavidin-IR 800CW (Li-Cor Odyssey) and scanned on the Odyssey Imaging system. (A) Protein 
Arrays are depicted with background correction (maximal fluorescence intensity is shown as white). 
Significantly altered cytokines are boxed. (B) Quantitation of fluorescence signals: a 3-pixel background 
was subtracted from the integrated fluorescence intensity of each spot and results were normalised. 
Cytokines demonstrating a 50% increase or decrease in expression relative to naive control mice were 
identified. Asterisks indicate statistical significance (<x=0.05, GraphPad Prism 4). 
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Discussion 
We previously reported that depletion of conventional and pDCs with DT treatment markedly 
inhibited clonal expansion of naive CD8+ VSV-N T cells in non-neuronal sites (Ciavarra et al, 2006). 
However, recent studies by Probst and colleagues (Probst et al, 2005) questioned the specificity of this 
ablation model because they reported that DCs and macrophages were depleted by DT treatment of DTRTg 
mice. In our experience, the dose of DT used by these investigators was toxic and killed a significant 
percentage of mice prior to virus infection. Furthermore, we titrated the dose of DT administered to deplete 
DCs and found efficient and systemic depletion of DCs was achieved with as little as 0.5 ng/g DT (data not 
shown) without any detectable morbidity. We also observed that different commercial preparations of DT 
vary in toxicity and potency. The lowest dose (per preparation of DT) that efficiently and specifically 
depleted DCs in vivo was used in the studies presented in this report. We previously reported that this 
treatment does not ablate T cells or macrophages, despite upregulation of CD1 lc on these cells following 
peripheral infection (Ciavarra et al., 2006). 
Our current studies expand the observed inhibition of peripheral CD8+ VSV-N T cells resulting 
from DT treatment to include the CNS. Thus, in both the periphery and the CNS, clonal expansion of naive 
VSV-specific T cells is DC-dependent, an observation consistent with studies demonstrating that CNS DCs 
are crucial for antigen presentation to CD4+ T cells (Bailey et al., 2007; Miller et al., 2007). Ablation of 
DCs also profoundly inhibited VSV-induced infiltration of peripheral leukocytes, including nonspecific 
macrophages, granulocytes, and neutrophils. These results were somewhat surprising, given that the 
traditional role for DCs is primarily as an activator of naive T cells. Although DT can penetrate the blood-
brain barrier and has been used to selectively kill oligodendrocytes in a similar DTR depletion model (Buch 
et al., 2005; Gropp et al., 2005), this required a high dose of DT (lOOng/injection) and 3 injections/day for 
one week. Diphtheria toxin has a very short serum T1/2 life (90% cleared in 6 hours) with poor CNS 
penetrance (low blood/CNS transfer constant (Wrobel et al, 1990), and this may explain why multiple high 
dose injections were required to deplete oligodendrocytes. Thus, it is very unlikely that we depleted DCs in 
the brain because such treatment conditions were not employed in our studies (<20ng/injection, two 
injections). This view is further supported by the observation that microgliosis was not diminished by DT 
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treatment despite upregulation of CD1 lc during virus infection (data not shown). These studies imply that 
activated microglia are not sufficient for a normal inflammatory response to VSV indicating that peripheral 
DCs provide a unique and essential function in the CNS. This function could be early chemokine 
production by these cells or, alternatively, reflect a DC-glial cell interaction essential for chemokine 
production and blood cell infiltration into the CNS. However, our results indicate few cytokines were 
dysregulated in the CNS following DC depletion, which indicates that DCs are not critical for glial 
activation or chemokine production. Although the lack of T cell infiltration is in keeping with the 
paradigm of lymphocyte activation in the CLN, the infiltration of monocytic cells was also profoundly 
inhibited by depletion of DCs. Previous characterization of the DTRTg model and our titration of DT 
demonstrated that our dosage did not deplete macrophages (Ciavarra et al., 2006); therefore, peripheral DC 
apparently play a role above and beyond that of T cell activation in regulation of the CNS immune 
response. 
Although DC ablation profoundly inhibited CNS inflammation and proliferation of VSV-N T 
cells, it reduced neither microgliosis nor the secretion of IFN-y in response to viral infection. While IFN-y 
is primarily considered a product of T cells, the levels observed in the brains of mice do not correspond 
with T cell infiltration and are not sensitive to DT-mediated loss of T cell infiltration. Thus, it is apparent 
that a cellular source of IFN-y is present in the native CNS and studies in other models suggest that 
microglia may represent one source of non-lymphoid derived IFN-y (Kawanokuchi et al., 2006; Suzuki et 
al., 2005; Wang and Suzuki, 2007). This view is further supported by the observation that IFN-y production 
in response to EAE was not significantly reduced in CD1 lb"'" mice (Bullard et al., 2005). Microglia can 
also produce significant amounts of IFN-y in response to antigenic stimulation (Bi et al., 1995b; Fischer 
and Reichmann, 2001; Mack et al., 2003; Speth et al, 2007). Perhaps importantly, IFN-y does not appear 
to have a significant protective effect in peripheral VSV infections (Muller et al., 1994), however, it does 
appear to promote VSV clearance in the CNS (Bergmann et al., 2003; Kundig et al, 1993; Parra et al., 
1999). Our results contrast sharply with these studies and indicate that IFN-y is insufficient to promote viral 
clearance or survival in the absence of infiltrating leukocytes. 
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Given the lack of leukocyte infiltrate seen by flow cytometry, it was surprising that so few 
cytokines were suppressed in the DT+VSV treated animals compared to the VSV-only controls. Loss of T 
cell infiltrate was anticipated in diphtheria-treated animals, and consistent with this finding, the T cell-
specific chemotactic TARC cytokine was depressed in DC-ablated mice. Of the 96 cytokines assayed, only 
four that were directly involved in the immune response appeared to be DC-dependent: HGF-R, SCF, 
MMP-3, and TARC. The role of TECK is still disputed, but it may play a noncanonical role in chemotaxis 
in the CNS. Dtk, which is highly expressed in the neurons of adult mouse brain (Lai et al., 1994), was 
markedly decreased in DC-depleted animals, which may simply reflect neuronal pathogenesis and 
morbidity in this group of mice. However, a few reports indicate that Dtk may also play a role in 
immunomodulation, particularly with regard to cellular adhesion (Lai et al, 1994; Lu and Lemke, 2001; 
Schulz et al., 1995). One study found that Dtk may also be expressed on peripheral macrophages and 
dendritic cells (but not lymphocytes), and may serve to dampen the immune system following antigen 
clearance (Lu and Lemke, 2001). Our results showing loss of Dtk and increased morbidity/mortality may 
indicate that macrophages and/or DCs infiltrating the CNS contribute to overall Dtk levels. A loss in Dtk 
could potentially be correlated with increased CNS inflammation, morbidity, and mortality. IGF-1 was 
also dysregulated, and may also reflect the morbidity noted in these animals. Several chemotactic 
cytokines were upregulated relative to VSV-infected mice with intact DC populations. The upregulation 
of these cytokines (Eotaxin, CXCL16, CTACK, and CXCL10) despite the lack of apparent leukocyte 
infiltrate indicates that a CNS-resident cell type is the source of these cytokines. The ELISPOT assay 
indicated a relative frequency of around 740 ELISPOTs/106 cells (0.07% of cells), which was not 
responsive to DT-mediated loss of DCs or other infiltrating leukocytes. We also evaluated IFN-y 
production by the protein array and found that it was not highly expressed (normalised intensities of 0.92 
and 1.01 for VSV and DT+VSV mice, respectively), although the protein array assay has a reported 
sensitivity of 500 pg/mL for IFN-y. This corresponds well with the low frequencies of IFN-y-producing 
cells found by ELISPOT assay. Unfortunately, IFN-y was not noticeably increased in VSV-infected mice 
relative to naive controls (a 12% increase), which may be due to assay sensitivity. An ELISA assay using 
the same antibodies as those used for the ELISPOT assays (at the same capture and detection 
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concentrations) is reported by eBioscience to have a linear detection range of 1.6-200 pg/mL, which is 
significantly more sensitive than the protein array. IL-2 and IL-4 were not detected in ELISPOT assays 
(sensitivity 4-500 pg/mL for each), but were detected in the protein array (sensitivity 10 pg/mL each). IL-2 
showed a 24% increase in VSV-infected animals relative to naive controls and a subsequent 11% increase 
in DT+VSV mice, whereas IL-4 was decreased in VSV infected mice relative to naive controls but 
increased by 14% in DT+VSV animals. These differences may reflect different harvest techniques (in vitro 
culture compared to snap-frozen and protease inhibited) or assay techniques. Cumulatively, these results 
provide early evidence that cytokine dysregulation is not the primary cause of the failure of leukocytes to 
infiltrate the virally infected CNS. 
The mechanistic basis for the failure of peripheral blood cells to infiltrate the brain in mice 
depleted of peripheral DCs remains to be clarified. However, our results indicate that the primary defect is 
in the failure of BBB breakdown, rather than failure to activate brain-resident microglia or lack of 
chemoattractant cytokines. This points to a peripheral dysfunction resulting from loss of DCs, although the 
specific cell type or cytokine(s) responsible for BBB breakdown in this model was not identified. Based on 
our data, the most likely candidate for a cytokine-mediated failure to open the BBB would be MMP-3, 
which was downregulated following DT-mediated depletion of DCs. However, DCs have not been shown 
to directly secrete MMP-3. Therefore, it is possible that DCs play a role in activating a currently 
unidentified cell type responsible for MMP-3 secretion and modulation of BBB integrity. Loss of DCs 
causes also failure of CD8+ T cells to infiltrate the CNS, a likely reason underlying the failure of viral 
clearance, morbidity, and mortality in DT-treated mice. 
In summary, VSV applied to the nasal mucosa caused reproducible encephalitis in mice 
characterized initially by microglia activation and microgliosis followed by a massive infiltrate of myeloid 
and lymphoid blood cells. CD8+ T cell infiltration into the brain correlated temporally with the rapid 
upregulation of MHC class I on microglia. Kinetic analysis of the development of VSV-N T cells 
supported a model wherein VSV-N T cells became initially sensitized to VSV in the CLN, underwent 
clonal expansion and then emigrated from the CLN into the brain. This view is consistent with studies by 
Mendez-Fernandez and colleagues who demonstrated that sensitization of naive CD8+ TMEV T cells 
86 
requires the presence of peripheral lymph nodes (Mendez-Fernandez et al., 2005). We were able to 
demonstrate that microglia are not primary APCs in CNS infections. It is possible that once in the CNS, 
sensitized VSV-N T cells underwent further clonal expansion and effector cell differentiation driven by 
peptide/MHC class I complexes displayed on activated microglia. In contrast, the lack of T cell clonal 
activation and proliferation in the CLN confirms that the primary APC for CNS infections is a DC. 
However, VSV-induced production of IFN-y was completely independent of conventional and pDCs 
suggesting that this response was driven by cells resident in the CNS. IFN-y was unable to rescue DC-
depleted mice from morbidity and mortality, which demonstrates that it is insufficient to mediate viral 
clearance alone or in combination with microglia. Thus, our data supported T cells as critical mediators of 
viral clearance; however, we were unable to rule out a contribution of macrophages to viral clearance. This 
possibility will be further explored in the next chapter. Our data also supported a novel role for peripheral 
DCs in regulating BBB integrity, possibly through direct or indirect production of MMP-3. The cellular 
interactions and underlying mechanism(s) that render both the innate and adaptive antiviral immune 
response dependent on peripheral DCs is currently being investigated. 
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CHAPTER VI 
IMPACT OF MACROPHAGE DEPLETION ON THE 
INFLAMMATORY RESPONSE IN THE CENTRAL NERVOUS 
SYSTEM 
Introduction 
Early characterisation of the cellular immune response to viral encephalitis revealed a pronounced 
infiltrate of CD1 lb+ cells. These cells are typically identified as macrophages. However, our previous 
results indicated that the CD1 lb+ population of infiltrating leukocytes also included CD8+ T cells, 
granulocytes, and DCs. Of particular note, loss of peripheral dendritic cells profoundly inhibited all 
CD1 lb+ infiltrate into the CNS. Although this population was heterogeneous, the loss of macrophage 
infiltrate was concerning because these cells are not DC-reliant. Macrophages are phagocytic, and in many 
models they mediate viral clearance. Our previous studies in the peripheral immune system indicated that 
they play a key role in clearance of VSV in immunocompetent mice (Ciavarra et al., 2006). Therefore, 
these cells, rather than CD8+ lymphocytes, may be responsible for viral clearance in the CNS of normal 
mice. The increased morbidity and mortality of DTRTg mice depleted of DCs, and concurrent loss of 
macrophage infiltrate to the CNS, supported this hypothesis. Whether or not peripheral macrophages 
contributed to CNS immunity either as mediators of viral clearance in our model of CNS infection 
remained unclear. This chapter focuses on testing the hypothesis that peripheral macrophages 
mediate viral clearance in the CNS of virally infected mice. In addition, we continued to monitor 
macrophages as ancillary APCs, although we had clearly demonstrated DCs as the primary APC for CNS 
infections. To more closely evaluate the contribution of macrophages to viral immunity of the CNS, 
several macrophage depletion strategies were employed. 
Depletion of macrophages in MAFIA mice 
In the MAFIA (macrophage fas-induced apoptosis) transgenic mouse line, depletion of 
macrophages was achieved with injection of AP20187, which induces apoptosis in cells expressing high 
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levels of c-fms (receptor for macrophage colony-stimulating factor-1). A more thorough description of the 
mechanism of depletion may be found in Chapter II) endogenously express enhanced green fluorescence 
protein (EGFP), which provides easy identification of the target cell population by flow cytometry. 
Furthermore, this mouse strain has the C57BL/6 genetic background (H-2b) and is thus appropriate for 
tetramer studies, but demonstrated slightly different kinetics from Balb/c and CB6F1 mouse strains. 
Therefore, our first studies in this mouse strain required calibration of viral dose to result in similar 
morbidity to that seen in the CB6F1 mouse strain. Despite similar severity in symptoms, the onset of 
morbidity was still delayed relative to CB6F1 mice. 
After establishing an appropriate dosing and infection regimen, we treated mice with AP20187 via 
intravenous injection daily for 5 days, followed by intranasal application of VSV. Mice were euthanized 
six days post-infection to evaluate successful macrophage depletion, a time point sufficiently early to note 
infiltrating leukocytes, but not at peak morbidity/mortality. We then characterised the phenotype of brain-
resident and infiltrating leukocytes in the CNS of AP20187-depleted, virally infected animals. 
We anticipated that treatment with AP20187 and subsequent VSV infection would result in the 
loss of macrophage infiltrate (CD1 lb+CD45high) to the CNS, while leaving the CD8+ T cell and DC 
infiltrating populations intact. The presence of a pronounced infiltrate of CD1 lb+CD45hlgh cells in the 
brains of VSV infected mice treated with dimeriser (Fig. 17A, panels a-c and data not shown) made us 
question the efficacy of our dimeriser (AP20187) treatment. To insure that we achieved peripheral 
depletion of macrophages, we repeated the experiment and also evaluated the extent to which CD1 lb+ cells 
remained depleted in the peritoneum and bone marrow. AP20187 treatment of MAFIA mice did not impair 
the infiltrating leukocyte response in the brain induced by VSV (Fig. 17A). The microglial population 
(CD45low/lntEGFP+) did not appear to expand in response to VSV infection in this mouse strain, and was 
unaffected by dimeriser treatment in conjunction with VSV infection. 
Analysis of the peritoneum of MAFIA mice indicated that naive mice contained a prominent 
population of CD45hlghCDl lb+ cells that diminished modestly in mice given VSV and then expanded in 
mice treated with VSV plus dimeriser (Fig. 17A, panels d-f). This population of CD45h'ghCDl lb+ cells 
contained both EGFPlow/int and EGFPhigh subsets (note that EGFP is endogenous), with the EGFPhigh subset 
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markedly diminished by VSV infection. The loss of these cells may reflect either sensitivity to VSV in the 
periphery, or migration from the peritoneum to another site in response to CNS infection. These EGFPhlgh 
cells were no longer detectable in mice given dimeriser and VSV (Fig. 17 A, panels g-i). This indicates that 
E G Fphi gh c e l l s ( m a c r o p h a g e s ) 
were in fact depleted by dimeriser treatment. These results were consistent 
with previously reported findings (Steel et al., 2008). The EGFPlow/int population was more stable in VSV 
infected mice and expanded slightly in mice given both dimeriser and VSV. CD45highCDl lb^CFP10"71"' 
cells were predominantly Gr-1", indicating that these cells were likely immature macrophages (monocytes) 
and not granulocytes (panels g-i). This corresponds with observed increases in band cells following 
dimeriser treatment (Sandra Burnett, unpublished observations/personal communication). The peritoneum 
of peripherally VSV infected mice given dimeriser remained essentially devoid of mature macrophages 
(CD45highCD 11 b+Gr-rEGFPhigh) even 8 days post-dimeriser treatment (unpublished observations). During 
peripheral infection studies, there appeared to be a compensatory increase in immature macrophages 
(CD45highCDllb+Gr-rEGFPlow/int) in the peritoneum (Steel et al., 2008). 
In the haematopoietic bone marrow, the number of CD45h,ghCDl lb+ cells remained fairly stable 
regardless of the experimental manipulation (Fig. 17A, panels j-1 and Fig. 17B). In naive mice, this 
CD45highCDl lb+ population contained only an EGFPlow/int subset that was markedly reduced in virus 
infected animals but expanded in the dimeriser treated group (panel m-o). In contrast to the peritoneum, 
virtually all CD1 lb+ cells in the bone marrow expressed Gr-1. When cells recoveries were calculated for 
these different populations, similar conclusions were reached (Fig. 17B). Perhaps not surprisingly, the bone 
marrow appears to have compensated for the loss of macrophages targeted by the dimeriser by production 
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Fig. 17., Continued. Sustained depletion ofEGFP+ macrophages following AP20187 treatment of MAFIA 
mice. 
MAFIA mice were treated with AP20187 intravenously for 5 consecutive days and on the following day 
given an intranasal application of VSV (2xl05 PFU). Six days post infection, brain leukocytes were isolated 
as described above along with bone marrow and peritoneal exudates cells. Cells were incubated with the 
indicated mAbs and then phenotyped by flow cytometry. (A) Cells were stained with mAbs to CD45 and 
endogenous EGFP to characterize the inflammatory infiltrate in the brain (panels a-c) and to evaluate the 
consequences of dimeriser treatment on macrophages derived from the peritoneum (panels d-f) and bone 
marrow (panels j-1). Coexpression of Gr-1 and endogenous EGFP on gated CD45highCDl lb+ cells was then 
evaluated on cells derived from the peritoneum (panels g-i) and bone marrow (m-o). (B) The absolute 
number of cells of the indicated phenotype was calculated by multiplying total leukocyte recoveries x 
percentage of cells with the selected phenotype. 
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Characterisation of antiviral response in macrophage-depleted MAFIA mice 
Next, transgenic MAFIA mice were treated with AP20187 and given an intranasal application of 
VSV one day after the last dimeriser injection. Control mice were either uninfected (nai've) or just given 
VSV. It should be noted that uninfected control mice are CB6F1 mice, which do not endogenously express 
EGFP on microglia and therefore appear as CD45low/intEGFF in Fig. 18, panel e. Treatment of MAFIA 
mice with AP20187 alone did not diminish resident microglia (CD45low/lntCDl lb+, box in panels a-b) 
because dimeriser treated MAFIA mice had approximately the same number of cells in the microglia gate 
as did untreated control mice (Fig. 18A, panels a, b and Fig. 18B). However, virus infection was associated 
with loss of microglia and this was exacerbated by prior treatment with dimeriser (panels a-d). Strikingly, 
microglia loss was selective in that only EGFP+ microglia disappeared from the encephalitic brain (panels 
e-h, quantified in Fig. 18 B). This loss could not be explained by upregulation of CD45 because EGFP+ 
cells were not detected in the CD45hlgh population. Thus, VSV infected mice (both control and macrophage 
depleted) contained only CD45low/intCDl lb+EGFP" microglia. These results were somewhat surprising, 
although they correspond well to the observed loss of EGFPhlgh cells in the peritoneum. Microglial EGFP 
intensity is tenfold lower than EGFP intensity noted in the peritoneum; however, it is possible that cells 
expressing the transgenic Fas construct are more sensitive to VSV infection. The dramatic loss of microglia 
in VSV-infected MAFIA mice is likely due to the loss of the EGFP+ population; the remaining microglia 
appear to have been activated normally. This activation occurred independent of peripheral macrophages 
because MHC class II antigens were upregulated on microglia isolated from dimeriser treated mice (panels 
i-1). Surprisingly, systemic depletion of monocytes/macrophages did not diminish the VSV-induced 
infiltrate of CD45highCDl lb+ cells (compare panels a-d). 
Further characterization revealed a trace population of resident DCs (CD1 lc+) in mock infected 
mice that expanded modestly in control and dimeriser treated mice following virus infection. However, 
plasmacytoid DCs (CD1 lc^PCDA-14) were not detected in either mock or VSV infected mice (panels m-
p). A trace population of CD8+ T cells was also identified in brains of mock infected mice that were not 
activated (CD49d") and did not recognize VSV (tetramer"). In contrast, encephalitic brains from both 
control and dimeriser treated mice contained two expanded CD8+CD49d+ populations, one specific for 
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VSV (tetramer ) and a second with unknown specificity (panels q-t). These results do not support a role for 
macrophages as crucial APCs in initiating the primary antiviral response in the CNS. 
Mice depleted of macrophages remained healthy during the course of this experiment indicating 
efficient viral clearance from the CNS, whereas two VSV infected mice developed hind limb paralysis 6 
days post infection. Thus, these data are in striking contrast with the DTRTg model where ablation of DCs 
profoundly suppressed both innate and adaptive antiviral immune response in the CNS. Therefore, 
macrophages also do not appear to mediate viral clearance in the CNS, and even appear to exacerbate 
encephalitis. Given that macrophages are generally associated with inflammation and tend to produce 
proinflammatory cytokines which mediate cellular damage, these results are not entirely surprising. This 
experiment lends additional support to the model wherein CD8+ T cells are responsible for viral clearance. 
The presence of antigen-specific CD8+T cells in the CNS implied that DCs were not affected by 
treatment with AP20187 and were thus available to present antigen in the CLN. To verify that antigen 
presentation was not impaired, we evaluated the CLN for tetramer+ CD8+ T cells. Fig. 19 (panels a-c) show 
a low frequency of cells in the CLN that show some slight impairment in AP20187-treated mice relative to 
VSV-only controls. However, this loss of T cells is most likely due to the extremely large influx seen in 
the CNS at the same time (Fig. 18). 
This model did not provide evidence for macrophages as either APCs or key mediators of viral 
clearance. These results confirm DCs as primary APCs for CNS infections as well as CD8+ T cells as the 
primary means of viral clearance. Thus, macrophages appear to play no critical role in antigen presentation 
or viral clearance and may be considered superfluous to antiviral immunity. However, the improved 
survival and health of mice suggests that macrophages may contribute to the pathogenesis noted in the CNS 
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Fig. 18. Systemic elimination of macrophages with AP20187 does not inhibit cellular immunity. 
MAFIA mice were treated with 20 mg/kg AP20187 via intravenous injection in the retro-orbital venous 
sinus for 5 consecutive days prior to virus infection with 2xl06 PFU VSV. A. Naive mice (left column, 
panels a, e, i, m) were left untreated. Additional mice were treated with AP20187 but uninfected (panels b, 
f, j , n), or were only infected with VSV (c, g, k, o). The fourth group of mice were treated with AP20187 
and infected with VSV (panels d, h, 1, p). Mice were euthanized 8 days post-infection. Gates were defined 
for microglia (panels a-d, box) and infiltrating leukocytes based on CD45 and CD l ib expression. Note 
that treatment of mice with AP20187 did not reduce the microglial population relative to untreated controls. 
Activation of microglia was evaluated based on expression of MHC II (panels e-h). The presence of 
DCs/pDCs (panels i-1) and antigen-specific CD8+ T cells (tetramer+, panels m-p) was also monitored during 
infection and were not diminished by AP20187 treatment. These data are derived from the pooled brains of 
3-5 mice per group. B. The absolute numbers of microglia and infiltrating leukocytes was calculated from 









Fig. 19. Antigen presentation in the cervical lymph nodes is not impaired by AP20187. 
MAFIA mice were treated with AP20187 intravenously for 5 consecutive days and on the following day 
given an intranasal application of VSV (2xl05 PFU). Six days post infection, brain leukocytes were isolated 
as described above along with bone marrow and peritoneal exudates cells. Cells were stained for antigen-
specific (Tet+) CD8+ T cells expressing CD49d. Panels a-c above were gated on the CD8+ subset of 
lymphocytes. 
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Inhibition of monocyte-macrophage maturation with MGBG 
Dr. Michael McGrath (University of California, San Francisco) reported that methylglyoxal 
bis(guanylhydrazone) (MGBG) inhibited the maturation of monocytic-lineage cells into mature 
macrophages with subsequent loss of macrophage infiltrate in a model of simian immunodeficiency virus 
encephalitis (McGrath and Hadlock, 2007). Therefore, it was possible that MGBG could act similarly in 
our model of VSV encephalitis. Furthermore, it provided an attractive alternative to the MAFIA model 
(which required daily intravenous injections of AP20187 to achieve depletion) because it could be 
administered intraperitoneally fewer doses. We also hoped to avoid some of the complications that arose in 
the MAFIA model, such as loss of microglia and a bone-marrow initiated expansion of immature peripheral 
macrophages. In this model of macrophage depletion, MGBG was administered intraperitoneally to 
CB6F1 mice, followed by intranasal infection. Again, we characterised the resident and infiltrating 
leukocyte responses to the viral infection. We treated CB6F1 (non-DTRTg) mice with 15 mg/kg MGBG 
i.p. starting one day before intranasal VSV infection and continuing every other day until euthanasia at 7 
days post-infection. Mice treated with MGBG alone had no observable reaction to the drug alone. 
However, virally-infected mice that had been treated with MGBG showed increased morbidity and 
mortality (50%) at 7 days post-infection relative to untreated virally infected control mice. One 
MGBG+VSV mouse died at 6 days post-infection and was not included in this analysis; the three 
remaining mice became ill and required euthanasia at 7 days post-infection. At the time of necropsy, no 
gross abnormalities were apparent in MGBG-treated mice. However, one mouse was excluded from the 
VSV-only group due to gross systemic abnormalities at autopsy. The brains and CLNs of mice were 
harvested for PFU assay and multicolour flow cytometry as previously described. 
Administration of MGBG alone did not deplete microglia (Fig. 20A, panels a-b, left box). 
However, in virally infected animals, microglia not only failed to proliferate (panels c-d), but they also 
demonstrated inhibition of MHC I and II upregulation relative to VSV-only mice (panels e-h), as well as 
inhibition of the costimulatory markers PD-1 and CD80 (panels i-1, compare to Fig. 5). The lack of these 
activation-dependent markers on migroglia implies that MGBG not only crossed the BBB, but also had a 
direct inhibitory effect on microglial response to VSV. 
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The percentage of infiltrate in infected animals was not reduced with MGBG treatment (panels c-
d, right box), including the granulocyte (Gr-14) and tetramer+ CD8+ subsets of the infiltrate (panels m-p and 
q-t). Notably, the percentage of DC infiltrate nearly doubled in MGBG-treated virally infected animals. 
However, when the absolute numbers of infiltrating leukocytes were calculated, a loss of granulocyte and T 
cell infiltrate was apparent (Fig. 20B), although the increase in DCs was maintained. Together, these three 
populations account for all of the infiltrating leukocytes; a purely macrophage population was not seen. 
The slight loss of antigen-specific CD8+ T cells in this model was surprising, given that 
macrophages are not demonstrated to be the primary cell type responsible for initiating adaptive immunity. 
To verify that this was due to loss of activation rather than failure to penetrate the CNS, we also evaluated 
the CLNs of uninfected, VSV-infected, and MGBG+VSV treated mice. Fig. 21 reveals low levels of 
antigen-specific T cells in the CLN of VSV infected mice, consistent with expectations and infiltration of 
activated T cells into the CNS. However, mice treated with MGBG showed impaired T cell activation 
relative to VSV-only mice. Despite the almost total loss of T cells in the CLN, inhibition was not 
complete, as levels in the CNS declined by only about 50% in MGBG mice (Fig. 20). 
In these studies, administration of MGBG inhibited microglial activation and proliferation. This 
may provide a novel model for assessing the role of microglia in antiviral immunity. However, since 
inhibition was incomplete and corresponded with inhibition of infiltrate, we were unable to directly relate 
CNS immune dysfunction to microglia. Mice typically clear VSV from peripheral organs within 24-48 
hours, and immunocompetent mice appear to clear virus from the CNS rapidly. Viral clearance was 
diminished by treatment with MGBG at 7 days post-infection (Fig. 20C), which is consistent with the loss 
of T cells and observed morbidity of mice. Given that the APC population (DCs) should not be inhibited 
by this drug, it is possible that some of the loss of T cell activation and infiltration may reflect restimulation 
requirements in the CNS (perivascular spaces or microglial). However, the loss of CLN T cell activation 
complicated interpretation of these results. Microglia were again demonstrated to be irrelevant as primary 
APCs. These results generally support T cells as the primary mediators of viral clearance in the CNS; 
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Fig. 20., Continued. Treatment of mice with MGBG alters microglial response, but not CNS-infiltrating 
leukocytes. 
CB6F1 mice were treated with 15 mg/kg MGBG via intraperitoneal injection every other day, beginning 
one day prior to virus infection with 2xl05 PFU VSV and continuing to 7 days post-infection (4 
treatments). A. Naive mice (left column, panels a, e, i, m, q) were left untreated. Additional mice were 
treated with MGBG but uninfected (panels b, f, j , n, r), or were only infected with VSV (c, g, k, o, s). The 
fourth group of mice were treated with MGBG and infected with VSV (panels d, h, 1, p, t). Mice were 
euthanized 7 days post-infection. Gates were defined for microglia (panels a-d, left box) and infiltrating 
leukocytes based on CD45 and CD1 lb expression (right box). Note that treatment of mice with MGBG did 
not reduce the microglial population relative to untreated controls. Activation of microglia was evaluated 
based on expression of MHC I and II (panels e-h), PD-1, and CD80 (panels i-1). The presence of infiltrating 
(CD45hlgh) DCs, granulocytes (panels m-p), and antigen-specific CD8+ T cells (tetramer+, panels q-t) was 
also monitored during infection and were not diminished by MGBG treatment. These data are derived 
from the pooled brains of 5 mice per group. B. The absolute numbers of microglia and infiltrating 
















Fig. 21. Antigen presentation is reduced in virally-infected mice treated with MGBG. 
CB6F1 mice were treated with 15 mg/kg MGBG via intraperitoneal injection every other day, beginning 
one day prior to virus infection with 2xl05 PFU VSV and continuing to 7 days post-infection (4 
treatments). Cervical lymph nodes (CLN) were harvested and stained for antigen-specific (Tet+) CD8+ T 
cells as evidence of antigen presentation (panels a-c, gated on CD8). These data are derived from the 
pooled brains of 3-5 mice per group. 
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Depletion of mature circulating macrophages with clodronate liposomes 
Thus far, we have attempted to globally deplete or inactivate peripheral macrophages. To 
compare these results to an established model of macrophage depletion, we utilised liposome-encapsulated 
clodronate (CL2MDP), which has previously been shown to target circulating monocytes/macrophages in 
the bone marrow, spleen and liver while leaving lymph nodes (including the draining cervical lymph 
nodes) intact (van Rooijen, 2006). We reasoned that if lymphocyte activation occurred in the cervical 
lymph nodes according to the current model, the VSV-specific adaptive T cell response should remain 
intact. This technique targets mature, circulating phagocytic macrophages for depletion. In our previous 
peripheral studies with clodronate liposomes, we did not observe the expansion of immature 
monocyte/macrophage lineage cells noted in the MAFIA model (Ciavarra et al., 2005). Therefore, we 
should be able to assess the contribution of infiltrating macrophages into the CNS during acute viral 
infection. 
MAFIA mice were treated with a single intravenous injection of 200 uL clodronate liposomes via 
the retro-orbital venous sinus while in a surgical plane of isoflurane-induced anaesthesia. Following 
depletion of circulating mature macrophages (24 hours), mice were infected with 2xl05 PFU VSV 
intranasally and monitored for signs of illness; control mice were infected with VSV only. Seven days 
post-infection, mice were euthanized and perfused with ~30 mL PBS. Tissue was homogenized and 
subjected to Percoll fractionation for flow cytometry. In these studies, we replaced CD1 lb with F4/80 in 
order to differentiate granulocytes (which may be CD1 lb+, but are F4/80") from macrophages (which are 
F4/80*). 
Recall that in this mouse strain, EGFP is endogenously expressed on macrophage lineage cells 
including macrophages. Consistent with previous results in the MAFIA mouse strain, we observed a loss of 
CD45low/intEGFPh,gh microglia in VSV-infected mice. However, this loss of EGFPhigh cells was not seen in 
CL2MDP+VSV infected brains (Fig. 22A, panels a-c), although this population did not exceed baseline 
levels observed in naive mice. These EGFPhlgh microglia may represent expanded cells from the small 
remaining population in VSV-infected animals. Alternatively, it is possible that treatment with CL2MDP 
conferred a protective effect on microglia. 
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The intent of this mode of depletion was to reduce or eliminate infiltration of peripheral 
macrophages into the CNS following VSV infection while leaving other cell populations intact. 
Granulocytes (Gr-1+) have low phagocytic activity and therefore should not be depleted by CL2MDP. 
These cells should thus comprise a large fraction of the CD45hl8h infiltrate during VSV infection. In the 
MAFIA mouse model, granulocytes should have a low endogenous expression of EGFP (Burnett et al, 
2004). VSV induced a pronounced infiltrate of granulocytes (Fig. 22 A, panels d-f), a subset of which were 
EGFP+ granulocytes (panels g-i). The lack of F4/80 coexpression with Gr-1 (panels j-1) indicated that these 
cells were not macrophages. However, a population of EGFPh,ghGr-l+ cells was observed in VSV infected 
mice. Tissue-variable EGFP expression on MAFIA macrophages has been reported and a cell type that 
was EGFPh,ghGr-r was noted in the lungs of MAFIA mice (Burnett et al., 2004 26). The presence of cells 
coexpressing high levels of endogenous EGFP and Gr-1 was not reported by Burnett et al. in the 
peritoneum, but their presence in the lung implies that populations of these cells may exist in other tissues. 
Because these cells do not coexpress F4/80, they are not considered to be mature macrophages, but may 
represent either an immature subpopulation that has not upregulated F4/80, or a subpopulation of 
granulocytes that express high levels of the EGFP transgenic construct. Treatment of mice with CL2MDP 
significantly depleted EGFPhlgh cells entering the CNS (panels c and i). This did not deplete or inhibit 
EGFP" granulocytic infiltration (panels h-i) relative to VSV-only mice, but did markedly reduce the fraction 
of EGFPh,gh granulocytes observed. Thus, the EGFPhlghGr-l+ cells appear to have phagocytic capability, 
and are eliminated by intravenous administration of CL2MDP. These cell types are quantified in Fig. 22C. 
In this experiment, infiltrating macrophages would be defined as CD45h,ghGr-rF4/80+ (Fig. 22A, 
panels j-1). A population of these cells was noticeable in the brains of naive mice, which may represent 
perivascular macrophages. These cells were virtually eliminated by VSV infection (panel k), which is 
consistent with the loss of macrophages noted previously in most MAFIA mice tissues (refer to Fig. 18). In 
CL2MDP-treated, VSV infected animals, macrophage infiltrate was increased relative to VSV-only control 
mice, but did not reach levels seen even in naive animals. Furthermore, the expression level of F4/80 on 
these cells was decreased relative to VSV-only controls. Therefore, these cells may represent some 
relatively immature, non-phagocytic monocyte precursors. Again, these cells are quantified in Fig. 22C. 
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Myeloid dendritic cells (CD8) have phagocytic capacity and have been demonstrated to be 
sensitive to CL2MDP-mediated depletion in the periphery. However, lymphoid (CD84) DCs were 
unaffected by peripheral depletion, implying lower phagocytic activity (Ciavarra et al., 2005). In these 
mice, serum titres of IFN-a remained high, which implies that plasmacytoid DC (CD1 lc+PDCA-l+) were 
also unaffected by CL2MDP-mediated depletion (unpublished observations). Because our results from the 
DTRTg model imply a crucial role for DCs in BBB regulation and activation of adaptive immunity, we 
phenotyped DCs infiltrating the VSV-infected CNS. As previously noted, CD1 lc+ cells were not 
detectable in the naive brains of mice (panels m and p). Plasmacytoid DCs were also not observed 
infiltrating the CNS (panels m-o). Encephalitic brains contained a CD1 lc"PDCA-l+ population whose 
lineage and function are unknown. However, these cells were also observed in peripheral studies of DC 
depletion using the DTRTg model (Ciavarra et al., 2006), and were not depleted byDT treatment. Both 
myeloid and lymphoid DCs did penetrate the CNS following viral infection (panels p-r), which is 
consistent with other mouse strains (Fig. 10). In addition, the absolute number of both myeloid and 
lymphoid populations of infiltrating DCs was reduced by approximately 50% (Fig. 22D). 
A prominent influx of CD8+ cells was also noted in encephalitic brains (panels s-u) containing a 
subset that bound class I tetramers indicating that this subset recognized the immunodominant epitope 
present in the nuclear protein of VSV (panels s-u). Mice rendered deficient of peripheral macrophages also 
displayed impaired adaptive immunity because clonal expansion of CDS^SV-N T cells was also 
suppressed in these mice (panels s-u and Fig. 22D). The inhibition of T cell response is reasonable given 
the depletion of antigen-presenting DCs noted above. 
Unlike the MAFIA+AP20187 model, clodronate-treated mice showed dramatically increased 
morbidity and mortality relative to VSV-only controls. Half of the mice (3/6) died at 6 days post-infection 
(two days earlier than typical onset of morbidity for this strain) and by 7 days post-infection the remaining 
mice were moribund, while VSV-only controls showed only early signs of pathogenesis. Despite the 
morbidity and mortality of mice, viral clearance was apparently unimpaired (Fig. 22B), which is surprising 
given the reduction in infiltrating T cells. These results may indicate that although suppressed, the small 
population of CD8+ T cells that still infiltrated the CNS were able to mediate viral clearance. However, it 
is more likely that the PFU assay results were abnormally low due to experimental error. For this 
experiment, supernatants from brain homogenate were used; we typically noted poor viral recoveries from 
such samples (data not shown). It should also be noted that the viral titres were obtained from a duplicate 
experiment with similar instances of morbidity/mortality and do not correspond exactly to the flow 
cytometry data shown. 
The lack of T cells and other leukocytes infiltrating the CNS implied a loss of antigen presentation 
in the CLN, which has been documented in both the DTRTg model (Fig. 14) and the MGBG model Fig. 
21). To verify that antigen presentation was inhibited, we evaluated the CLNs for the presence of antigen-
specific (tetramer+) CD8+ T cells. Fig. 23 demonstrates effective antigen presentation in the CLNs of VSV-
only mice (panel b). Surprisingly, antigen presentation and clonal expansion of antigen-specific CD8+ T 
cells was preserved in mice treated with intravenous clodronate (panel c). This indicates that the functional 
APC for the CNS was not depleted by this technique. In Fig. 22, we note that PDCA-1+ cells (a phenotype 
typically associated with plasmacytoid DCs) were not depleted. These data corresponds with previous 
observations in the DTRTg model of peripheral DC depletion (Ciavarra et al., 2006). Although these cells 
have not been reported in the literature, it is possible that they represent either immature pDCs or a novel 
pool of circulating pDCs. If the latter explanation were true, they may represent the APC for CNS 
infections. Differences in both route of administration and depletion mechanism might account for the 
discrepancies between the DTRTg model (where APC function is lost) and the IV-LIPO model (where 
APC function is retained). Further characterisation of these CD1 lc"PDCA-l+ cells is required. 
Our previous studies did not support a role for IFN-y as the sole mediator for viral clearance in the 
CNS of VSV-infected mice. However, it did not rule out a supporting role. Given that viral clearance was 
not significantly inhibited in LIPO+VSV mice, we anticipated a robust IFN-y response. Therefore, we 
determined the frequency of IFN-y producing cells in the CNS of VSV infected and mice treated 
intravenously with CL2MDP prior to viral infection. Fig. 24 demonstrates that only trace numbers of IFN-
y-secreting cells were detected in the brain of naive mice. However, this population expanded in the brains 
of VSV infected mice, whereas clodronate treatment prior to virus infection markedly suppressed this 
response. This was true when data was expressed either as the number of ELISPOTS/106 cells or total 
106 
number of ELISPOTs per brain (top and bottom panels, respectively). Thus, the VSV-induced IFN- y 
response in the CNS was markedly impaired in mice rendered deficient of peripheral macrophages and 
DCs. In the DTRTg model, we suggested that microglia may represent a source of IFN-y in the CNS. If 
these cells are in fact the major producers of this cytokine, CL2MDP treatment may have functionally 
impaired microglia despite their ability to proliferate somewhat. The lack of IFN-y in this experiment 
agrees with the findings from the DTRTg model wherein the presence of IFN-y alone was insufficient to 
mediate viral clearance. 
In summary, this experiment revealed a marked loss of infiltrating leukocytes following depletion 
of peripheral macrophages and DCs. This depletion technique impaired both innate and adaptive antiviral 
immune responses, but did not impact viral clearance for unknown reasons. The loss of both aspects of the 
immune response in this model of depletion is likely due to the concurrent depletion of DC populations in 
the periphery, and is more similar to results seen in the DTRTg mouse model than in the MAFIA mouse 
models. This comparison is further supported by the loss of IFN-y, which did not correlate with viral 
clearance in the CL2MDP model. Despite successful viral clearance, mice exhibited significant morbidity 
and mortality, which implies that viral infection contributes to, but is not solely responsible for, CNS 
pathogenesis in infected animals. We were also able to demonstrate that the crucial DC responsible for 
antigen presentation in the CNS does not fit the classical definition of either lymphoid or myeloid, but is of 
an undetermined type that is not sensitive to clodronate-mediated depletion. However, the integrity of the 
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Fig. 22., Continued. Intravenous administration ofclodronate liposomes inhibits antiviral 
immunity. 
MAFIA mice were treated with 200|o.L clodronate-bearing liposomes i.v. via the retro-orbital venous sinus 
while in a surgical plane of anaesthesia using isoflurane (2%). Mice were allowed to recover for 24 hours 
prior to i.n. infection with 2xl06 PFU VSV. A. Multicolour flow cytometry was performed on brains from 
naive (left column, panels a, d, g, j , m, p, s), VSV-infected (centre column, panels b, e, h, k, n, q, t) and 
LIPO+VSV mice (right column, panels c, 1, i, f, o, r, u). B. Viral titres from standard PFU assay for VSV-
infected and LIPO+VSV mice. C. Quantitation of data presented for ungated (m-r) cell populations. These 
data are representative of three to six mice per group and was repeated three times. D. Quantitation of 
data presented for infiltrating leukocytes (g-1) and CD8 (s-u) gated leukocytes. Note that these results are 
from a duplicate experiment and do not correspond exactly to the flow data shown in parts A-C. 
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Fig. 23. Antigen presentation is not impaired in the cervical lymph nodes of mice treated with intravenous 
clodronate. 
MAFIA mice were treated with 200uL clodronate-bearing liposomes i.v. via the retro-orbital venous sinus 
while in a surgical plane of anaesthesia using isoflurane (2%). Mice were allowed to recover for 24 hours 
prior to i.n. infection with 2xl06 PFU VSV. Cervical lymph nodes were harvested and subjected to 
multicolour flow cytometry for antigen specific (Tet+) CD8+ T cells (panels a-c, gated on CD8). 
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Fig. 24. Ablation of peripheral macrophages suppresses the VSV-induced interferon gamma 
response in the CNS. 
MAFIA mice (3-6 per group) were either untreated or given intravenous clodronate. The following day 
mice were infected with VSV via the intranasal route and brain leukocytes isolated seven days post 
infection. An IFN-y ELISPOT assay was then performed as previously described using three replicates per 
input cell number. Cells were not re-stimulated with VSV in vitro to more accurately estimate the number 
of cytokine-producing cells in vivo. Data are expressed as either the number of cytokine-producing 
cells/10 cells (upper panel) or total number of cytokine-producing cells per brain (bottom panel). 
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Depletion of perivascular macrophages with clodronate 
Several recent studies have demonstrated that macrophages residing in the perivascular spaces in 
the CNS play a key role in mediating the antiviral immune response and may be more important than 
microglia for antiviral immunity in our model. Perivascular macrophages have been shown to express 
MHC II and present antigen (Fabriek et al., 2005; Fischer and Reichmann, 2001; Griffin, 2003; Perry, 
1998; Polfliet et al., 2001b; Stoll and Jander, 1999; Williams et al., 2001). Their unique location at entry 
points to the CNS (vascular spaces) made them attractive targets as an in situ APC. We reasoned that this 
brain-resident pool of macrophages may be insensitive to AP20187-mediated depletion in MAFIA mice, as 
the drug does not cross the BBB. Because these cells have differentiated from monocyte precursors upon 
entry into the CNS, it was also unlikely that they were affected by MGBG. Therefore, we hypothesized 
that perivascular macrophages may play a role in initiation and/or propagation of the adaptive immune 
response of the CNS and/or in viral clearance. Intracerebroventricular administration of clodronate 
liposomes was shown to deplete perivascular macrophages, but not microglia, in the rat CNS (Polfliet et al , 
2001a). This technique therefore allowed us to assess the contribution of perivascular macrophages to 
antiviral immunity in the CNS. 
To assess the contribution of perivascular macrophages to CNS antiviral immunity, CB6F1 (non-
DTRTg male) mice were surgically administered 8 uL C12MDP in the left lateral ventricle of the brain 
(intracerebroventricular injection, ICV). Surgical procedures were performed by Laurie Wellman of Dr. 
Sanford's lab. Because this was a difficult and time-consuming procedure, ICV-LIPO only mice were not 
assessed. Mice were allowed to recover for 3 days post-surgery and maintained on ibuprofen during that 
time. In contrast to the IV administration of liposomes, this technique targeted CNS-resident perivascular 
and meningeal macrophages. Following ICV depletion of perivascular macrophages, mice were then 
infected with 2xl05 PFU VSV intranasally and monitored for signs of illness; control mice were infected 
with VSV only. Six days post-infection, mice were euthanized and perfused with -30 mL PBS. Tissue 
was homogenized and subjected to Percoll fractionation for flow cytometry. Naive (uninfected) mice are 
not shown; refer to Fig. 2 and Fig. 5. 
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Fig. 25A demonstrates that microglia were not depleted by ICV-LIPO treatment; in fact, microglia 
in the ICV-LIPO+VSV animals expanded more than microglia from VSV-only mice (panels panels a-b, 
quantified in Fig. 25B). Microglial activation was also significantly increased as evidenced by 
upregulation of MHC I and/or CD1 lc (panels c-d, also quantified in Fig. 25B). These results indicated that 
microglial activation and proliferation were independent of perivascular or meningeal macrophages in 
response to VSV infection. The lack of microglial depletion was consistent with previous reports on the 
specificity of this technique (Polfliet et al., 2001a). 
Infiltration of leukocytes (Fig. 25A, panels a-b, region R3) and lymphocytes (Fig. 25 A, panels e-h) 
was also markedly enhanced in mice depleted of perivascular macrophages. Granulocytes (Gr-1+, Fig. 25A 
panels i-j) were also found at a high frequency in the CNS of clodronate-treated mice. These cell types 
were quantified in Fig. 25B-C. 
By 6 days post-infection, the VSV-only mice were morbid, (Fig. 25D), although two of the 
moribund mice had no detectable virus remaining in their brains. This suggests that the observed morbidity 
may be related to the inflammatory response and not to the cytopathic activity of the virus. Mice given 
ICV clodronate exhibited no evidence of illness and were not moribund at this time. The lack of virus in 
the brain indicates successful viral clearance (Fig. 25D) and corresponds well with animal health. 
Based on the health and infiltration of lymphocytes, we predicted that antigen presentation would 
remain intact in ICV-LIPO mice. Fig. 26 shows that APC function was intact in both VSV and ICV-LIPO 
mice. This confirms that macrophages are not required for antigen presentation, and that the APC is not a 
brain-resident cell type sensitive to clodronate-mediated depletion. 
These data from the ICV-LIPO study is highly consistent with the MAFIA model of macrophage 
depletion, where mice exhibited enhanced infiltrate, viral clearance, and survival relative to VSV-only 
controls and exhibited fewer symptoms of infection. Thus, it is possible that macrophages contribute to the 
pathogenesis seen in VSV-infected animals, which is plausible given their pro-inflammatory nature. 
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Fig. 25., Continued. Impact of systemic depletion of perivascular macrophages on microglia and 
infiltrating leukocytes. 
CB6F1 mice were depleted of perivascular macrophages by surgical administration of 8 uL clodronate-
liposomes into the left lateral ventricle of the brain (intracerebroventricular injection, ICV). Mice were 
allowed to recover from surgery for 3 days, then intranasally infected with VSV. Six days post-infection, 
mice were euthanized and brain tissues were harvested. A. Multicolour flow cytometry was performed on 
brains from VSV-infected (left column, panels a, c, e, g) and ICV-LIPO+VSV mice (right column, panels 
b, d, f, h). B. Quantitation of data presented for microglia (a, b) and microglia-gated (c, d) populations. C. 
Quantitation of data presented for infiltrating leukocytes (a, b) and CD8 (e, f) or CD45hlgh (g, h) gated 
leukocytes. Note that depletion of perivascular macrophages with ICV-LIPO did not deplete microglia, but 
markedly reduced infiltrating antigen-specific CD8+ and CD4+ lymphocytes. These data are representative 
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Fig. 26. Antigen preservation is preserved in mice depleted of perivascular macrophages. 
CB6F1 mice were depleted of perivascular macrophages by surgical administration of 8 uL clodronate-
liposomes into the left lateral ventricle of the brain (intracerebroventricular injection, ICV). Mice were 
allowed to recover from surgery for 3 days, then intranasally infected with VSV. Six days post-infection, 
cervical lymph nodes (CLN) were harvested from animals and subjected to multicolour flow cytometry. 
Cells were stained for antigen-specific (Tet+) CD8+ T cells that coexpressed CD49d (panels a-c). These 
data are representative of four mice per group. 
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Protein Array Results for ICV-LIPO+VSV Mice 
We also assayed protein cytokine production in ICV-LIPO treated mice. These mice were 
harvested in a separate experiment from previously reported arrays, although normalisation across the 
assays was possible. Brain tissues from four ICV-LIPO mice were harvested and treated identically to 
naive, VSV, and DT+VSV brains used for protein arrays. In these experiments, two cytokines, SCF and 
TECK, were significantly inhibited in ICV-LIPO+VSV mice relative to VSV-only controls (Fig. 27). 
Again, several cytokines were dysregulated to a lesser extent (25-50%) in ICV-LIPO treated mice relative 
to VSV-only controls (Table 4). Almost all upregulated cytokines were chemotactic for granulocytes or 
monocyte/macrophages, although two were mitogenic (bFGF, basic fibroblast growth factor; IL-
12p40/p70). It should be noted that IL-12p70, also assayed separately, did not increase in ICV-LIPO 
infected mice; therefore, it is likely that most of the increased levels noted for the heterodimer are due to 
the IL-12p40 subunit. Axl, which is structurally similar to Dtk, was also found to be increased. It 
typically forms part of the BBB and is cleaved by MMPs in response to hyperosmotic stress. 
Downregulated cytokines included VEGF Rl, VEGF R2, and VEGF-D. Although VEGF receptors were 
increased, no increase in their ligand (VEGF) was noted. IL-9 and RANTES, which both increased in VSV 
infection, were suppressed in ICV-LIPO treated mice to naive levels. Expression of Fas ligand was also 
suppressed to near-basal levels, which may reflect the loss of infiltrating T cells noted in this model. 
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Fig. 27., Continued. Protein Cytokine Array Results for ICV-LIPO treated, VSV-infected mice. 
CB6F1 mice were depleted of perivascular macrophages by surgical administration of 8 uL clodronate-
liposomes into the left lateral ventricle of the brain (intracerebroventricular injection, ICV). Mice were 
allowed to recover from surgery for 3 days, then intranasally infected with VSV. Seven days post-
infection, mice were euthanized and brain tissues were harvested. For VSV-only mice, brain tissues were 
harvested 8 days post-infection and snap-frozen using liquid nitrogen before assays for cytokines were 
performed. Tissues from VSV and ICV-LIPO+VSV groups were pooled (25 mg tissue/mouse, 4-5 
mice/group). Protein extracts were prepared in the presence of a protease inhibitor cocktail (Calbiochem) 
and protein concentrations adjusted to 250 ug/mL prior to use with RayBiotech Cytokine Arrays. Protein 
spots were revealed with Streptavidin-IR 800CW (Li-Cor Odyssey) and scanned on the Odyssey Imaging 
system. (A) Protein Arrays are depicted with background correction (maximal fluorescence intensity is 
shown as white). Significantly altered cytokines are boxed. (B) Quantitation of fluorescence signals: a 3-
pixel background was subtracted from the integrated fluorescence intensity of each spot and results were 
normalised. Cytokines demonstrating a 50% increase or decrease in expression relative to naive control 
mice were identified. Asterisks indicate statistical significance (a=0.05, GraphPad Prism 4). 
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Discussion 
These sets of experiments offered disparate results, despite having the same aim: to deplete 
macrophages. The MAFIA model allowed us to selectively deplete cells that expressed the CSF-1 receptor, 
which is primarily expressed by cells of the monocyte/macrophage lineage, including immature precursors 
in the bone marrow (Rettenmier et al., 1988; Rothwell and Rohrschneider, 1987). Although the c-fms gene 
is expressed in both macrophages and DCs (Rieser et al., 1998), Burnett et al. demonstrated that it is 
expressed at nearly tenfold lower levels in DCs (Burnett et al., 2004), which may explain the relative 
preservation of DCs following dimeriser treatment. We have made similar observations about DCs in our 
initial studies of MAFIA mice (data not shown). Microglia were not depleted by treatment with AP20187, 
which indicates that it may not effectively cross the blood-brain barrier. This idea is supported by 
historical observations that large molecules in excess of 500 Da do not cross the blood-brain barrier 
successfully; the molecular weight of AP20187 is 1428.8 Da (Ariad Pharmaceuticals, Cambridge, MA). 
Dimeriser treatment did not inhibit activation of microglia as defined by cellular expansion and/or 
upregulation of MHC II, which indicates that microglial activation was independent of peripheral 
macrophages. This is also consistent with failure of AP20187 to cross the blood-brain barrier. To confirm 
that successful depletion of monocyte/macrophage lineage cells had occurred, we also observed the bone 
marrow and spleens for characteristic blanching (Steel et al., 2008). Flow cytometric analysis performed 
on bone marrow and peritoneal exudate cells (PECs) revealed that normal MAFIA bone marrow contained 
a prominent population of CD45h,ghCDl lb+ cells which expressed Gr-1 and were approximately one-third 
EGFPlow/int. VSV infection resulted in the selective disappearance of Gr-rEGFPlow/int cells from the bone 
marrow, whereas prior dimeriser treatment resulted in expansion of Gr-l+EGFPlow/mt cells. In contrast, 
CD45highCDl lb+ cells in the peritoneum were exclusively macrophages. Two macrophage populations 
based on EGFP expression were present in the normal peritoneum. Macrophages with high EGFP 
expression were dramatically reduced by VSV infection and this loss was exacerbated by prior dimeriser 
treatment. Although the number of EGFPlow/mt macrophages was also reduced by virus infection, this 
population expanded in mice depleted of macrophages. These results also correspond well with our 
previously published work in the MAFIA model which showed depletion of EGFPh,gh cells and a 
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corresponding compensatory increase in granulocytes in the absence of viral infection (Steel et al., 2008). 
Leukocytes isolated from VSV infected brains included a significant population of CD45h,ghCDl lb+ cells 
as well as a small but detectable infiltrate of CD1 lc+ DCs. These results were consistent with our 
previously reported studies that showed a surprising expansion of CD1 lb+ cells in the periphery following 
AP20187 treatment, which we attributed to an immature macrophage or granulocyte phenotype resulting 
from a compensatory precursor haematopoietic response in the spleen and bone marrow. Further analysis 
studies demonstrated that these cells were most likely neutrophils because they expressed a 
CD45h,ghCDl lb+F4/80"Gr-l+ phenotype, consistent with the work of Reiss et al. who demonstrated that 
neutrophils were the first cell population to infiltrate the virally infected CNS (Bi et al, 1995a; Ireland and 
Reiss, 2006). Mature neutrophils do not express CSF-1 receptor (Hume et al., 2002) and would be 
expected to be insensitive to AP20187 treatment. It seems likely that these cells emigrated from the bone 
marrow to infiltrate the brain and contribute to the granulocytic response seen in this organ. This view is 
consistent with the accumulation of CD45highEGFPlow/int cells in the brains of mice depleted of 
macrophages. As previously noted, we did not detect pDCs, B cells or NK cells in VSV-infected brains. 
Although the CD1 lb- infiltrate was minimal, CD8+ T cells were abundant, suggesting that lymphocytes 
upregulated CD1 lb on activation. This observation was confirmed by back-gating analysis in Fig. 12. As 
noted in the previous studies, a significant percentage of CD8+ T cells were antigen-specific, though not all. 
The specificity of the remaining activated T cells remains to be determined. Despite their dual 
functionality as APCs and effector cells, mice rendered deficient of peripheral macrophages mounted a 
normal innate and adaptive antiviral immune response in the CNS. This also implies preservation of 
peripheral DCs in dimeriser treated mice because depletion of these cells markedly inhibited antiviral 
immunity and viral clearance in the DTRTg model. Thus, peripheral depletion of macrophages failed to 
suppress the inflammatory response in the brain because the predominant myeloid cell type infiltrating the 
brain was neutrophils and not macrophages. As noted previously, low expression of the transgene in DCs 
apparently prevented significant loss of these essential APCs resulting in normal cellular expansion and 
CNS penetration of CDSVSV-N T cells. 
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MGBG does not directly kill target cells; rather, it blocks maturation of monocytes into 
macrophages. This mechanism is therefore unique as a depletion strategy, because it should not induce a 
compensatory proliferation of haematopoietic precursors noted in the MAFIA model. Specifically, MGBG 
inhibits S-adenosyl L-methionine decarboxylase, which catalyzes the synthesis of spermidine (McGrath 
and Hadlock, 2007). Spermidine is a naturally-occurring polyamine, while MGBG is a synthetic 
polyamine with similar activity. With regard to immunity, spermidine has been shown to kill lymphocytes 
at concentrations above 100 uM in vitro (Swanson and Gibbs, 1980) and was inhibitory to concanavalin-A 
and LPS-stimulated lymphoproliferation in vivo (Ishizuka et al., 1982) but increased production of the T-
cell mitogen IL-2. Spermidine has also been demonstrated to be inhibitory to monocyte maturation and 
differentiation into macrophages (Kaczmarek et al., 1992; Messina et al., 1992; Zhang et al., 2000). 
Although initially inhibition of spermidine production by MGBG would appear to be proinflammatory, it 
should be noted that the drug likely acts as a biochemical competitor and replaces the actions of spermidine 
in immunoregulation. Treatment of mice with MGBG prior to viral infection caused a marked loss of 
microglia in the CNS and inhibited activation of remaining cells as determined by upregulation of MHC 
l/II, and the expression of the negative regulator PD-1 was increased nearly twofold in MGBG-treated 
mice. MGBG may therefore also block maturation of microglia if it is capable of crossing the blood-brain 
barrier. Due to its relative size (MW=282 Da), it is likely that MGBG is directly responsible for the 
alterations in microglia noted during this experiment, although studies demonstrating its capacity to 
penetrate the blood-brain barrier have not been reported. In addition to inhibition of microglia, MGBG-
treated mice showed a reduction in the absolute numbers of infiltrating CD45h,gh leukocytes, with a small 
decrease in the number of infiltrating granulocytes (Gr-1+) and antigen-specific CD8+ lymphocytes. The 
remaining CD1 lb+ leukocytes were not further phenotyped; however, it is likely that the bulk of depletion 
occurred in this heterogeneous population. A loss of CD1 lb+ macrophages was anticipated, and these data 
reflects successful inhibition of monocyte/macrophage differentiation. This conclusion is also supported by 
the observation that MGBG-treated mice showed significantly less VSV-induced morbidity relative to 
untreated controls, which may indicate a loss of tissue-destructive inflammation. The loss of antigen-
specific CD8+ response was somewhat surprising, given that these cells were not reported to be targets of 
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MGBG; however, research indicates that the natural analogue spermidine has inhibitory effects on 
lymphoproliferation as well. Thus, the inhibition of antigen-specific CD8+ T cells may also be a direct 
result of MGBG treatment. Although the results from this experiment are preliminary, it is possible that 
MGBG may provide a good model for observing the role of microglia in the CNS. If directly infused into 
the CNS (intracerebroventricular administration), MGBG may selectively inhibit CNS-resident leukocytes. 
Additional studies would be required to determine the efficacy of this technique and whether MGBG 
subsequently leaked into the peripheral immune system. 
Depletion by liposome-encapsulated clodronate requires functional maturation of phagocytic cells 
(van Rooijen and van Nieuwmegen, 1984) and active phagocytosis. Intravenous administration of 
clodronate-encapsulated liposomes into nai've MAFIA mice suppressed the inflammatory response in the 
brain. Thus, the global influx of blood-derived leukocytes (CD45hlgh) was dramatically diminished. As 
noted previously, this infiltrate was composed primarily of neutrophils (CD45hlghCDl lb+F4/80"Gr- 1+), T 
cells and relatively small numbers of DCs. For reasons that are not clear, neutrophils do not appear to be 
depleted by clodronate despite their phagocytic activity (Qian et al., 1994) and were therefore unavailable 
to infiltrate the VSV infected brain. Their diminished numbers in the brain suggests that they may lack the 
ability to penetrate the blood-brain barrier. The total number T cells (CD4+ and CD8+) detected in the brain 
were reduced including the CD8+ T cell subset specific for VSV, despite a normal CD8+ T cell response in 
the draining CLN. This implies that the impaired infiltrate of leukocytes in the encephalitic brain may 
reflect a failure of leukocyte extravasation across the blood-brain barrier or lack of permeability as noted in 
the DTRTg model. The impaired IFN-y response may reflect the diminished numbers of T cells that 
infiltrated the brains of mice depleted of macrophages if T cells represent the cellular source of this 
cytokine; however, this interpretation would conflict with the DTRTg model, which demonstrated a robust 
IFN-y response in the absence of infiltrating T cells. The effects of clodronate were not limited solely to 
macrophages but also depleted marginal (CD8) DCs in the spleen (Leenen et al., 1998), which may explain 
the reduction in lymphocytic infiltrate. In some experiments, we detected a population of CD1 lc"PDCA-l+ 
cells whose function remains to be elucidated. Clodronate treatment was associated with increased 
morbidity/mortality that did not correlate with impaired viral clearance in the CNS. 
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Early studies demonstrate that when given intracerebroventricularly (ICV), macrophages in the 
perivascular spaces and meninges were susceptible to liposome-mediated depletion, while microglial cells 
remained intact (Polfliet et al., 2001a). This may reflect differences in basal phagocytic activity. It is also 
important to note that the liposomes used in this study were mannosylated, which has been demonstrated to 
improve blood-brain barrier permeability (Polfliet et al., 2001a). Flow cytometric analysis showed a 
markedly inhibited infiltrate of leukocytes, particularly a loss of macrophages and granulocytes. However, 
we also noted a loss of both CD8+ and CD4+ T cells despite a weak VSV-induced response in virally 
infected controls. These data appears very similar to the DT+VSV depletion model in that the leukocyte 
infiltrate was broadly inhibited. The loss of a T cell infiltrate was unexpected because clodronate delivered 
into the brain did not deplete macrophages or DCs in the draining CLN and therefore should not have 
inhibited accumulation of antigen-specific T cells in the CNS. Consistent with reports that microglia are not 
depleted by clodronate, the activation and proliferation of these parenchymal-resident leukocytes remained 
normal in these studies. Overtly, the mice in this group appeared healthier than VSV-only cohorts. This 
led us to think that inflammation, a generally destructive process, would be suppressed in these mice. 
Therefore, investigation of the cytokine profile was also interesting. In this model, similar to the DT+VSV 
model, many chemotactic cytokines were upregulated, including the T-cell chemokines Lymphotactin and 
CTACK. However, it was upregulated to a much lesser extent in ICV-LIPO+VSV mice than in DT+VSV 
mice. Chemokines involved in neutrophil, granulocyte, and monocyte/macrophage recruitment continued 
to be expressed at slightly elevated levels. Again, these findings indicate that the failure of leukocyte 
infiltration was not due to cytokine dysregulation, and further imply that these cytokines are not dependent 
on perivascular macrophages. IL-12p40/p70, but not IL-12p70, was increased in response to ICV-LIPO 
treatment. The IL-12p40 subunit is antagonistic to the heterodimer and has been shown to exert protective 
effects in CNS infections (Bi et al., 1995b; Chesler and Reiss, 2002; Komatsu et al., 1997). The increased 
expression of Axl in the ICV-LIPO group could have a few potential sources. This protein forms part of 
the BBB and is cleaved by MMPs in response to hyperosmotic stress. Such stress might have been induced 
during the surgical administration of clodronate-liposomes, but this response may also reflect an immune-
mediated difference in response to the viral infection. Notably, VEGF receptors were inhibited in this 
model. Although the VEGF ligand is primarily responsible for proliferation of vascular endothelial cells, it 
also plays a critical role in vascular permeability (Brown et al., 1992; Clauss et al., 1990; Connolly, 1991) 
and may promote monocyte migration (Clauss et al., 1990). The loss of the receptors from the vascular 
endothelium may therefore be partially responsible for the failure of leukocyte infiltration. In this model, a 
few unusual cytokines were found to be altered relative to VSV-only controls, including thrombopoeitin 
(TPO) and basic fibroblast growth factor (bFGF). Both these cytokines may be involved in wound healing 
and may reflect the surgical administration of clodronate liposomes into the CNS. These preliminary 
studies suggest perivascular/meningeal macrophages provide some nonredundant function essential for 
enhancing permeability of the blood-brain barrier, similar to DCs in the DTRTg model. Taken together, the 
loss of cellular infiltrate despite a robust cytokine response and normal response in the draining cervical 
lymph nodes (in the ICV-clodronate model) imply that disruption of the blood-brain barrier may require an 
interaction between perivascular/meningeal macrophages and infiltrating DCs. This view is further 
supported by the observation that CD1 lc+ DCs also reside in the perivascular spaces and may have been 
depleted by the direct CNS infusion of clodronate liposomes as they were also susceptible to DT-mediated 
depletion (Fig. 7). This population of DCs may be especially critical to modulating the integrity of the 
blood-brain barrier. 
Because each of these depletion strategies employs a unique mechanism of action, we were able to 
evaluate several facets of macrophage-mediated immunity. In striking contrast to the AP20187 conditional 
ablation model, intravenous administration of liposome-encapsulated clodronate into naive MAFIA mice 
suppressed the inflammatory response in the brain. The different outcome achieved with clodronate versus 
dimeriser may reflect the different populations targeted by these treatments. In the MAFIA model, 
AP20187 dimeriser targets macrophages with high c-fms activity and leaves relatively intact cells with low 
expression levels of the transgene such as DCs and immature and mature granulocytes. Marked differences 
between the intravenous and intracerebroventricular models of clodronate administration were also 
apparent. Intravenous injection of clodronate liposomes affects diverse tissues, such as the spleen, liver, 
and bone marrow (van Rooijen, 2006), while the effects of ICV-administered clodronate are localised to the 
CNS (Polfliet et al., 2001a). Functional differences between routes of injection (intraperitoneal versus 
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intravenous) have been reported. Depletion of peripheral DCs in the DTRTg model or 
perivascular/meningeal macrophages in the ICV-clodronate model results in similarly impaired innate and 
adaptive antiviral immune responses. Perivascular and/or meningeal macrophages apparently do not 
function as APCs in the brain because depletion of these cells does not inhibit infiltration of antigen-
specific CD8+ T cells into the CNS (Galea et al., 2007b). How these different cell populations regulate 
leukocyte infiltration is currently unknown. It should be noted that none of these depletion strategies are 
exclusive to a particular cell or lineage; they are all cross-reactive to some extent. This complicates the 
data analysis and interpretation of results, but some general trends can be noted. Systemic depletion of 
macrophages did not inhibit viral clearance, regardless of the mechanism employed. Loss of dendritic cells, 
whether in the periphery or possibly in the perivascular spaces, results in the maintained integrity of the 
blood-brain barrier with resultant failure of peripheral leukocyte infiltration into the CNS. Further studies 
will be required to delineate how these distinct macrophage populations regulate blood-brain barrier 
permeability and enhance viral encephalitis. 
Taken together, these results demonstrated that a population of DCs that is neither myeloid nor 
lymphoid drove antigen presentation in the CLN in response to CNS infections. Furthermore, myeloid 
DCs, lymphoid DCs, or both played a key role in modulating BBB integrity and subsequent leukocyte 
extravasation into the brain parenchyma. Microglia alone or in combination with IFN-y were insufficient 
to mediate viral clearance in the CNS; these studies further confirmed CD8+ T cells as the primary 
mediators of viral clearance. Macrophages did not contribute to antiviral immunity as APCs or in viral 
clearance, but appeared to exacerbate CNS injury in response to viral infection. 
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CHAPTER VII 
CONCLUSIONS AND FUTURE DIRECTIONS 
The studies presented in this work investigated the roles of resident microglia as well as peripheral 
dendritic cells and macrophages in the adaptive immune response to acute viral infections of the central 
nervous system. We began by characterising the normal cellular and cytokine response to VSV infection in 
the CNS. As previously reported, the peak of infection occurred between 6-8 days post-infection, which 
varied somewhat with mouse strain and gender. At this time, the leukocyte response was characterised by 
an expansion of resident microglia and an infiltrate of peripheral leukocytes which consisted largely of 
granulocytes, macrophages, and T cells. In the encephalitic brain, microglia upregulated surface 
molecules including MHC I/II and CD1 lc, which implied that they may be able to serve as a resident 
antigen-presenting population within the CNS. However, we have no direct evidence that these cells 
function as APCs for VSV T cells. Future studies should address this capacity. In vitro antigen-
presentation assays have been performed in other models of CNS infections and demyelinating, recurrent 
models of infection and generally show little to no antigen-presenting capacity; however, in vivo 
experiments are lacking. The complexity of the adaptive immune response in vivo is poorly represented in 
cell culture models where crucial cytokines and accessory cells may not be present to fully activate T cells. 
Therefore, in vivo experiments should be utilised, and could be performed with highly purified adoptively 
transferred T cells derived from syngeneic mice intravenously injected into lethally-irradiated recipient 
mice. Brain-resident microglia are typically protected from irradiation and could continue to serve as 
antigen-presenting cells. This technique carries a risk of failure: the adoptively transferred T cells may not 
be sufficient to rescue mice from fatal encephalitis. This risk could be mediated by performing the 
adoptive transfer early during viral infection (~ 3 days post-infection), at a time when microglia have 
upregulated appropriate antigen-presenting markers but at which mice are still asymptomatic. The role of 
granulocytes during viral infection remains unclear and also requires extended study. These cells are 
typically the first to infiltrate the CNS in response to infection, and have been reported to produce a 
tremendous variety of cytokines/chemokines, including several that may alter BBB permeability (elastase, 
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collagenase, metalloproteinases) and aid in subsequent recruitment of lymphocytes. However, these cells 
also fail to penetrate the CNS with DT treatment, indicating that they alone are insufficient to initiate BBB 
breakdown and leukocyte infiltration. The role of granulocytes during VSV infection could be easily 
addressed with antibody depletion studies in vivo. Finally, the cytokine profiles we observed by protein 
array did not match well with RNase protection assays that had been previously reported; these results bear 
further investigation. RNA-based PCR arrays are available for a wide variety of cytokines/chemokines (SA 
Biosciences) and should be performed in tandem with protein detection methods (ELISA or protein 
cytokine arrays) on the same samples to determine whether the discrepancy in results is due to 
dysregulation of mRNA or protein, or whether our preliminary results are erroneous. Using these methods, 
it is also possible and critically important to determine the cellular origin of dysregulated cytokines; mRNA 
and protein-based assays can be performed on specific cell populations that have been highly purified by 
magnetic bead sorting and/or fluorescence-activated cell sorting (FACS) for cell populations that represent 
likely cytokine/chemokine sources (microglia, astroglia, perivascular macrophages). Microglia can be 
detected and FACS purified by endogenous expression of EGFP in either the MAFIA model or a 
CD1 lb/DTRTg mouse strain available from Jackson Laboratories. Astroglia may similarly be purified 
from FVB/N-Tg[GFAPGFP]14Mes/J mice, which express EGFP under the control of the glial fibrillary 
acidic protein promoter in astrocytes. Perivascular macrophages require in vitro labelling with CD206 
(mannose receptor, Hycult Biotechnology, clone MR5D3). This molecule is exclusively expressed on PVM 
and not microglia or blood-derived monocytes/macrophages even in the inflamed brain (Galea et al., 2005). 
Additional markers for macrophages (CD1 lb or F4/80) would be required, although endogenous EGFP 
expression could be used for the CD1 lb/DTRTg or MAFIA mouse strains. Together, these additional 
studies will help clarify the cellular and cytokine responses to viral infection. Following these assays, it 
would be important to evaluate the in vivo contributions of these cytokines/chemokines to antiviral 
immunity by using antibody-mediated cytokine depletion. 
The loss of peripheral classical APCs (DCs) with diphtheria toxin treatment was anticipated to 
result in a failure in the activation and expansion of T cells. We performed experiments in which we 
conditionally ablated this peripheral APC population, and observed a failure in proliferation and activation 
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of T cells. However, these results were confounded somewhat by a surprising broad-spectrum inhibition of 
leukocyte infiltration into the CNS following viral infection. The concurrent loss of infiltrating myeloid 
cells was surprising, and did not match our predictions. Further evaluation of this model in the experiments 
described herein point to a general failure of leukocytes to extravasate across the blood-brain barrier and 
penetrate the CNS following viral infection. These findings need to be extended with additional studies of 
BBB integrity, which can be evaluated with Evans' blue staining of brain parenchyma (or, alternatively, 
FITC-dextran). To determine whether peripheral DCs are required for disruption of the BBB, splenic CD8+ 
T N15Tg (VSV-specific) T cells isolated from VSV-infected (intraperitoneal infection) N15Tg mice would 
be labelled with CFSE and infused into VSV-infected (CNS) DTRTg mice with intact or depleted 
peripheral DC populations. This model would also determine the extent to which activated CD8+ VSV-N T 
cells undergo further cell division in the absence (control) or presence of viral antigen in the CNS. It may 
also be important to demonstrate that DCs residing in the perivascular spaces are not sensitive to DT-
mediated depletion; this can be readily accomplished with immunohistochemistry in the CD1 lc/DTRTg 
model. Our results also implied that DCs may produce MMP-3 in response to viral infection: this should 
be directly evaluated by immunohistochemistry and/or confocal microscopy. It is also critical to confirm 
that MMP-3 is a key regulator of BBB integrity. Strains of MMP knockout mice have been described as 
recently as 2005, but do not appear to be commercially available. Chemical means of MMP-3 inhibition 
are relatively simpler and can be achieved by administration of select TIMPs (tissue inhibitors of 
metalloproteinases). 
Additional observations of chemokines involved in regulation of the BBB are recommended; 
particularly the matrix metalloproteinases (MMPs) and their inhibitors (TIMPs, tissue inhibitors of 
metalloproteinases) by both RNA and protein detection methods, which include but are not limited to 
ELISA assays, protein cytokine arrays, and RNA-based arrays. It was surprising that so few 
cytokines/chemokines appeared to be dysregulated based on the protein cytokine array; these results also 
need to be confirmed with tandem mRNA/protein methods as previously described. Furthermore, the 
cellular source of IFN-y in the CNS remains to be confirmed; immunohistochemistry and/or confocal 
microscopy are recommended approaches due to difficulty in isolation and purification of microglia. 
131 
Our macrophage depletion models provided consistent results, despite differences in depletion 
mechanisms and target cell populations. The CD1 lb/DTRTg mouse strain may allow a more specific 
depletion of target macrophages than was achieved by the techniques described herein. In this strain, 
expression of the simian diphtheria toxin receptor is driven by the integrin a-M (CD1 lb) promoter, which 
is active in cells of the macrophage and microglial lineages. Based on our studies, most macrophage 
depletion techniques are cross-reactive with granulocyte or DC populations. Therefore, it would be critical 
to first verify the specificity of this model with regard to depletion of macrophage subpopulations, with 
subsequent focus on perivascular macrophages and microglia in the CNS. Given that DT does not cross the 
BBB effectively, it is unlikely that peripheral (intraperitoneal or intravenous) administration of DT would 
deplete microglia. However, it is possible that direct infusion of DT into the CNS of transgenic mice might 
provide a novel means of depleting microglial populations, which would allow us to evaluate antiviral 
immunity in the absence of this population and clarify the contribution of microglia to antiviral immunity 
in the CNS. A potential drawback to this mouse model is that we observed a prevalent upregulation of 
CD1 lb on leukocytes infiltrating the CNS; administration of DT may therefore deplete activated leukocytes 
in addition to target macrophage populations. However, careful timing of administration may reduce these 
effects, given that the serum half-life of DT is relatively short. It would be critical to observe the 
repopulation kinetics of macrophage populations in this mouse model to determine whether it would be 
possible to selectively deplete macrophages and maintain depletion for the required 6-8 day duration of the 
experiment without adversely affecting activated/infiltrating leukocyte populations. 
The MAFIA model of macrophage depletion would also benefit from additional study in CNS 
infections. Microglial activation and proliferation appeared enhanced in our studies, but only rudimentary 
phenotyping was performed. Additional flow cytometry with extended markers and functional indicators 
(such as IFN-y secretion) for microglial activation and kinetic studies would greatly improve the 
understanding of this model. Additional studies directed toward the cytokine response (either RNA or 
protein arrays) may shed new light on the molecular mechanisms underlying enhanced microglial and 
lymphocyte activation and viral clearance. 
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Of the techniques employed here for macrophage depletion or inhibition, only administration of 
MGBG appeared to have a significant inhibitory effect on resident microglia. It may be possible to 
selectively inhibit microglia in future studies by modifying the dose, route, or timing of MGBG 
administration. Additional studies with this technique are recommended to conclusively determine whether 
macrophage infiltration into the CNS was inhibited; adoptive transfer of CFSE-labelled monocytes 
followed by flow cytometry should demonstrate functional impairment of monocyte-macrophage 
differentiation and penetration into the brain parenchyma. Additionally, it is crucial to determine whether 
the observed microglial inhibition resulted in impaired IFN-y production, which can be evaluated with 
ELISPOT assasys. 
In summary, these studies provided several new insights into regulation of the immune response to 
acute viral infections and allowed us to develop a working model for the primary antiviral immune 
response in the CNS. In the immunocompetent mouse, VSV successfully infects the CNS via the olfactory 
nerve and spreads caudally throughout the brain. Shortly after infection, microglia become activated and 
proliferate, and may secrete IFN-y. During early infection (3 days post-infection), an unidentified DC 
subtype (neither lymphoid nor myeloid) acquires antigen and migrates to the CLN to globally activate T 
cells. These T cells, along with macrophages and granulocytes, home toward the infected CNS via 
chemokine/cytokine chemotaxis. However, macrophages are not required and appear to exacerbate 
pathogenesis. Extravasation across the BBB is dependent on lymphoid DCs, myeloid DCs, or both and 
may be MMP-3 dependent. Additional stimulation from perivascular cells or microglia may be required 
for full antiviral activity in the CNS. Once these cells have penetrated into the parenchyma of the brain, 
CD8+ T cells mediate viral clearance in conjuction with IFN-y, resulting in mouse survival and recovery. 
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